Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2758563,bioavailability,This study confirms previous observations that etoposide absorption is dose-dependent and that a mean bioavailability of approximately 50% cannot be assumed at total oral doses greater than 200 mg.,The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758563/),%,50,123,DB00773,Etoposide
,8431968,beta-elimination half-life (t 1/2 beta),"After the exclusion of patients who had previously been given cisplatin or who exhibited renal impairment and of one patient who showed extremely high levels of alkaline phosphatase, gamma-GT and SGPT, the mean values calculated for the pharmacokinetic parameters evaluated were: beta-elimination half-life (t 1/2 beta), 4.9 +/- 1.2 h; mean residence time (MRT), 6.7 +/- 1.4 h; area under the concentration-time curve (AUC), 5.43 +/- 1.74 mg min ml-1; volume of distribution at steady state (Vdss), 6.8 +/- 2.7 l/m2; and clearance (Cl), 18.8 +/- 5.3 ml min-1 m-2.",Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431968/),h,4.9,690,DB00773,Etoposide
,8431968,mean residence time (MRT),"After the exclusion of patients who had previously been given cisplatin or who exhibited renal impairment and of one patient who showed extremely high levels of alkaline phosphatase, gamma-GT and SGPT, the mean values calculated for the pharmacokinetic parameters evaluated were: beta-elimination half-life (t 1/2 beta), 4.9 +/- 1.2 h; mean residence time (MRT), 6.7 +/- 1.4 h; area under the concentration-time curve (AUC), 5.43 +/- 1.74 mg min ml-1; volume of distribution at steady state (Vdss), 6.8 +/- 2.7 l/m2; and clearance (Cl), 18.8 +/- 5.3 ml min-1 m-2.",Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431968/),h,6.7,691,DB00773,Etoposide
,8431968,area under the concentration-time curve (AUC),"After the exclusion of patients who had previously been given cisplatin or who exhibited renal impairment and of one patient who showed extremely high levels of alkaline phosphatase, gamma-GT and SGPT, the mean values calculated for the pharmacokinetic parameters evaluated were: beta-elimination half-life (t 1/2 beta), 4.9 +/- 1.2 h; mean residence time (MRT), 6.7 +/- 1.4 h; area under the concentration-time curve (AUC), 5.43 +/- 1.74 mg min ml-1; volume of distribution at steady state (Vdss), 6.8 +/- 2.7 l/m2; and clearance (Cl), 18.8 +/- 5.3 ml min-1 m-2.",Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431968/),[mg·min] / [ml],5.43,692,DB00773,Etoposide
,8431968,volume of distribution at steady state (Vdss),"After the exclusion of patients who had previously been given cisplatin or who exhibited renal impairment and of one patient who showed extremely high levels of alkaline phosphatase, gamma-GT and SGPT, the mean values calculated for the pharmacokinetic parameters evaluated were: beta-elimination half-life (t 1/2 beta), 4.9 +/- 1.2 h; mean residence time (MRT), 6.7 +/- 1.4 h; area under the concentration-time curve (AUC), 5.43 +/- 1.74 mg min ml-1; volume of distribution at steady state (Vdss), 6.8 +/- 2.7 l/m2; and clearance (Cl), 18.8 +/- 5.3 ml min-1 m-2.",Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431968/),[l] / [m2],6.8,693,DB00773,Etoposide
,8431968,clearance (Cl),"After the exclusion of patients who had previously been given cisplatin or who exhibited renal impairment and of one patient who showed extremely high levels of alkaline phosphatase, gamma-GT and SGPT, the mean values calculated for the pharmacokinetic parameters evaluated were: beta-elimination half-life (t 1/2 beta), 4.9 +/- 1.2 h; mean residence time (MRT), 6.7 +/- 1.4 h; area under the concentration-time curve (AUC), 5.43 +/- 1.74 mg min ml-1; volume of distribution at steady state (Vdss), 6.8 +/- 2.7 l/m2; and clearance (Cl), 18.8 +/- 5.3 ml min-1 m-2.",Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431968/),[ml] / [(m)^2·min],18.8,694,DB00773,Etoposide
,26029029,peak plasma concentration,"While the mean etoposide peak plasma concentration in the first cycle of chemotherapy was 17.6 mg/l, the highest levels of 27.07 and 27.49 mg/l were determined in two patients with febrile neutropenia.",Febrile neutropenia in chemotherapy treated small-cell lung cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26029029/),[mg] / [l],17.6,1280,DB00773,Etoposide
,26029029,peak plasma concentration,"While the mean etoposide peak plasma concentration in the first cycle of chemotherapy was 17.6 mg/l, the highest levels of 27.07 and 27.49 mg/l were determined in two patients with febrile neutropenia.",Febrile neutropenia in chemotherapy treated small-cell lung cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26029029/),[mg] / [l],27.07,1281,DB00773,Etoposide
,26029029,peak plasma concentration,"While the mean etoposide peak plasma concentration in the first cycle of chemotherapy was 17.6 mg/l, the highest levels of 27.07 and 27.49 mg/l were determined in two patients with febrile neutropenia.",Febrile neutropenia in chemotherapy treated small-cell lung cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26029029/),[mg] / [l],27.49,1282,DB00773,Etoposide
,1312906,peak plasma concentration,"The peak plasma concentration after intravenous administration ranged from 7.01 to 10.47 micrograms/ml, varying in proportion to the injected dose, whereas that after oral administration was lower, namely, 1.44-4.99 micrograms/ml, and was unstable when the oral dose was 150 mg daily.",Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1312906/),[μg] / [ml],7.01 to 10.47,4357,DB00773,Etoposide
,1312906,peak plasma concentration,"The peak plasma concentration after intravenous administration ranged from 7.01 to 10.47 micrograms/ml, varying in proportion to the injected dose, whereas that after oral administration was lower, namely, 1.44-4.99 micrograms/ml, and was unstable when the oral dose was 150 mg daily.",Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1312906/),[μg] / [ml],1.44-4.99,4358,DB00773,Etoposide
>,15814645,time to platelet recovery,"Median time to platelet recovery > or =100,000/microL of rhTPO at 1.2, 2.4, and 3.6 microg/kg/d was 24 days (22-24 d), 25 days (23-29 d), and 22 days (16-37 d), respectively.","A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15814645/),,100,5009,DB00773,Etoposide
,15814645,time to platelet recovery,"Median time to platelet recovery > or =100,000/microL of rhTPO at 1.2, 2.4, and 3.6 microg/kg/d was 24 days (22-24 d), 25 days (23-29 d), and 22 days (16-37 d), respectively.","A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15814645/),d,24,5010,DB00773,Etoposide
,15814645,time to platelet recovery,"Median time to platelet recovery > or =100,000/microL of rhTPO at 1.2, 2.4, and 3.6 microg/kg/d was 24 days (22-24 d), 25 days (23-29 d), and 22 days (16-37 d), respectively.","A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15814645/),d,25,5011,DB00773,Etoposide
,15814645,time to platelet recovery,"Median time to platelet recovery > or =100,000/microL of rhTPO at 1.2, 2.4, and 3.6 microg/kg/d was 24 days (22-24 d), 25 days (23-29 d), and 22 days (16-37 d), respectively.","A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15814645/),d,22,5012,DB00773,Etoposide
,15814645,maximum serum concentrations,"Mean (+/- SD) rhTPO maximum serum concentrations were 63.3 +/- 9.7 and 89.3 +/- 15.7 ng/mL and terminal half-lives were 47 +/- 13 and 64 +/- 42 hours after 2.4 and 3.6 microg/kg/d, respectively.","A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15814645/),[ng] / [ml],63.3,5013,DB00773,Etoposide
,15814645,maximum serum concentrations,"Mean (+/- SD) rhTPO maximum serum concentrations were 63.3 +/- 9.7 and 89.3 +/- 15.7 ng/mL and terminal half-lives were 47 +/- 13 and 64 +/- 42 hours after 2.4 and 3.6 microg/kg/d, respectively.","A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15814645/),[ng] / [ml],89.3,5014,DB00773,Etoposide
,15814645,terminal half-lives,"Mean (+/- SD) rhTPO maximum serum concentrations were 63.3 +/- 9.7 and 89.3 +/- 15.7 ng/mL and terminal half-lives were 47 +/- 13 and 64 +/- 42 hours after 2.4 and 3.6 microg/kg/d, respectively.","A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15814645/),h,47,5015,DB00773,Etoposide
,15814645,terminal half-lives,"Mean (+/- SD) rhTPO maximum serum concentrations were 63.3 +/- 9.7 and 89.3 +/- 15.7 ng/mL and terminal half-lives were 47 +/- 13 and 64 +/- 42 hours after 2.4 and 3.6 microg/kg/d, respectively.","A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15814645/),h,64,5016,DB00773,Etoposide
,26391155,t,"In NHL patients, cumulative higher trough concentrations over the eight administrations of the first cycle (TotC min, categorized by the median 58.71 mg/L) had significant prognostic value regarding the 5-year progression-free survival (PFS: 73.6 vs 46.5 %, P = 0.015) and 5-year overall survival (OS: 74.0 vs 52.2 %, P = 0.034).",Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391155/),[mg] / [l],58.71,5582,DB00773,Etoposide
,31041509,progress-free survival,"The median progress-free survival was 129 days and the median overall survival was 238 days, which caused a significantly prolonged survival rate of 38.5% and a higher disease control rate of 80%.",Pharmacokinetics and safety of lobaplatin plus etoposide in Chinese men older than 65 years with extensive-stage small cell lung cancer: a phase II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31041509/),d,129,7379,DB00773,Etoposide
,31041509,overall survival,"The median progress-free survival was 129 days and the median overall survival was 238 days, which caused a significantly prolonged survival rate of 38.5% and a higher disease control rate of 80%.",Pharmacokinetics and safety of lobaplatin plus etoposide in Chinese men older than 65 years with extensive-stage small cell lung cancer: a phase II clinical trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31041509/),d,238,7380,DB00773,Etoposide
,8021734,overall response rate,"The overall response rate was 81% in the 5-day arm and 87% in the 8-day arm, with median survival durations of 7.1 and 9.4 months, respectively (no significant differences).",A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021734/),%,81,8272,DB00773,Etoposide
,8021734,overall response rate,"The overall response rate was 81% in the 5-day arm and 87% in the 8-day arm, with median survival durations of 7.1 and 9.4 months, respectively (no significant differences).",A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021734/),%,87,8273,DB00773,Etoposide
,8021734,nadir neutrophil count,"Hematologic toxicity was significantly worse in the 5-day arm of the study (cycle no. 1 nadir neutrophil count, 0.8 x 10(9)/L v 1.7 x 10(9)/L).",A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021734/),,0.8 x 10(9),8274,DB00773,Etoposide
,8021734,nadir neutrophil count,"Hematologic toxicity was significantly worse in the 5-day arm of the study (cycle no. 1 nadir neutrophil count, 0.8 x 10(9)/L v 1.7 x 10(9)/L).",A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021734/),,1.7 x 10(9),8275,DB00773,Etoposide
,3580943,plasma t1/2,"The plasma t1/2 in the IC group of dogs was 1.0 hr, the volume of distribution was 1.7 L/kg and the clearance was 1.5 ml/hr/kg.","Comparison of CNS penetration, tissue distribution, and pharmacology of VP 16-213 by intracarotid and intravenous administration in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580943/),h,1.0,9210,DB00773,Etoposide
,3580943,volume of distribution,"The plasma t1/2 in the IC group of dogs was 1.0 hr, the volume of distribution was 1.7 L/kg and the clearance was 1.5 ml/hr/kg.","Comparison of CNS penetration, tissue distribution, and pharmacology of VP 16-213 by intracarotid and intravenous administration in dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580943/),[l] / [kg],1.7,9211,DB00773,Etoposide
,3580943,clearance,"The plasma t1/2 in the IC group of dogs was 1.0 hr, the volume of distribution was 1.7 L/kg and the clearance was 1.5 ml/hr/kg.","Comparison of CNS penetration, tissue distribution, and pharmacology of VP 16-213 by intracarotid and intravenous administration in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580943/),[ml] / [h·kg],1.5,9212,DB00773,Etoposide
,11473400,limits of detection,"The limits of detection were 200 ng ml(-1) etoposide and 10 ng ml(-1) catechol metabolite in human plasma and 25 ng ml(-1) etoposide and 2.5 ng ml(-1) catechol metabolite in protein-free plasma, respectively.",Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473400/),[ng] / [ml],200,9559,DB00773,Etoposide
,11473400,limits of detection,"The limits of detection were 200 ng ml(-1) etoposide and 10 ng ml(-1) catechol metabolite in human plasma and 25 ng ml(-1) etoposide and 2.5 ng ml(-1) catechol metabolite in protein-free plasma, respectively.",Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473400/),[ng] / [ml],10,9560,DB00773,Etoposide
,11473400,limits of detection,"The limits of detection were 200 ng ml(-1) etoposide and 10 ng ml(-1) catechol metabolite in human plasma and 25 ng ml(-1) etoposide and 2.5 ng ml(-1) catechol metabolite in protein-free plasma, respectively.",Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473400/),[ng] / [ml],25,9561,DB00773,Etoposide
,11473400,limits of detection,"The limits of detection were 200 ng ml(-1) etoposide and 10 ng ml(-1) catechol metabolite in human plasma and 25 ng ml(-1) etoposide and 2.5 ng ml(-1) catechol metabolite in protein-free plasma, respectively.",Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473400/),[ng] / [ml],2.5,9562,DB00773,Etoposide
,20920295,AUC₀₋₇,"Mean AUC₀₋₇ (days) was 155.9 versus 152.4 mg*h/mL for Prolastin-C and Prolastin, respectively.",Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920295/),[h·mg] / [ml],155.9,10708,DB00773,Etoposide
,20920295,AUC₀₋₇,"Mean AUC₀₋₇ (days) was 155.9 versus 152.4 mg*h/mL for Prolastin-C and Prolastin, respectively.",Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920295/),[h·mg] / [ml],152.4,10709,DB00773,Etoposide
,24499798,plasma protein binding,Etoposide possess high plasma protein binding (97 percent) and is degraded via complex metabolic pathways.,Pharmaceutical and pharmacological approaches for bioavailability enhancement of etoposide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24499798/),%,97,11152,DB00773,Etoposide
,29980894,MTD,"The MTD was 25 mg/day, increasing to 40 mg/day with G-CSF.","A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29980894/),[mg] / [d],25,11966,DB00773,Etoposide
,29980894,MTD,"The MTD was 25 mg/day, increasing to 40 mg/day with G-CSF.","A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29980894/),[mg] / [d],40,11967,DB00773,Etoposide
,29980894,duration of response,"During dose expansion, 3/29 (10.3%, 95% CI: 2.0%-28.0%) evaluable patients with ovarian cancer experienced partial response by central imaging per RECIST 1.1; median duration of response was 24.1 weeks (95% CI: 16.1-34.1).","A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29980894/),weeks,24.1,11968,DB00773,Etoposide
,17315145,AUC,"However, orally administered morin (15 mg/kg) significantly increased the AUC (45.8%), C(max) (32.0%) and the absolute bioavailability (35.9%) of orally administered etoposide compared with the control, which could be mainly due to inhibition of CYP isoenzyme and P-gp in the intestine by morin.",Effects of morin on the pharmacokinetics of etoposide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315145/),%,45.8,11972,DB00773,Etoposide
,17315145,C(max),"However, orally administered morin (15 mg/kg) significantly increased the AUC (45.8%), C(max) (32.0%) and the absolute bioavailability (35.9%) of orally administered etoposide compared with the control, which could be mainly due to inhibition of CYP isoenzyme and P-gp in the intestine by morin.",Effects of morin on the pharmacokinetics of etoposide in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315145/),%,32.0,11973,DB00773,Etoposide
,17315145,absolute bioavailability,"However, orally administered morin (15 mg/kg) significantly increased the AUC (45.8%), C(max) (32.0%) and the absolute bioavailability (35.9%) of orally administered etoposide compared with the control, which could be mainly due to inhibition of CYP isoenzyme and P-gp in the intestine by morin.",Effects of morin on the pharmacokinetics of etoposide in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315145/),%,35.9,11974,DB00773,Etoposide
,9835899,Css plasma concentrations,"The Css plasma concentrations of ara-C and ara-U averaged 10.33 +/- 0.81 microM and 139.14 +/- 17.8 microM, respectively.",Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9835899/),μM,10.33,12079,DB00773,Etoposide
,9835899,Css plasma concentrations,"The Css plasma concentrations of ara-C and ara-U averaged 10.33 +/- 0.81 microM and 139.14 +/- 17.8 microM, respectively.",Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9835899/),μM,139.14,12080,DB00773,Etoposide
,8603456,AUC,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[min·μg] / [ml],334,13160,DB00773,Etoposide
,8603456,AUC,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[min·μg] / [ml],1540,13161,DB00773,Etoposide
,8603456,total clearance,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[ml] / [min],4.8,13162,DB00773,Etoposide
,8603456,total clearance,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[ml] / [min],1.1,13163,DB00773,Etoposide
,8603456,biliary clearance,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[ml] / [min],2.6,13164,DB00773,Etoposide
,8603456,biliary clearance,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[ml] / [min],0.5,13165,DB00773,Etoposide
,8603456,elimination half-life,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),min,62,13166,DB00773,Etoposide
,8603456,elimination half-life,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),min,40,13167,DB00773,Etoposide
,8603456,volume of distribution,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),ml,424,13168,DB00773,Etoposide
,8603456,volume of distribution,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),ml,65,13169,DB00773,Etoposide
,24037992,area under the plasma concentration-time curve,"The plasma concentration of free platinum at the end of the infusion was 31,000 ng/ml, and the area under the plasma concentration-time curve was 2.9 minute·mg/ml.",Carboplatin pharmacokinetics in a patient receiving hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24037992/),[mg·min] / [ml],2.9,14540,DB00773,Etoposide
>,7628187,t,"Degree of neutropenia was best predicted by the estimated duration that steady-state plasma etoposide concentrations were maintained above 1 microgram/ml (t > 1 microgram/ml) rather than peak plasma concentrations, AUC(0-8hr), dosage, or other patient characteristics.",Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628187/),[μg] / [ml],1,16844,DB00773,Etoposide
,7628187,bioavailability,"Assuming a bioavailability of the oral solution of approximately 50%, the median etoposide systemic clearance was 21.4 ml/min/m2, a value similar to clearance estimates after intravenous etoposide in pediatric populations.",Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628187/),%,50,16845,DB00773,Etoposide
,7628187,systemic clearance,"Assuming a bioavailability of the oral solution of approximately 50%, the median etoposide systemic clearance was 21.4 ml/min/m2, a value similar to clearance estimates after intravenous etoposide in pediatric populations.",Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628187/),[ml] / [m2·min],21.4,16846,DB00773,Etoposide
>,7628187,t,We conclude that a parameter reflective of etoposide systemic exposure (t > 1 microgram/ml) correlates more strongly with neutropenia than does dosage or other patient characteristics.,Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628187/),[μg] / [ml],1,16847,DB00773,Etoposide
,26875154,unbound cisplatin plasma concentrations,"Treatment of a child aged 2 weeks with a recommended cisplatin dose reduction for weight to 1.8 mg/kg resulted in achievement of unbound cisplatin plasma concentrations of 0.01-0.08 µg/mL, markedly lower than exposures previously reported in infants and older children.",Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26875154/),[μg] / [ml],0.01-0.08,17294,DB00773,Etoposide
,2981622,terminal half-life,"The drug disappeared from plasma biexponentially, with a terminal half-life of 4.1 +/- 0.4 hours, an apparent volume of distribution of 9 +/- 1.1 L/m2, and clearance of 21.5 +/- 3.1 ml/minute/m2.",Pharmacokinetics of etoposide in gestochoriocarcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2981622/),h,4.1,17671,DB00773,Etoposide
,2981622,apparent volume of distribution,"The drug disappeared from plasma biexponentially, with a terminal half-life of 4.1 +/- 0.4 hours, an apparent volume of distribution of 9 +/- 1.1 L/m2, and clearance of 21.5 +/- 3.1 ml/minute/m2.",Pharmacokinetics of etoposide in gestochoriocarcinoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2981622/),[l] / [m2],9,17672,DB00773,Etoposide
,2981622,clearance,"The drug disappeared from plasma biexponentially, with a terminal half-life of 4.1 +/- 0.4 hours, an apparent volume of distribution of 9 +/- 1.1 L/m2, and clearance of 21.5 +/- 3.1 ml/minute/m2.",Pharmacokinetics of etoposide in gestochoriocarcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2981622/),[ml] / [m2·min],21.5,17673,DB00773,Etoposide
,6539169,alpha-phase half-life,"The alpha-phase half-life, beta-phase half-life, volume of distribution, and elimination rate constant averaged 0.82 hr, 6.5 hr, 4.0 liters/sq m, and 0.25 hr-1, respectively.",Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6539169/),h,0.82,17989,DB00773,Etoposide
,6539169,beta-phase half-life,"The alpha-phase half-life, beta-phase half-life, volume of distribution, and elimination rate constant averaged 0.82 hr, 6.5 hr, 4.0 liters/sq m, and 0.25 hr-1, respectively.",Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6539169/),h,6.5,17990,DB00773,Etoposide
,6539169,beta-phase half-life,"The alpha-phase half-life, beta-phase half-life, volume of distribution, and elimination rate constant averaged 0.82 hr, 6.5 hr, 4.0 liters/sq m, and 0.25 hr-1, respectively.",Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6539169/),[l] / [m·sq],4.0,17991,DB00773,Etoposide
,6539169,volume of distribution,"The alpha-phase half-life, beta-phase half-life, volume of distribution, and elimination rate constant averaged 0.82 hr, 6.5 hr, 4.0 liters/sq m, and 0.25 hr-1, respectively.",Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6539169/),h,6.5,17992,DB00773,Etoposide
,6539169,volume of distribution,"The alpha-phase half-life, beta-phase half-life, volume of distribution, and elimination rate constant averaged 0.82 hr, 6.5 hr, 4.0 liters/sq m, and 0.25 hr-1, respectively.",Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6539169/),[l] / [m·sq],4.0,17993,DB00773,Etoposide
,6539169,elimination rate constant,"The alpha-phase half-life, beta-phase half-life, volume of distribution, and elimination rate constant averaged 0.82 hr, 6.5 hr, 4.0 liters/sq m, and 0.25 hr-1, respectively.",Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6539169/),1/[h],0.25,17994,DB00773,Etoposide
,6539169,systemic clearance,"Noncompartmental parameters such as systemic clearance, mean residence time, and volume of distribution at steady-state averaged 20.9 ml/min/sq m, 7.8 hr, and 7.2 liters/sq m, respectively.",Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6539169/),[ml] / [m·min·sq],20.9,17995,DB00773,Etoposide
,6539169,mean residence time,"Noncompartmental parameters such as systemic clearance, mean residence time, and volume of distribution at steady-state averaged 20.9 ml/min/sq m, 7.8 hr, and 7.2 liters/sq m, respectively.",Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6539169/),h,7.8,17996,DB00773,Etoposide
,6539169,volume of distribution at steady-state,"Noncompartmental parameters such as systemic clearance, mean residence time, and volume of distribution at steady-state averaged 20.9 ml/min/sq m, 7.8 hr, and 7.2 liters/sq m, respectively.",Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6539169/),[l] / [m·sq],7.2,17997,DB00773,Etoposide
,17579865,peak plasma level,Mean peak plasma level after intravenous etoposide was significantly higher compared to oral administration (16.3+/-3.7 vs. 12.0+/-4.2 microg/ml; P=0.015).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[μg] / [ml],16.3,19185,DB00773,Etoposide
,17579865,peak plasma level,Mean peak plasma level after intravenous etoposide was significantly higher compared to oral administration (16.3+/-3.7 vs. 12.0+/-4.2 microg/ml; P=0.015).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[μg] / [ml],12.0,19186,DB00773,Etoposide
,17579865,bioavailability,The mean bioavailability of oral etoposide was 58+/-15% with an interpatient variability of 26%.,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,58,19187,DB00773,Etoposide
,17579865,AUC,Mean AUC after a 100 mg/m2 intravenous and a 200 mg/m2 oral dose of etoposide were 74.0+/-18.3 and 84.9+/-29.6 microg h/ml (P=0.481).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[h·μg] / [ml],74.0,19188,DB00773,Etoposide
,17579865,AUC,Mean AUC after a 100 mg/m2 intravenous and a 200 mg/m2 oral dose of etoposide were 74.0+/-18.3 and 84.9+/-29.6 microg h/ml (P=0.481).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[h·μg] / [ml],84.9,19189,DB00773,Etoposide
,17579865,excretion,Urinary etoposide excretion as percentage of administered dose was 39.4+/-10.6% after intravenous infusion versus 35.4+/-9.4% after oral intake (P=0.422).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,39.4,19190,DB00773,Etoposide
,17579865,excretion,Urinary etoposide excretion as percentage of administered dose was 39.4+/-10.6% after intravenous infusion versus 35.4+/-9.4% after oral intake (P=0.422).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,35.4,19191,DB00773,Etoposide
,17579865,Renal clearance,Renal clearance was also very similar with intravenous and oral route (18.5+/-7.4 vs. 16.7+/-6.6 ml/min; P=0.546).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[ml] / [min],18.5,19192,DB00773,Etoposide
,17579865,Renal clearance,Renal clearance was also very similar with intravenous and oral route (18.5+/-7.4 vs. 16.7+/-6.6 ml/min; P=0.546).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[ml] / [min],16.7,19193,DB00773,Etoposide
,10587290,apparent bioavailability',"Despite an 'apparent bioavailability' of 59%, oral administration of ETO was associated with the same time of exposure to a predefined 'therapeutic range' of 0.5-3 mg/l and a significantly higher pAUC compared to i.v. administration.",Population pharmacokinetic approach to compare oral and i.v. administration of etoposide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587290/),%,59,19784,DB00773,Etoposide
,9443640,clearance,"On day 1, the median PIXY321 clearance was 657 ml/min per m2 (range 77 1804 ml/min per m2) and the median half-life was 3.7 h (range 2.1-20.8 h).",Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443640/),[ml] / [m2·min],657,19999,DB00773,Etoposide
,9443640,half-life,"On day 1, the median PIXY321 clearance was 657 ml/min per m2 (range 77 1804 ml/min per m2) and the median half-life was 3.7 h (range 2.1-20.8 h).",Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443640/),h,3.7,20000,DB00773,Etoposide
<,9443640,Maximum concentrations,"Maximum concentrations were < 1 ng/ml in 81% of patients, and only two patients had maximum plasma concentrations equivalent to those required for consistent activity in vitro.",Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443640/),[ng] / [ml],1,20001,DB00773,Etoposide
,1929451,T 1/2 beta,T 1/2 beta was 11.29 hours.,[Pharmacokinetic study of etoposide in aged patient with non Hodgkin lymphoma receiving hemodialysis]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929451/),h,11.29,20103,DB00773,Etoposide
,1929451,Total body clearance,Total body clearance was 13.65 mg/min/m2 on day 1 and 12.83 mg/min/m2 on day 3 respectively.,[Pharmacokinetic study of etoposide in aged patient with non Hodgkin lymphoma receiving hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929451/),[mg] / [m2·min],13.65,20104,DB00773,Etoposide
,1929451,Total body clearance,Total body clearance was 13.65 mg/min/m2 on day 1 and 12.83 mg/min/m2 on day 3 respectively.,[Pharmacokinetic study of etoposide in aged patient with non Hodgkin lymphoma receiving hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929451/),[mg] / [m2·min],12.83,20105,DB00773,Etoposide
,1929451,AUC,AUC was 41.53 micrograms.h/ml on day 1 and 44.18 micrograms.h/ml on day 3 respectively.,[Pharmacokinetic study of etoposide in aged patient with non Hodgkin lymphoma receiving hemodialysis]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929451/),[h·μg] / [ml],41.53,20106,DB00773,Etoposide
,1929451,AUC,AUC was 41.53 micrograms.h/ml on day 1 and 44.18 micrograms.h/ml on day 3 respectively.,[Pharmacokinetic study of etoposide in aged patient with non Hodgkin lymphoma receiving hemodialysis]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1929451/),[h·μg] / [ml],44.18,20107,DB00773,Etoposide
,30512187,AUC1,"The mean AUC1 was 7.20 ± 1.48 mg • h/L, which ranged from 4.70 to 9.46 mg • h/L.",Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[h·mg] / [l],7.20,20380,DB00773,Etoposide
below,30512187,AUC1,The AUC1 was below the therapeutic concentration of 7.38 mg • h/L in 45% (9 of 20) of the patients.,Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[h·mg] / [l],7.38,20381,DB00773,Etoposide
,30512187,CLT,The CLT of 3.05 ± 0.56 mL/min/kg was not significantly different with the CL1 of 3.03 ± 0.69 mL/min/kg (P = .901).,Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[ml] / [kg·min],3.05,20382,DB00773,Etoposide
,30512187,CL1,The CLT of 3.05 ± 0.56 mL/min/kg was not significantly different with the CL1 of 3.03 ± 0.69 mL/min/kg (P = .901).,Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30512187/),[ml] / [kg·min],3.03,20383,DB00773,Etoposide
,12560443,duration,"In addition, the mean duration of grade 4 neutropenia was similar in both groups (2.8 and 2.4 days, respectively).","Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12560443/),d,2.8,20431,DB00773,Etoposide
,12560443,duration,"In addition, the mean duration of grade 4 neutropenia was similar in both groups (2.8 and 2.4 days, respectively).","Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12560443/),d,2.4,20432,DB00773,Etoposide
,8765435,Peak plasma concentrations,Peak plasma concentrations occurred between 1 and 4.1 h postdosing and averaged 1.56 mg/l for the trans-isomer and 1.10 mg/l for cis isomer.,Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765435/),[mg] / [l],1.56,20781,DB00773,Etoposide
,8765435,Peak plasma concentrations,Peak plasma concentrations occurred between 1 and 4.1 h postdosing and averaged 1.56 mg/l for the trans-isomer and 1.10 mg/l for cis isomer.,Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765435/),[mg] / [l],1.10,20782,DB00773,Etoposide
,8765435,Plasma half-lives,"Plasma half-lives of the metabolites were 3.1 h (range 1.1-4.5 h) for the trans-isomer and 3.5 h (range 1.3-6.4 h) for the cis- isomer, and varied linearly with increasing patient body weight.",Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765435/),h,3.1,20783,DB00773,Etoposide
,8765435,Plasma half-lives,"Plasma half-lives of the metabolites were 3.1 h (range 1.1-4.5 h) for the trans-isomer and 3.5 h (range 1.3-6.4 h) for the cis- isomer, and varied linearly with increasing patient body weight.",Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765435/),h,3.5,20784,DB00773,Etoposide
,8070033,response rates,The response rates of patients with small-cell lung cancer receiving a 24-h infusion was only 10% as compared with 89% when the same dose was given over 5 days.,Schedule-dependent topoisomerase II-inhibiting drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070033/),%,10,23294,DB00773,Etoposide
,8070033,response rates,The response rates of patients with small-cell lung cancer receiving a 24-h infusion was only 10% as compared with 89% when the same dose was given over 5 days.,Schedule-dependent topoisomerase II-inhibiting drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070033/),%,89,23295,DB00773,Etoposide
,25603122,bioavailability,"The modification of compounds 8 and 22 with the introduction of a methoxy instead of a hydroxy group enhanced endogenous topo inhibitory activity, metabolic stability in diverse types of liver microsomes and improved pharmacokinetic parameters in rat plasma such as augmentation of bioavailability (41.3% and 33.2% for 2-(3-methoxyphenyl)-4-phenylbenzofuro[3,2-b]pyridine (8-M) and 3-(4-phenylchromeno[4,3-b]pyridine-2-yl)methoxybenzene (22-M), respectively).",A series of novel terpyridine-skeleton molecule derivants inhibit tumor growth and metastasis by targeting topoisomerases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25603122/),%,41.3,24590,DB00773,Etoposide
,25603122,bioavailability,"The modification of compounds 8 and 22 with the introduction of a methoxy instead of a hydroxy group enhanced endogenous topo inhibitory activity, metabolic stability in diverse types of liver microsomes and improved pharmacokinetic parameters in rat plasma such as augmentation of bioavailability (41.3% and 33.2% for 2-(3-methoxyphenyl)-4-phenylbenzofuro[3,2-b]pyridine (8-M) and 3-(4-phenylchromeno[4,3-b]pyridine-2-yl)methoxybenzene (22-M), respectively).",A series of novel terpyridine-skeleton molecule derivants inhibit tumor growth and metastasis by targeting topoisomerases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25603122/),%,33.2,24591,DB00773,Etoposide
,9081397,Vss,The mean Vss was 0.21 L/kg in the 6-hour group and 0.36 in the 3 x 1-hour group.,The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081397/),[l] / [kg],0.21,24908,DB00773,Etoposide
,9081397,Vss,The mean Vss was 0.21 L/kg in the 6-hour group and 0.36 in the 3 x 1-hour group.,The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081397/),,0.36,24909,DB00773,Etoposide
,9081397,total drug exposure time,The total drug exposure time with plasma levels > 100 ng/ml is significantly longer in the 'split' group (74 vs. 143 h).,The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081397/),h,74,24910,DB00773,Etoposide
,9081397,total drug exposure time,The total drug exposure time with plasma levels > 100 ng/ml is significantly longer in the 'split' group (74 vs. 143 h).,The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081397/),h,143,24911,DB00773,Etoposide
,9081397,Leukocyte recovery,"Leukocyte recovery to WBC levels > 0.2 and > 0.5/nl as well as platelet recovery to stable counts > 50/nl was significantly (p = 0.002, 0.009 and 0.04) prolonged in the 'split' group (3.7 vs. 12.3, 8.3 vs. 14.3 and 25 vs. 35 d).",The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081397/),d,3.7,24912,DB00773,Etoposide
,9081397,Leukocyte recovery,"Leukocyte recovery to WBC levels > 0.2 and > 0.5/nl as well as platelet recovery to stable counts > 50/nl was significantly (p = 0.002, 0.009 and 0.04) prolonged in the 'split' group (3.7 vs. 12.3, 8.3 vs. 14.3 and 25 vs. 35 d).",The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081397/),d,12.3,24913,DB00773,Etoposide
,9081397,Leukocyte recovery,"Leukocyte recovery to WBC levels > 0.2 and > 0.5/nl as well as platelet recovery to stable counts > 50/nl was significantly (p = 0.002, 0.009 and 0.04) prolonged in the 'split' group (3.7 vs. 12.3, 8.3 vs. 14.3 and 25 vs. 35 d).",The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081397/),d,8.3,24914,DB00773,Etoposide
,9081397,Leukocyte recovery,"Leukocyte recovery to WBC levels > 0.2 and > 0.5/nl as well as platelet recovery to stable counts > 50/nl was significantly (p = 0.002, 0.009 and 0.04) prolonged in the 'split' group (3.7 vs. 12.3, 8.3 vs. 14.3 and 25 vs. 35 d).",The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081397/),d,14.3,24915,DB00773,Etoposide
,9081397,Leukocyte recovery,"Leukocyte recovery to WBC levels > 0.2 and > 0.5/nl as well as platelet recovery to stable counts > 50/nl was significantly (p = 0.002, 0.009 and 0.04) prolonged in the 'split' group (3.7 vs. 12.3, 8.3 vs. 14.3 and 25 vs. 35 d).",The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081397/),d,25,24916,DB00773,Etoposide
,9081397,Leukocyte recovery,"Leukocyte recovery to WBC levels > 0.2 and > 0.5/nl as well as platelet recovery to stable counts > 50/nl was significantly (p = 0.002, 0.009 and 0.04) prolonged in the 'split' group (3.7 vs. 12.3, 8.3 vs. 14.3 and 25 vs. 35 d).",The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081397/),d,35,24917,DB00773,Etoposide
,9081397,peak levels,The liver toxicity as indicated by bilirubin peak levels was significantly (p = 0.02) more severe in the 'split' group (1.7 vs. 5.4 mg/dl).,The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081397/),mg,1.7,24918,DB00773,Etoposide
,9081397,peak levels,The liver toxicity as indicated by bilirubin peak levels was significantly (p = 0.02) more severe in the 'split' group (1.7 vs. 5.4 mg/dl).,The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081397/),mg,5.4,24919,DB00773,Etoposide
,12172704,AUC (0-24 h,"Following administration of 210+/-29, 278+/-41, 1143+/-79 and 1143+/-79 mg ETO, the AUC (0-24 h, normalized to 150 mg/m(2)) was 123+/-23, 113+/-22, 92+/-11 and 100+/-22 microgxh/ml.",Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172704/),[h·μg] / [ml],123,25813,DB00773,Etoposide
,12172704,AUC (0-24 h,"Following administration of 210+/-29, 278+/-41, 1143+/-79 and 1143+/-79 mg ETO, the AUC (0-24 h, normalized to 150 mg/m(2)) was 123+/-23, 113+/-22, 92+/-11 and 100+/-22 microgxh/ml.",Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172704/),[h·μg] / [ml],113,25814,DB00773,Etoposide
,12172704,AUC (0-24 h,"Following administration of 210+/-29, 278+/-41, 1143+/-79 and 1143+/-79 mg ETO, the AUC (0-24 h, normalized to 150 mg/m(2)) was 123+/-23, 113+/-22, 92+/-11 and 100+/-22 microgxh/ml.",Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172704/),[h·μg] / [ml],92,25815,DB00773,Etoposide
,12172704,AUC (0-24 h,"Following administration of 210+/-29, 278+/-41, 1143+/-79 and 1143+/-79 mg ETO, the AUC (0-24 h, normalized to 150 mg/m(2)) was 123+/-23, 113+/-22, 92+/-11 and 100+/-22 microgxh/ml.",Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172704/),[h·μg] / [ml],100,25816,DB00773,Etoposide
,9400949,terminal half-life,Post-infusion total plasma levels of topotecan declined in a biphasic manner with a terminal half-life of 2.1 +/- 0.3 h.,Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9400949/),h,2.1,26220,DB00773,Etoposide
,9400949,Total body clearance,Total body clearance was 13.8 +/- 2.7 l h-1 m-2 with a steady-state volume of distribution of 36.7 +/- 6.2 l m-2.,Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9400949/),[l] / [(m)^2·h],13.8,26221,DB00773,Etoposide
,9400949,steady-state volume of distribution,Total body clearance was 13.8 +/- 2.7 l h-1 m-2 with a steady-state volume of distribution of 36.7 +/- 6.2 l m-2.,Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9400949/),[l] / [(m)^2],36.7,26222,DB00773,Etoposide
,9400949,maximal concentrations,"Mean maximal concentrations ranged from 0.23 to 0.53 nmol l-1, and were reached at 3.4 +/- 1.0 h after infusion.",Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9400949/),[nM] / [l],0.23 to 0.53,26223,DB00773,Etoposide
,9400949,Maximal etoposide plasma concentrations,Maximal etoposide plasma concentrations of 0.75 +/- 0.54 and 1.23 +/- 0.57 micromol l-1 were reached at 2.4 +/- 1.2 and 2.3 +/- 1.0 h after ingestion of 20 and 40 mg respectively.,Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9400949/),[μM] / [l],0.75,26224,DB00773,Etoposide
,9400949,Maximal etoposide plasma concentrations,Maximal etoposide plasma concentrations of 0.75 +/- 0.54 and 1.23 +/- 0.57 micromol l-1 were reached at 2.4 +/- 1.2 and 2.3 +/- 1.0 h after ingestion of 20 and 40 mg respectively.,Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9400949/),[μM] / [l],1.23,26225,DB00773,Etoposide
,7521905,beta half-life,"Elimination of CPT-11 was biphasic, with a mean +/- SD beta half-life of 18.17 +/- 9.09 hours.",Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7521905/),h,18.17,27007,DB00773,Etoposide
,7521905,terminal half-life,The mean terminal half-life of 7-ethyl-10-hydroxycamptothecin (SN-38; the major metabolite of CPT-11) was 43.40 +/- 37.84 hours.,Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7521905/),h,43.40,27008,DB00773,Etoposide
,7521905,overall response rate,"There was one complete response (5%) and eight partial responses (38%) among 21 assessable patients, for an overall response rate of 43%.",Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7521905/),%,43,27009,DB00773,Etoposide
,7521905,response rates,"The response rates for small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) were 58% (seven of 12 patients) and 22% (two of nine patients), respectively.",Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7521905/),%,58,27010,DB00773,Etoposide
,7521905,response rates,"The response rates for small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) were 58% (seven of 12 patients) and 22% (two of nine patients), respectively.",Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7521905/),%,22,27011,DB00773,Etoposide
,1540981,IC50,Etoposide (IC50 22 microM) was 100 times more toxic than etoposide-P (20% growth inhibition at 200 microM).,Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540981/),μM,22,29042,DB00773,Etoposide
,1540981,IC50,Pretreatment of the cells with BW431/26-AP prior to etoposide-P exposure resulted in a dramatic increase in cytotoxicity (IC50 70 microM).,Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540981/),μM,70,29043,DB00773,Etoposide
,2220657,oral bioavailability,The oral bioavailability of etoposide was 21% and 36% in the two patients who had had prior gastrectomy.,"Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2220657/),%,21,30030,DB00773,Etoposide
,2220657,oral bioavailability,The oral bioavailability of etoposide was 21% and 36% in the two patients who had had prior gastrectomy.,"Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2220657/),%,36,30031,DB00773,Etoposide
,8220130,Plas,Plasma protein binding of etoposide is extensive (94%) and alterations of the non-proteinbound fraction affect pharmacokinetic behavior of the drug.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),%,94,30213,DB00773,Etoposide
,8220130,area under the concentration versus time curve AUC(0-infinity),The mean area under the concentration versus time curve AUC(0-infinity) in plasma was at the lower dose level 78.4 +/- 29.1 (mean +/- S.D.) micrograms/ml x h and 201.0 +/- 56.5 micrograms/ml x h at the higher dose level.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),[μg] / [h·ml],78.4,30214,DB00773,Etoposide
,8220130,area under the concentration versus time curve AUC(0-infinity),The mean area under the concentration versus time curve AUC(0-infinity) in plasma was at the lower dose level 78.4 +/- 29.1 (mean +/- S.D.) micrograms/ml x h and 201.0 +/- 56.5 micrograms/ml x h at the higher dose level.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),[μg] / [h·ml],201.0,30215,DB00773,Etoposide
,8220130,fraction of non-proteinbound,The fraction of non-proteinbound etoposide in plasma was 5.2 +/- 3.4 and 5.4 +/- 2.1% in the two treatment groups.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),%,5.2,30216,DB00773,Etoposide
,8220130,fraction of non-proteinbound,The fraction of non-proteinbound etoposide in plasma was 5.2 +/- 3.4 and 5.4 +/- 2.1% in the two treatment groups.,In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),%,5.4,30217,DB00773,Etoposide
,8220130,AUC(0-16h),"AUC(0-16h) in leukemic cells was 8.4 +/- 8.7 and 22.4 +/- 12.1 micrograms/ml x h at the two dose levels, respectively.",In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),[μg] / [h·ml],8.4,30218,DB00773,Etoposide
,8220130,AUC(0-16h),"AUC(0-16h) in leukemic cells was 8.4 +/- 8.7 and 22.4 +/- 12.1 micrograms/ml x h at the two dose levels, respectively.",In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220130/),[μg] / [h·ml],22.4,30219,DB00773,Etoposide
,11023708,area under the concentration vs time curve,Encapsulation in cationic liposomes increased the area under the concentration vs time curve to 42.98 microghml(-1)from 24.18 microghml(-1)in the case of the free drug.,Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11023708/),1/[μghml],42.98,30881,DB00773,Etoposide
,11023708,area under the concentration vs time curve,Encapsulation in cationic liposomes increased the area under the concentration vs time curve to 42.98 microghml(-1)from 24.18 microghml(-1)in the case of the free drug.,Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11023708/),1/[μghml],24.18,30882,DB00773,Etoposide
,11023708,Half-life (beta),Half-life (beta) was 58.,Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11023708/),,58,30883,DB00773,Etoposide
,23192689,flow rate,"The chromatographic separation was carried out on a Gemini C18 column with a mixture of methanol (A) and water (B) (0~5 min, volume of A was 45-50%, 5~10 min, volume of A was 50-90%) used as mobile phase at a flow rate of 0.4 ml/min.",Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192689/),[ml] / [min],0.4,31357,DB00773,Etoposide
,23192689,T1/2,"Etoposide nanoparticles and injection pharmacokinetic parameters were as follows: T1/2, 2.26 (0.71) and 1.74 (0.43) h;Cmax, 13.24 (5.32) and 8.12 (3.61) µg/ml; AUC0-t, 41.32 (7.33) and 16.53 (4.12) µg · ml - 1 · h; AUC0-∞, 49.54 (9.62) and 19.64 (8.22) µg · ml - 1 · h; MRT, 3.13 (0.54) and 2.06 (0.33) h and CL 7.35 (1.53) and 12.61 (2.22), respectively.",Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192689/),h,2.26,31358,DB00773,Etoposide
,23192689,T1/2,"Etoposide nanoparticles and injection pharmacokinetic parameters were as follows: T1/2, 2.26 (0.71) and 1.74 (0.43) h;Cmax, 13.24 (5.32) and 8.12 (3.61) µg/ml; AUC0-t, 41.32 (7.33) and 16.53 (4.12) µg · ml - 1 · h; AUC0-∞, 49.54 (9.62) and 19.64 (8.22) µg · ml - 1 · h; MRT, 3.13 (0.54) and 2.06 (0.33) h and CL 7.35 (1.53) and 12.61 (2.22), respectively.",Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192689/),h,1.74,31359,DB00773,Etoposide
,23192689,Cmax,"Etoposide nanoparticles and injection pharmacokinetic parameters were as follows: T1/2, 2.26 (0.71) and 1.74 (0.43) h;Cmax, 13.24 (5.32) and 8.12 (3.61) µg/ml; AUC0-t, 41.32 (7.33) and 16.53 (4.12) µg · ml - 1 · h; AUC0-∞, 49.54 (9.62) and 19.64 (8.22) µg · ml - 1 · h; MRT, 3.13 (0.54) and 2.06 (0.33) h and CL 7.35 (1.53) and 12.61 (2.22), respectively.",Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192689/),[μg] / [ml],13.24,31360,DB00773,Etoposide
,23192689,Cmax,"Etoposide nanoparticles and injection pharmacokinetic parameters were as follows: T1/2, 2.26 (0.71) and 1.74 (0.43) h;Cmax, 13.24 (5.32) and 8.12 (3.61) µg/ml; AUC0-t, 41.32 (7.33) and 16.53 (4.12) µg · ml - 1 · h; AUC0-∞, 49.54 (9.62) and 19.64 (8.22) µg · ml - 1 · h; MRT, 3.13 (0.54) and 2.06 (0.33) h and CL 7.35 (1.53) and 12.61 (2.22), respectively.",Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192689/),[μg] / [ml],8.12,31361,DB00773,Etoposide
,23192689,AUC0-t,"Etoposide nanoparticles and injection pharmacokinetic parameters were as follows: T1/2, 2.26 (0.71) and 1.74 (0.43) h;Cmax, 13.24 (5.32) and 8.12 (3.61) µg/ml; AUC0-t, 41.32 (7.33) and 16.53 (4.12) µg · ml - 1 · h; AUC0-∞, 49.54 (9.62) and 19.64 (8.22) µg · ml - 1 · h; MRT, 3.13 (0.54) and 2.06 (0.33) h and CL 7.35 (1.53) and 12.61 (2.22), respectively.",Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192689/),-·1·h·ml·μg,41.32,31362,DB00773,Etoposide
,23192689,AUC0-t,"Etoposide nanoparticles and injection pharmacokinetic parameters were as follows: T1/2, 2.26 (0.71) and 1.74 (0.43) h;Cmax, 13.24 (5.32) and 8.12 (3.61) µg/ml; AUC0-t, 41.32 (7.33) and 16.53 (4.12) µg · ml - 1 · h; AUC0-∞, 49.54 (9.62) and 19.64 (8.22) µg · ml - 1 · h; MRT, 3.13 (0.54) and 2.06 (0.33) h and CL 7.35 (1.53) and 12.61 (2.22), respectively.",Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192689/),-·1·h·ml·μg,16.53,31363,DB00773,Etoposide
,23192689,AUC0-∞,"Etoposide nanoparticles and injection pharmacokinetic parameters were as follows: T1/2, 2.26 (0.71) and 1.74 (0.43) h;Cmax, 13.24 (5.32) and 8.12 (3.61) µg/ml; AUC0-t, 41.32 (7.33) and 16.53 (4.12) µg · ml - 1 · h; AUC0-∞, 49.54 (9.62) and 19.64 (8.22) µg · ml - 1 · h; MRT, 3.13 (0.54) and 2.06 (0.33) h and CL 7.35 (1.53) and 12.61 (2.22), respectively.",Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192689/),-·1·h·ml·μg,49.54,31364,DB00773,Etoposide
,23192689,AUC0-∞,"Etoposide nanoparticles and injection pharmacokinetic parameters were as follows: T1/2, 2.26 (0.71) and 1.74 (0.43) h;Cmax, 13.24 (5.32) and 8.12 (3.61) µg/ml; AUC0-t, 41.32 (7.33) and 16.53 (4.12) µg · ml - 1 · h; AUC0-∞, 49.54 (9.62) and 19.64 (8.22) µg · ml - 1 · h; MRT, 3.13 (0.54) and 2.06 (0.33) h and CL 7.35 (1.53) and 12.61 (2.22), respectively.",Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192689/),-·1·h·ml·μg,19.64,31365,DB00773,Etoposide
,23192689,MRT,"Etoposide nanoparticles and injection pharmacokinetic parameters were as follows: T1/2, 2.26 (0.71) and 1.74 (0.43) h;Cmax, 13.24 (5.32) and 8.12 (3.61) µg/ml; AUC0-t, 41.32 (7.33) and 16.53 (4.12) µg · ml - 1 · h; AUC0-∞, 49.54 (9.62) and 19.64 (8.22) µg · ml - 1 · h; MRT, 3.13 (0.54) and 2.06 (0.33) h and CL 7.35 (1.53) and 12.61 (2.22), respectively.",Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192689/),h,3.13,31366,DB00773,Etoposide
,23192689,MRT,"Etoposide nanoparticles and injection pharmacokinetic parameters were as follows: T1/2, 2.26 (0.71) and 1.74 (0.43) h;Cmax, 13.24 (5.32) and 8.12 (3.61) µg/ml; AUC0-t, 41.32 (7.33) and 16.53 (4.12) µg · ml - 1 · h; AUC0-∞, 49.54 (9.62) and 19.64 (8.22) µg · ml - 1 · h; MRT, 3.13 (0.54) and 2.06 (0.33) h and CL 7.35 (1.53) and 12.61 (2.22), respectively.",Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192689/),h,2.06,31367,DB00773,Etoposide
,23192689,CL,"Etoposide nanoparticles and injection pharmacokinetic parameters were as follows: T1/2, 2.26 (0.71) and 1.74 (0.43) h;Cmax, 13.24 (5.32) and 8.12 (3.61) µg/ml; AUC0-t, 41.32 (7.33) and 16.53 (4.12) µg · ml - 1 · h; AUC0-∞, 49.54 (9.62) and 19.64 (8.22) µg · ml - 1 · h; MRT, 3.13 (0.54) and 2.06 (0.33) h and CL 7.35 (1.53) and 12.61 (2.22), respectively.",Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192689/),,7.35,31368,DB00773,Etoposide
,23192689,CL,"Etoposide nanoparticles and injection pharmacokinetic parameters were as follows: T1/2, 2.26 (0.71) and 1.74 (0.43) h;Cmax, 13.24 (5.32) and 8.12 (3.61) µg/ml; AUC0-t, 41.32 (7.33) and 16.53 (4.12) µg · ml - 1 · h; AUC0-∞, 49.54 (9.62) and 19.64 (8.22) µg · ml - 1 · h; MRT, 3.13 (0.54) and 2.06 (0.33) h and CL 7.35 (1.53) and 12.61 (2.22), respectively.",Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192689/),,12.61,31369,DB00773,Etoposide
,8541103,AUC,"The following model was selected as ""most accurate"": AUC = 343 (min)C4h(micrograms/ml) + 650(min)C8h(micrograms/ml) + 1252 (min micrograms/mol), where C4h is the plasma concentration of etoposide at 4 h after the end of infusion and C8h at 8 h.",Limited sampling models for reliable estimation of etoposide area under the curve. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541103/),,34,31589,DB00773,Etoposide
,8541103,AUC,"The following model was selected as ""most accurate"": AUC = 343 (min)C4h(micrograms/ml) + 650(min)C8h(micrograms/ml) + 1252 (min micrograms/mol), where C4h is the plasma concentration of etoposide at 4 h after the end of infusion and C8h at 8 h.",Limited sampling models for reliable estimation of etoposide area under the curve. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541103/),,650,31590,DB00773,Etoposide
,8541103,AUC,"The following model was selected as ""most accurate"": AUC = 343 (min)C4h(micrograms/ml) + 650(min)C8h(micrograms/ml) + 1252 (min micrograms/mol), where C4h is the plasma concentration of etoposide at 4 h after the end of infusion and C8h at 8 h.",Limited sampling models for reliable estimation of etoposide area under the curve. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541103/),[min·μg] / [mol],1252,31591,DB00773,Etoposide
,21530654,drug entrapment efficiency,"The average drug entrapment efficiency, particle size and zeta potential of VP16-NLCs, VP16-PEG40-St-modified NLCs (VP16-PEG40-NLCs) and VP16-DSPE-PE- modified NLCs (VP16-DSPE-NLCs) were 57.9-89.7%, 125.9-91.2 nm and -28.49 to -15.34 mV, respectively.",Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21530654/),%,57.9-89.7,32313,DB00773,Etoposide
,2009523,dwelling time,"The dwelling time was 4 h, followed by peritoneal drainage.",Phase I pharmacokinetic study of intraperitoneal etoposide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2009523/),h,4,32537,DB00773,Etoposide
,2009523,half-life,"Peritoneal levels over the 4-h dwelling time declined monoexponentially with a harmonic mean half-life of 3.5 h (range, 1.9 to 7.8).",Phase I pharmacokinetic study of intraperitoneal etoposide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2009523/),h,3.5,32538,DB00773,Etoposide
,2009523,terminal half-life,"Plasma levels rose to a peak at 2.9 +/- 1.7 (SD) h and then declined exponentially with a harmonic mean terminal half-life of 7.7 h (range, 4.2 to 15.6).",Phase I pharmacokinetic study of intraperitoneal etoposide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2009523/),h,7.7,32539,DB00773,Etoposide
,2009523,plasma protein binding,"Based on the high plasma protein binding of etoposide (94%) and the minimal protein binding in the fluid instilled i.p., the ratio of the areas under the concentration-time curves of free drug is estimated to be 4%.",Phase I pharmacokinetic study of intraperitoneal etoposide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2009523/),%,94,32540,DB00773,Etoposide
,21506134,50% inhibition concentration (IC(50) ),Curcumin inhibited CYP3A4 enzyme activity with a 50% inhibition concentration (IC(50) ) of 2.7 µM.,Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21506134/),μM,2.7,32959,DB00773,Etoposide
,8708727,objective response rate,"Of 48 patients, none had a complete response and 19 had a partial response, for an objective response rate of 39% (95% confidence interval [CI], 25.2% to 53.0%).",Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708727/),%,39,34898,DB00773,Etoposide
,8708727,response duration,"The median response duration was 4.8 months (95% CI, 3.0 to 7.3).",Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708727/),month,4.8,34899,DB00773,Etoposide
,8708727,overall median survival time,"After a median follow-up duration of 18.2 months, the overall median survival time was 10.0 months (95% CI, 8.2 to 12.7); the 1-year survival rate was 39% (95% CI, 25.2% to 53.0%).",Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708727/),month,10.0,34900,DB00773,Etoposide
,9815952,overall bioavailability,The overall bioavailability of etoposide (mean +/- SD) was 67% +/- 22% and was not affected by fasting.,Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815952/),%,67,35486,DB00773,Etoposide
,9815952,absolute neutrophil count nadir,Neutropenia was dose limiting and of varying degrees (mean +/- SD of absolute neutrophil count nadir at the first cycle: 1.5 +/- 1.2 x 10(3)/microliter).,Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815952/),,1.5,35487,DB00773,Etoposide
,30365396,Cmax,"Similarly, the mean value for Cmax of VP-16 in SNEDDS (1.13± 0.07 µg/ml µg.h/mL) was higher than VePesid® (0.62± 0.09 µg/mL) and drug suspension (0.13± 0.07 µg/mL).",Nano-sized Droplets of Self-Emulsifying System for Enhancing Oral Bioavailability of Chemotherapeutic Agent VP-16 in Rats: A Nano Lipid Carrier for BCS Class IV Drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30365396/),[μg] / [h·ml·ml·μg],1.13,36092,DB00773,Etoposide
,30365396,Cmax,"Similarly, the mean value for Cmax of VP-16 in SNEDDS (1.13± 0.07 µg/ml µg.h/mL) was higher than VePesid® (0.62± 0.09 µg/mL) and drug suspension (0.13± 0.07 µg/mL).",Nano-sized Droplets of Self-Emulsifying System for Enhancing Oral Bioavailability of Chemotherapeutic Agent VP-16 in Rats: A Nano Lipid Carrier for BCS Class IV Drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30365396/),[μg] / [ml],0.62,36093,DB00773,Etoposide
,30365396,Cmax,"Similarly, the mean value for Cmax of VP-16 in SNEDDS (1.13± 0.07 µg/ml µg.h/mL) was higher than VePesid® (0.62± 0.09 µg/mL) and drug suspension (0.13± 0.07 µg/mL).",Nano-sized Droplets of Self-Emulsifying System for Enhancing Oral Bioavailability of Chemotherapeutic Agent VP-16 in Rats: A Nano Lipid Carrier for BCS Class IV Drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30365396/),[μg] / [ml],0.13,36094,DB00773,Etoposide
,14752063,serum clearance half-life,N-acetylcysteine serum clearance half-life was 9 to 11 min.,Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14752063/),min,9 to 11,36319,DB00773,Etoposide
,14752063,tumor volume,Enhanced chemotherapy reduced intracerebral tumor volume to 4.3 +/- 1.0 mm(3) compared with 29.1 +/- 4.1 mm(3) in untreated animals (P < 0.0001).,Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14752063/),mm(3),4.3,36320,DB00773,Etoposide
,14752063,tumor volume,Enhanced chemotherapy reduced intracerebral tumor volume to 4.3 +/- 1.0 mm(3) compared with 29.1 +/- 4.1 mm(3) in untreated animals (P < 0.0001).,Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14752063/),mm(3,29.1,36321,DB00773,Etoposide
,14752063,Tumor volume,Tumor volume was 3.7 +/- 0.6 mm(3) in rats that received N-acetylcysteine before and sodium thiosulfate after chemotherapy.,Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14752063/),mm(3),3.7,36322,DB00773,Etoposide
,10664921,t1/2 beta,"The mean +/- SD values for t1/2 beta, tmax, Cmax, CLTor, and MRT observed following the first oral dose were 8.98 +/- 4.84 h, 1.39 +/- 0.96 h, 0.083 +/- 0.046 mg.L-1/mg.m-2, 1.89 +/- 1.2 L.h-1/m2, and 10.37 +/- 2.76 h, respectively, and those observed following the first intravenous dose were 8.05 +/- 5.11 h, 1.57 +/- 0.17 h, 0.142 +/- 0.043 mg.L-1/mg.m-2, 1.25 +/- 0.44 L.h-1/m2, and 7.69 +/- 1.53 h, respectively.",Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664921/),h,8.98,36683,DB00773,Etoposide
,10664921,MRT,"The mean +/- SD values for t1/2 beta, tmax, Cmax, CLTor, and MRT observed following the first oral dose were 8.98 +/- 4.84 h, 1.39 +/- 0.96 h, 0.083 +/- 0.046 mg.L-1/mg.m-2, 1.89 +/- 1.2 L.h-1/m2, and 10.37 +/- 2.76 h, respectively, and those observed following the first intravenous dose were 8.05 +/- 5.11 h, 1.57 +/- 0.17 h, 0.142 +/- 0.043 mg.L-1/mg.m-2, 1.25 +/- 0.44 L.h-1/m2, and 7.69 +/- 1.53 h, respectively.",Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664921/),h,10.37,36684,DB00773,Etoposide
,10664921,MRT,"The mean +/- SD values for t1/2 beta, tmax, Cmax, CLTor, and MRT observed following the first oral dose were 8.98 +/- 4.84 h, 1.39 +/- 0.96 h, 0.083 +/- 0.046 mg.L-1/mg.m-2, 1.89 +/- 1.2 L.h-1/m2, and 10.37 +/- 2.76 h, respectively, and those observed following the first intravenous dose were 8.05 +/- 5.11 h, 1.57 +/- 0.17 h, 0.142 +/- 0.043 mg.L-1/mg.m-2, 1.25 +/- 0.44 L.h-1/m2, and 7.69 +/- 1.53 h, respectively.",Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664921/),h,8.05,36685,DB00773,Etoposide
,10664921,MRT,"The mean +/- SD values for t1/2 beta, tmax, Cmax, CLTor, and MRT observed following the first oral dose were 8.98 +/- 4.84 h, 1.39 +/- 0.96 h, 0.083 +/- 0.046 mg.L-1/mg.m-2, 1.89 +/- 1.2 L.h-1/m2, and 10.37 +/- 2.76 h, respectively, and those observed following the first intravenous dose were 8.05 +/- 5.11 h, 1.57 +/- 0.17 h, 0.142 +/- 0.043 mg.L-1/mg.m-2, 1.25 +/- 0.44 L.h-1/m2, and 7.69 +/- 1.53 h, respectively.",Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664921/),h,1.57,36686,DB00773,Etoposide
,10664921,MRT,"The mean +/- SD values for t1/2 beta, tmax, Cmax, CLTor, and MRT observed following the first oral dose were 8.98 +/- 4.84 h, 1.39 +/- 0.96 h, 0.083 +/- 0.046 mg.L-1/mg.m-2, 1.89 +/- 1.2 L.h-1/m2, and 10.37 +/- 2.76 h, respectively, and those observed following the first intravenous dose were 8.05 +/- 5.11 h, 1.57 +/- 0.17 h, 0.142 +/- 0.043 mg.L-1/mg.m-2, 1.25 +/- 0.44 L.h-1/m2, and 7.69 +/- 1.53 h, respectively.",Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664921/),[mg] / [(mg·l·m)^2],0.142,36687,DB00773,Etoposide
,10664921,F,The mean +/- SD of F was 0.80 +/- 0.34.,Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664921/),,0.80,36688,DB00773,Etoposide
,8295700,half-lives,"The overall plasma platinum curves were biphasic, with mean half-lives of 35 minutes and 56 hrs.",[Pharmacokinetics of plasma and cerebrospinal fluid cisplatin in patients with malignant glioma and metastatic brain tumor after selective intraarterial or intravenous and intracarotid administration of etoposide and cisplatin]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8295700/),min,35,37494,DB00773,Etoposide
,8295700,half-lives,"The overall plasma platinum curves were biphasic, with mean half-lives of 35 minutes and 56 hrs.",[Pharmacokinetics of plasma and cerebrospinal fluid cisplatin in patients with malignant glioma and metastatic brain tumor after selective intraarterial or intravenous and intracarotid administration of etoposide and cisplatin]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8295700/),h,56,37495,DB00773,Etoposide
,7799020,Cmean,Cmean was 1.1 +/- 0.3 micrograms/mL.,Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799020/),[μg] / [ml],1.1,37759,DB00773,Etoposide
,7799020,Peak concentrations,Peak concentrations ranged from 0.6 to 2.5 micrograms/mL.,Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799020/),[μg] / [ml],0.6 to 2.5,37760,DB00773,Etoposide
> or =,7799020,Cmean,All responders had a Cmean > or = 1.0 microgram/mL.,Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799020/),[μg] / [ml],1.0,37761,DB00773,Etoposide
,11781625,AUC per 6 h,Doses were adjusted to reach a target mean AUC per 6 h between 4 and 6 microg.h.ml(+1).,Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11781625/),h·ml(+1)·μg,4 and 6,38713,DB00773,Etoposide
,8674164,terminal elimination half-life (t1/2 beta),"The calculated pharmacokinetic parameters (mean values +/- SD) were similar after i.v. infusion and HAI, viz., 6.4 +/- 0.7 versus 6.5 +/- 0.2 h for the terminal elimination half-life (t1/2 beta), 98.5 +/- 1.3 versus 101.3 +/- 5.9 mg l(-1) h for the area under the plasma concentration-time curve (AUC), 21.2 +/- 0.3 versus 20.6 +/- 1.2 ml min-1 m-2 for clearance (Cl), 17.7 +/- 1.9 versus 18.1 +/- 2.6 mg/l for the peak concentration, and 11.7 +/- 1.3 versus 11.6 +/- 1.01/m2 for the volume of distribution (Vd), respectively.",Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674164/),h,6.4,39147,DB00773,Etoposide
,8674164,terminal elimination half-life (t1/2 beta),"The calculated pharmacokinetic parameters (mean values +/- SD) were similar after i.v. infusion and HAI, viz., 6.4 +/- 0.7 versus 6.5 +/- 0.2 h for the terminal elimination half-life (t1/2 beta), 98.5 +/- 1.3 versus 101.3 +/- 5.9 mg l(-1) h for the area under the plasma concentration-time curve (AUC), 21.2 +/- 0.3 versus 20.6 +/- 1.2 ml min-1 m-2 for clearance (Cl), 17.7 +/- 1.9 versus 18.1 +/- 2.6 mg/l for the peak concentration, and 11.7 +/- 1.3 versus 11.6 +/- 1.01/m2 for the volume of distribution (Vd), respectively.",Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674164/),h,6.5,39148,DB00773,Etoposide
,8674164,clearance (Cl),"The calculated pharmacokinetic parameters (mean values +/- SD) were similar after i.v. infusion and HAI, viz., 6.4 +/- 0.7 versus 6.5 +/- 0.2 h for the terminal elimination half-life (t1/2 beta), 98.5 +/- 1.3 versus 101.3 +/- 5.9 mg l(-1) h for the area under the plasma concentration-time curve (AUC), 21.2 +/- 0.3 versus 20.6 +/- 1.2 ml min-1 m-2 for clearance (Cl), 17.7 +/- 1.9 versus 18.1 +/- 2.6 mg/l for the peak concentration, and 11.7 +/- 1.3 versus 11.6 +/- 1.01/m2 for the volume of distribution (Vd), respectively.",Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674164/),[ml] / [(m)^2·min],21.2,39149,DB00773,Etoposide
,8674164,clearance (Cl),"The calculated pharmacokinetic parameters (mean values +/- SD) were similar after i.v. infusion and HAI, viz., 6.4 +/- 0.7 versus 6.5 +/- 0.2 h for the terminal elimination half-life (t1/2 beta), 98.5 +/- 1.3 versus 101.3 +/- 5.9 mg l(-1) h for the area under the plasma concentration-time curve (AUC), 21.2 +/- 0.3 versus 20.6 +/- 1.2 ml min-1 m-2 for clearance (Cl), 17.7 +/- 1.9 versus 18.1 +/- 2.6 mg/l for the peak concentration, and 11.7 +/- 1.3 versus 11.6 +/- 1.01/m2 for the volume of distribution (Vd), respectively.",Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674164/),[ml] / [(m)^2·min],20.6,39150,DB00773,Etoposide
,8674164,peak concentration,"The calculated pharmacokinetic parameters (mean values +/- SD) were similar after i.v. infusion and HAI, viz., 6.4 +/- 0.7 versus 6.5 +/- 0.2 h for the terminal elimination half-life (t1/2 beta), 98.5 +/- 1.3 versus 101.3 +/- 5.9 mg l(-1) h for the area under the plasma concentration-time curve (AUC), 21.2 +/- 0.3 versus 20.6 +/- 1.2 ml min-1 m-2 for clearance (Cl), 17.7 +/- 1.9 versus 18.1 +/- 2.6 mg/l for the peak concentration, and 11.7 +/- 1.3 versus 11.6 +/- 1.01/m2 for the volume of distribution (Vd), respectively.",Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674164/),[mg] / [l],17.7,39151,DB00773,Etoposide
,8674164,peak concentration,"The calculated pharmacokinetic parameters (mean values +/- SD) were similar after i.v. infusion and HAI, viz., 6.4 +/- 0.7 versus 6.5 +/- 0.2 h for the terminal elimination half-life (t1/2 beta), 98.5 +/- 1.3 versus 101.3 +/- 5.9 mg l(-1) h for the area under the plasma concentration-time curve (AUC), 21.2 +/- 0.3 versus 20.6 +/- 1.2 ml min-1 m-2 for clearance (Cl), 17.7 +/- 1.9 versus 18.1 +/- 2.6 mg/l for the peak concentration, and 11.7 +/- 1.3 versus 11.6 +/- 1.01/m2 for the volume of distribution (Vd), respectively.",Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674164/),[mg] / [l],18.1,39152,DB00773,Etoposide
,8674164,volume of distribution (Vd),"The calculated pharmacokinetic parameters (mean values +/- SD) were similar after i.v. infusion and HAI, viz., 6.4 +/- 0.7 versus 6.5 +/- 0.2 h for the terminal elimination half-life (t1/2 beta), 98.5 +/- 1.3 versus 101.3 +/- 5.9 mg l(-1) h for the area under the plasma concentration-time curve (AUC), 21.2 +/- 0.3 versus 20.6 +/- 1.2 ml min-1 m-2 for clearance (Cl), 17.7 +/- 1.9 versus 18.1 +/- 2.6 mg/l for the peak concentration, and 11.7 +/- 1.3 versus 11.6 +/- 1.01/m2 for the volume of distribution (Vd), respectively.",Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674164/),1/[m],11.7,39153,DB00773,Etoposide
,8674164,volume of distribution (Vd),"The calculated pharmacokinetic parameters (mean values +/- SD) were similar after i.v. infusion and HAI, viz., 6.4 +/- 0.7 versus 6.5 +/- 0.2 h for the terminal elimination half-life (t1/2 beta), 98.5 +/- 1.3 versus 101.3 +/- 5.9 mg l(-1) h for the area under the plasma concentration-time curve (AUC), 21.2 +/- 0.3 versus 20.6 +/- 1.2 ml min-1 m-2 for clearance (Cl), 17.7 +/- 1.9 versus 18.1 +/- 2.6 mg/l for the peak concentration, and 11.7 +/- 1.3 versus 11.6 +/- 1.01/m2 for the volume of distribution (Vd), respectively.",Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674164/),1/[m],11.6,39154,DB00773,Etoposide
>,11165404,AUC,"In patients with etoposide AUC>254.8 mg h/l, 1-year survival was 50.0 vs.",The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165404/),[h·mg] / [l],254.8,39599,DB00773,Etoposide
,11165404,survival,"In patients with extensive disease only (n=15), 1-year survival was 42.9 vs. 0% (median 11.3 vs. 5.3 months, P=0.01).",The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165404/),%,42,39600,DB00773,Etoposide
,11165404,survival,"In patients with extensive disease only (n=15), 1-year survival was 42.9 vs. 0% (median 11.3 vs. 5.3 months, P=0.01).",The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165404/),%,0,39601,DB00773,Etoposide
,11165404,survival,"In patients with extensive disease only (n=15), 1-year survival was 42.9 vs. 0% (median 11.3 vs. 5.3 months, P=0.01).",The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165404/),month,11,39602,DB00773,Etoposide
,11165404,survival,"In patients with extensive disease only (n=15), 1-year survival was 42.9 vs. 0% (median 11.3 vs. 5.3 months, P=0.01).",The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165404/),month,5.3,39603,DB00773,Etoposide
,8478658,persistent plasma levels,A pharmacokinetic study of VP16 was conducted in eight patients to determine whether the goal of persistent plasma levels between 1 and 5 micrograms/mL was achieved.,Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478658/),[μg] / [ml],1 and 5,39919,DB00773,Etoposide
,8478658,overall response rate,"In the 28 assessable patients, the overall response rate was 43%, with one CRem and 11 partial remissions (PRems).",Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478658/),%,43,39920,DB00773,Etoposide
greater,8478658,steady-state plasma levels (Css),Pharmacokinetic analysis showed that mean steady-state plasma levels (Css) of VP16 were greater than 1 microgram/mL during all the courses.,Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8478658/),[μg] / [ml],1,39921,DB00773,Etoposide
,2748532,equilibrium aqueous solubility,"The equilibrium aqueous solubility of etoposide at 37 degrees C was low, 148.5-167.25 micrograms/ml, and did not vary over the pH range of 2 to 6.",Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748532/),[μg] / [ml],148.5-167.25,39949,DB00773,Etoposide
,2748532,degradation half-lives,"The pH-stability profile indicated rapid degradation of etoposide at pH 1.3 and 10, with degradation half-lives of 2.88 and 3.83 hr, respectively, at 25 degrees C.",Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748532/),h,2.88,39950,DB00773,Etoposide
,2748532,degradation half-lives,"The pH-stability profile indicated rapid degradation of etoposide at pH 1.3 and 10, with degradation half-lives of 2.88 and 3.83 hr, respectively, at 25 degrees C.",Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748532/),h,3.83,39951,DB00773,Etoposide
,2748532,half-life,The half-life at pH 7.30 was 27.72 days.,Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748532/),d,27.72,39952,DB00773,Etoposide
,2748532,half-lives,"Maximum stability at 25 degrees C was reached at pH 5 to 6.15, with half-lives of 63 and 49.5 days, respectively.",Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748532/),d,63,39953,DB00773,Etoposide
,2748532,half-lives,"Maximum stability at 25 degrees C was reached at pH 5 to 6.15, with half-lives of 63 and 49.5 days, respectively.",Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748532/),d,49.5,39954,DB00773,Etoposide
,2748532,intrinsic dissolution rate,"The intrinsic dissolution rate, determined on a Wood's apparatus, was slow, 0.0094 mg/min/cm2, while the etoposide partition coefficient between n-octanol and water was 9.94.",Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748532/),[mg] / [cm2·min],0.0094,39955,DB00773,Etoposide
,2748532,partition coefficient,"The intrinsic dissolution rate, determined on a Wood's apparatus, was slow, 0.0094 mg/min/cm2, while the etoposide partition coefficient between n-octanol and water was 9.94.",Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748532/),,9.94,39956,DB00773,Etoposide
,3548841,disease-free survival rate,"The actuarial disease-free survival rate of the 33 acute leukemia patients is 43% (2 SEM, 18%) and the actuarial relapse rate is 32% (2 SEM, 20%).",Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3548841/),%,43,40345,DB00773,Etoposide
,3548841,relapse rate,"The actuarial disease-free survival rate of the 33 acute leukemia patients is 43% (2 SEM, 18%) and the actuarial relapse rate is 32% (2 SEM, 20%).",Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3548841/),%,32,40346,DB00773,Etoposide
,10224342,maximum concentrations,"The pharmacokinetic profiles showed high maximum concentrations of CDDP (free form, 88 microg/ml) and etoposide (182. 4 microg/ml) in intrapleural fluids.",Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224342/),[μg] / [ml],88,41279,DB00773,Etoposide
,10224342,maximum concentrations,"The pharmacokinetic profiles showed high maximum concentrations of CDDP (free form, 88 microg/ml) and etoposide (182. 4 microg/ml) in intrapleural fluids.",Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224342/),[μg] / [ml],182. 4,41280,DB00773,Etoposide
,10224342,beta-phase half-life,"CDDP did not remain for a long period (free form, beta-phase half-life = 10.51 h) in the fluids, while etoposide persisted for a long period (beta-phase half-life = 62.53 h).",Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224342/),h,10.51,41281,DB00773,Etoposide
,10224342,beta-phase half-life,"CDDP did not remain for a long period (free form, beta-phase half-life = 10.51 h) in the fluids, while etoposide persisted for a long period (beta-phase half-life = 62.53 h).",Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224342/),h,62.53,41282,DB00773,Etoposide
,10224342,overall response rate,"The overall response rate was 46.2%, the median survival time 32.3 weeks, the 1-year survival rate 28.7% and the 2-year survival rate 12.8%.",Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224342/),%,46.2,41283,DB00773,Etoposide
,10224342,survival time,"The overall response rate was 46.2%, the median survival time 32.3 weeks, the 1-year survival rate 28.7% and the 2-year survival rate 12.8%.",Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224342/),weeks,32.3,41284,DB00773,Etoposide
,12389073,absolute bioavailability,"Median absolute bioavailability with and without pretreatment with grapefruit juice was 52.4% and 73.2%, respectively.",Effect of grapefruit juice intake on etoposide bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389073/),%,52.4,42555,DB00773,Etoposide
,12389073,absolute bioavailability,"Median absolute bioavailability with and without pretreatment with grapefruit juice was 52.4% and 73.2%, respectively.",Effect of grapefruit juice intake on etoposide bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389073/),%,73.2,42556,DB00773,Etoposide
,10071979,bioavailability [F,"We found slightly high etoposide bioavailability [F, 61% (17-95%)] and clearance [CL, 1.1 (0.7-2.3)l h(-1) m(-2)] resulting in a normal degree of systemic exposure (AUC(oral) 27 microg h ml(-1)).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),%,61,43362,DB00773,Etoposide
,10071979,clearance [CL,"We found slightly high etoposide bioavailability [F, 61% (17-95%)] and clearance [CL, 1.1 (0.7-2.3)l h(-1) m(-2)] resulting in a normal degree of systemic exposure (AUC(oral) 27 microg h ml(-1)).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),[l] / [(m)^2·h],1.1,43363,DB00773,Etoposide
,10071979,AUC(oral),"We found slightly high etoposide bioavailability [F, 61% (17-95%)] and clearance [CL, 1.1 (0.7-2.3)l h(-1) m(-2)] resulting in a normal degree of systemic exposure (AUC(oral) 27 microg h ml(-1)).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),[h·μg] / [ml],27,43364,DB00773,Etoposide
,10071979,"AUC(f, oral)","Normal protein binding [PB 93.2% (84.4-98.1%)] contributed to a normal level of exposure to free drug (AUC(f, oral) 1.9 microg h ml(-1)).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),[h·μg] / [ml],1.9,43365,DB00773,Etoposide
,10071979,distribution volume [V(SS),"The distribution volume [V(SS) 8.4 (6.1-13.2) l/m2] and the effective half-life [t1/2eff, 5.1 (3.0-9.6) h] were normal.",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),[l] / [m2],8.4,43366,DB00773,Etoposide
,10071979,effective half-life [t1/2eff,"The distribution volume [V(SS) 8.4 (6.1-13.2) l/m2] and the effective half-life [t1/2eff, 5.1 (3.0-9.6) h] were normal.",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),h,5.1,43367,DB00773,Etoposide
,10071979,CL,"Median CL and protein binding did not differ in the seven patients with total bilirubin value of > 1.2 mg/dl as compared with the ten patients with total bilirubin levels of < or = 1.2 mg/dl (1.3 versus 1.01 h(-1) m(-2) and 92.5% versus 93.4%, respectively).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),1/[(m)^2·h],1.3,43368,DB00773,Etoposide
,10071979,CL,"Median CL and protein binding did not differ in the seven patients with total bilirubin value of > 1.2 mg/dl as compared with the ten patients with total bilirubin levels of < or = 1.2 mg/dl (1.3 versus 1.01 h(-1) m(-2) and 92.5% versus 93.4%, respectively).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),1/[(m)^2·h],1.01,43369,DB00773,Etoposide
,10071979,protein binding,"Median CL and protein binding did not differ in the seven patients with total bilirubin value of > 1.2 mg/dl as compared with the ten patients with total bilirubin levels of < or = 1.2 mg/dl (1.3 versus 1.01 h(-1) m(-2) and 92.5% versus 93.4%, respectively).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),%,92.5,43370,DB00773,Etoposide
,10071979,protein binding,"Median CL and protein binding did not differ in the seven patients with total bilirubin value of > 1.2 mg/dl as compared with the ten patients with total bilirubin levels of < or = 1.2 mg/dl (1.3 versus 1.01 h(-1) m(-2) and 92.5% versus 93.4%, respectively).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),%,93.4,43371,DB00773,Etoposide
,21159109,C(max),The median value of VP-16 C(max) measured at the end of infusion was 188.0 μg/mL (range 148.0-407.0 μg/mL).,Pharmacokinetics of high-dose etoposide administered in combination with fractionated total-body irradiation as conditioning for allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21159109/),[μg] / [ml],188.0,43575,DB00773,Etoposide
,8353095,bioavailability,"Mean bioavailability value of 75%, ranging from 44% to 100%.",Low-dose oral etoposide in epithelial cancer of the ovary. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8353095/),%,75,44156,DB00773,Etoposide
,8353095,bioavailability,"Mean bioavailability value of 75%, ranging from 44% to 100%.",Low-dose oral etoposide in epithelial cancer of the ovary. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8353095/),%,100,44157,DB00773,Etoposide
,10447584,area under the plasma concentration-versus-time curves (AUC),"The mean paclitaxel area under the plasma concentration-versus-time curves (AUC) for the 125-mg/m(2) dose level (II) was 7.0 +/- 3.6 h micromol(-1) l(-1), for the 175-mg/m(2) dose level (III) 10.6 +/- 2.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[h] / [l·μmol],7.0,44420,DB00773,Etoposide
,10447584,area under the plasma concentration-versus-time curves (AUC),"The mean paclitaxel area under the plasma concentration-versus-time curves (AUC) for the 125-mg/m(2) dose level (II) was 7.0 +/- 3.6 h micromol(-1) l(-1), for the 175-mg/m(2) dose level (III) 10.6 +/- 2.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),,10.6,44421,DB00773,Etoposide
,10447584,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) values for dose levels II-V were 1.9 +/- 1.1 micromol/l, 3.4 +/- 1.2 micromol/l, 4.3 +/- 1.0 micromol/l and 3.8 +/- 1.2 h micromol/l, respectively.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[μM] / [l],1.9,44422,DB00773,Etoposide
,10447584,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) values for dose levels II-V were 1.9 +/- 1.1 micromol/l, 3.4 +/- 1.2 micromol/l, 4.3 +/- 1.0 micromol/l and 3.8 +/- 1.2 h micromol/l, respectively.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[μM] / [l],3.4,44423,DB00773,Etoposide
,10447584,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) values for dose levels II-V were 1.9 +/- 1.1 micromol/l, 3.4 +/- 1.2 micromol/l, 4.3 +/- 1.0 micromol/l and 3.8 +/- 1.2 h micromol/l, respectively.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[μM] / [l],4.3,44424,DB00773,Etoposide
,10447584,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) values for dose levels II-V were 1.9 +/- 1.1 micromol/l, 3.4 +/- 1.2 micromol/l, 4.3 +/- 1.0 micromol/l and 3.8 +/- 1.2 h micromol/l, respectively.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[h·μM] / [l],3.8,44425,DB00773,Etoposide
>,10447584,t,"In this study, relevant pharmacokinetic parameters of paclitaxel like AUC, C(max) and the paclitaxel plasma concentration above the pharmacologically relevant 0.1-micromol/l threshold concentration (t > 0.1 microM) when administered in combination with cisplatin, etoposide and bleomycin (PEB) were not statistically different from paclitaxel data of historical controls.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),μM,0.1,44426,DB00773,Etoposide
,23373755,AUC 0 - 12h,"Similar pharmacokinetic behavior in beagle dogs was obtained and the AUC 0 - 12h values were 1196.73 ± 320.85 and 1505.56 ± 617.93 µg.h/L for EPE and EPS (p > 0.5), respectively.","A stable and practical etoposide-containing intravenous long-/medium-chain triglycerides-based lipid emulsion formulation: pharmacokinetics, biodistribution, toxicity, and antitumor efficacy. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373755/),[h·μg] / [l],1196.73,46845,DB00773,Etoposide
,23373755,AUC 0 - 12h,"Similar pharmacokinetic behavior in beagle dogs was obtained and the AUC 0 - 12h values were 1196.73 ± 320.85 and 1505.56 ± 617.93 µg.h/L for EPE and EPS (p > 0.5), respectively.","A stable and practical etoposide-containing intravenous long-/medium-chain triglycerides-based lipid emulsion formulation: pharmacokinetics, biodistribution, toxicity, and antitumor efficacy. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373755/),[h·μg] / [l],1505.56,46846,DB00773,Etoposide
,23373755,tumor suppression rate (TSR),"Furthermore, significant and comparable antitumor activities to EPS were also demonstrated by EPE with tumor suppression rate (TSR) of 66.63, 55.94, and 60.16% against H460, Hep G2, and BCAP-37 human cancer cell lines in nude mice at the dose of 15 mg/kg, respectively.","A stable and practical etoposide-containing intravenous long-/medium-chain triglycerides-based lipid emulsion formulation: pharmacokinetics, biodistribution, toxicity, and antitumor efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373755/),%,66.63,46847,DB00773,Etoposide
,23373755,tumor suppression rate (TSR),"Furthermore, significant and comparable antitumor activities to EPS were also demonstrated by EPE with tumor suppression rate (TSR) of 66.63, 55.94, and 60.16% against H460, Hep G2, and BCAP-37 human cancer cell lines in nude mice at the dose of 15 mg/kg, respectively.","A stable and practical etoposide-containing intravenous long-/medium-chain triglycerides-based lipid emulsion formulation: pharmacokinetics, biodistribution, toxicity, and antitumor efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373755/),%,55.94,46848,DB00773,Etoposide
,23373755,tumor suppression rate (TSR),"Furthermore, significant and comparable antitumor activities to EPS were also demonstrated by EPE with tumor suppression rate (TSR) of 66.63, 55.94, and 60.16% against H460, Hep G2, and BCAP-37 human cancer cell lines in nude mice at the dose of 15 mg/kg, respectively.","A stable and practical etoposide-containing intravenous long-/medium-chain triglycerides-based lipid emulsion formulation: pharmacokinetics, biodistribution, toxicity, and antitumor efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23373755/),%,60.16,46849,DB00773,Etoposide
,8270970,Duration of neutropenia,Duration of neutropenia was longer for patients treated with 90 mg/m2 (31.7 days) than for patients treated with doses up to 75 mg/m2 (22.1 days) (P < .05).,"Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270970/),d,31.7,47385,DB00773,Etoposide
,8270970,Duration of neutropenia,Duration of neutropenia was longer for patients treated with 90 mg/m2 (31.7 days) than for patients treated with doses up to 75 mg/m2 (22.1 days) (P < .05).,"Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270970/),d,22.1,47386,DB00773,Etoposide
,3971483,Absorption,Absorption of etoposide from the pleural cavity was slow (approximately 0.2 ml/min).,A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971483/),[ml] / [min],0.2,47768,DB00773,Etoposide
,33497706,AUC,"Rat PK study demonstrated significantly higher etoposide bioavailability from TPGS vs. PEG-400 or suspension (AUC of 72, 41, and 26 µg·min/mL, respectively).","Adequate formulation approach for oral chemotherapy: Etoposide solubility, permeability, and overall bioavailability from cosolvent- vs. vitamin E TPGS-based delivery systems. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33497706/),[min·μg] / [ml],72,47920,DB00773,Etoposide
,33497706,AUC,"Rat PK study demonstrated significantly higher etoposide bioavailability from TPGS vs. PEG-400 or suspension (AUC of 72, 41, and 26 µg·min/mL, respectively).","Adequate formulation approach for oral chemotherapy: Etoposide solubility, permeability, and overall bioavailability from cosolvent- vs. vitamin E TPGS-based delivery systems. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33497706/),[min·μg] / [ml],41,47921,DB00773,Etoposide
,33497706,AUC,"Rat PK study demonstrated significantly higher etoposide bioavailability from TPGS vs. PEG-400 or suspension (AUC of 72, 41, and 26 µg·min/mL, respectively).","Adequate formulation approach for oral chemotherapy: Etoposide solubility, permeability, and overall bioavailability from cosolvent- vs. vitamin E TPGS-based delivery systems. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33497706/),[min·μg] / [ml],26,47922,DB00773,Etoposide
,8651950,corrected brain-blood ratio (BBR (corr)),"The corrected brain-blood ratio (BBR (corr)) was 0.36 +/- 0.18 prior to CSA treatment, and although CNS concentrations increased upon the addition of CSA, there was no increase in the BBR(corr) (0.24 +/- 0.10).",Modulation effects of cyclosporine on etoposide pharmacokinetics and CNS distribution in the rat utilizing microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8651950/),,0.36,48665,DB00773,Etoposide
,8651950,BBR(corr),"The corrected brain-blood ratio (BBR (corr)) was 0.36 +/- 0.18 prior to CSA treatment, and although CNS concentrations increased upon the addition of CSA, there was no increase in the BBR(corr) (0.24 +/- 0.10).",Modulation effects of cyclosporine on etoposide pharmacokinetics and CNS distribution in the rat utilizing microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8651950/),,0.24,48666,DB00773,Etoposide
,8377449,AUC,"In the subgroup of patients who received 150 mg/m2 (n = 10) the AUC was 106 +/- 15 micrograms.h/ml (range 82-139), clearance 24 +/- 3 ml/min/m2 (18-31), t1/2 3.5 +/- 0.4.",[Pharmacokinetics of etoposide short-term infusions within the scope of the GPOH therapy protocol]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8377449/),[h·μg] / [ml],106,49413,DB00773,Etoposide
,8377449,clearance,"In the subgroup of patients who received 150 mg/m2 (n = 10) the AUC was 106 +/- 15 micrograms.h/ml (range 82-139), clearance 24 +/- 3 ml/min/m2 (18-31), t1/2 3.5 +/- 0.4.",[Pharmacokinetics of etoposide short-term infusions within the scope of the GPOH therapy protocol]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8377449/),[ml] / [m2·min],24,49414,DB00773,Etoposide
,8377449,t1/2,"In the subgroup of patients who received 150 mg/m2 (n = 10) the AUC was 106 +/- 15 micrograms.h/ml (range 82-139), clearance 24 +/- 3 ml/min/m2 (18-31), t1/2 3.5 +/- 0.4.",[Pharmacokinetics of etoposide short-term infusions within the scope of the GPOH therapy protocol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8377449/),,3.5,49415,DB00773,Etoposide
,8377449,AUC,The AUC then was (68 +/- 17 micrograms.h/ml)/(100 mg/m2).,[Pharmacokinetics of etoposide short-term infusions within the scope of the GPOH therapy protocol]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8377449/),[h·μg] / [ml)],68,49416,DB00773,Etoposide
,8377449,Half-life,"Half-life was 3.3 +/- 0.7 h and total clearance 26 +/- 6 ml/min/m2, respectively.",[Pharmacokinetics of etoposide short-term infusions within the scope of the GPOH therapy protocol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8377449/),h,3.3,49417,DB00773,Etoposide
,8377449,total clearance,"Half-life was 3.3 +/- 0.7 h and total clearance 26 +/- 6 ml/min/m2, respectively.",[Pharmacokinetics of etoposide short-term infusions within the scope of the GPOH therapy protocol]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8377449/),[ml] / [m2·min],26,49418,DB00773,Etoposide
,11918453,time from diagnosis to inclusion,The median time from diagnosis to inclusion in the study was 21 mo (range: 0.5-144 mo) and most patients had advanced disease and were heavily pretreated.,Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11918453/),mo,21,54659,DB00773,Etoposide
less,11918453,Platelet count nadir,Platelet count nadir was less than 25 x 10(9)/L in 24% of evaluable patients.,Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11918453/),,25 x,54660,DB00773,Etoposide
,3621455,Peak plasma levels,"Peak plasma levels (9.5-63.3 micrograms . ml-1), the area under the curve (AUC) (2707-10192 micrograms . ml-1 . min-1), the mean transit time MTT (2.7-10.6 h), etoposide half-lives t1/2 alpha (0.10-0.52 h) and t1/2 beta (2.18-8.17 h), the volume of distribution at steady state (Vdss) (2.5-15.1 .",Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621455/),[μg] / [ml],9.5-63.3,56149,DB00773,Etoposide
,3621455,area under the curve (AUC),"Peak plasma levels (9.5-63.3 micrograms . ml-1), the area under the curve (AUC) (2707-10192 micrograms . ml-1 . min-1), the mean transit time MTT (2.7-10.6 h), etoposide half-lives t1/2 alpha (0.10-0.52 h) and t1/2 beta (2.18-8.17 h), the volume of distribution at steady state (Vdss) (2.5-15.1 .",Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621455/),[μg] / [min·ml],2707-10192,56150,DB00773,Etoposide
,3621455,mean transit time MTT,"Peak plasma levels (9.5-63.3 micrograms . ml-1), the area under the curve (AUC) (2707-10192 micrograms . ml-1 . min-1), the mean transit time MTT (2.7-10.6 h), etoposide half-lives t1/2 alpha (0.10-0.52 h) and t1/2 beta (2.18-8.17 h), the volume of distribution at steady state (Vdss) (2.5-15.1 .",Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621455/),h,2.7-10.6,56151,DB00773,Etoposide
,3621455,half-lives t1/2 alpha,"Peak plasma levels (9.5-63.3 micrograms . ml-1), the area under the curve (AUC) (2707-10192 micrograms . ml-1 . min-1), the mean transit time MTT (2.7-10.6 h), etoposide half-lives t1/2 alpha (0.10-0.52 h) and t1/2 beta (2.18-8.17 h), the volume of distribution at steady state (Vdss) (2.5-15.1 .",Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621455/),h,0.10-0.52,56152,DB00773,Etoposide
,3621455,t1/2 beta,"Peak plasma levels (9.5-63.3 micrograms . ml-1), the area under the curve (AUC) (2707-10192 micrograms . ml-1 . min-1), the mean transit time MTT (2.7-10.6 h), etoposide half-lives t1/2 alpha (0.10-0.52 h) and t1/2 beta (2.18-8.17 h), the volume of distribution at steady state (Vdss) (2.5-15.1 .",Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621455/),h,2.18-8.17,56153,DB00773,Etoposide
,3621455,volume of distribution at steady state (Vdss),"Peak plasma levels (9.5-63.3 micrograms . ml-1), the area under the curve (AUC) (2707-10192 micrograms . ml-1 . min-1), the mean transit time MTT (2.7-10.6 h), etoposide half-lives t1/2 alpha (0.10-0.52 h) and t1/2 beta (2.18-8.17 h), the volume of distribution at steady state (Vdss) (2.5-15.1 .",Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621455/),,2.5-15.1,56154,DB00773,Etoposide
,3621455,systemic clearance (Cls),l/m-2) and the systemic clearance (Cls) (10.1-35.1 ml min-1 .,Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621455/),[ml] / [min],10.1-35.1,56155,DB00773,Etoposide
>,10550566,trough,"Significant granulocytopenia could be predicted for the twice-daily regimen according to the formula ln(AGC nadir)=7.80 - 1.88(trough), with an increased incidence of granulocytopenia if the etoposide trough value was >/=1.49 microg/ml.",Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550566/),[μg] / [ml],1.49,56806,DB00773,Etoposide
,8765431,area under the serum concentration versus time curve (TAUC),"Carboplatin doses were calculated to achieve a targeted area under the serum concentration versus time curve (TAUC) of 5, 6.5 or 8 mg/ml.min based on each patient's measured glomerular filtration rate (GFR).",Carboplatin pharmacokinetics in young children with brain tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765431/),[mg] / [min·ml],5,57190,DB00773,Etoposide
,8765431,area under the serum concentration versus time curve (TAUC),"Carboplatin doses were calculated to achieve a targeted area under the serum concentration versus time curve (TAUC) of 5, 6.5 or 8 mg/ml.min based on each patient's measured glomerular filtration rate (GFR).",Carboplatin pharmacokinetics in young children with brain tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765431/),[mg] / [min·ml],6.5,57191,DB00773,Etoposide
,8765431,area under the serum concentration versus time curve (TAUC),"Carboplatin doses were calculated to achieve a targeted area under the serum concentration versus time curve (TAUC) of 5, 6.5 or 8 mg/ml.min based on each patient's measured glomerular filtration rate (GFR).",Carboplatin pharmacokinetics in young children with brain tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765431/),[mg] / [min·ml],8,57192,DB00773,Etoposide
,8765431,clearance,"The median carboplatin clearance and GFR after course 1 were 118 and 98 ml/min per m2, respectively.",Carboplatin pharmacokinetics in young children with brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765431/),[ml] / [m2·min],118,57193,DB00773,Etoposide
,8765431,GFR,"The median carboplatin clearance and GFR after course 1 were 118 and 98 ml/min per m2, respectively.",Carboplatin pharmacokinetics in young children with brain tumors. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765431/),[ml] / [m2·min],98,57194,DB00773,Etoposide
,8765431,clearance,"The median (range) carboplatin clearance for four children less than 1 year of age was 76 (66-84) ml/min per m2, significantly lower (P = 0.05) than the value of 131 (80-158) ml/min per m2 for children from 1 to 4 years of age.",Carboplatin pharmacokinetics in young children with brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765431/),[ml] / [m2·min],76,57195,DB00773,Etoposide
,8765431,clearance,"The median (range) carboplatin clearance for four children less than 1 year of age was 76 (66-84) ml/min per m2, significantly lower (P = 0.05) than the value of 131 (80-158) ml/min per m2 for children from 1 to 4 years of age.",Carboplatin pharmacokinetics in young children with brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765431/),[ml] / [m2·min],131,57196,DB00773,Etoposide
,8765431,TAUC,Toxicity was acceptable for patients treated at a TAUC of 6.5 mg/ml.min for carboplatin given with etoposide and cyclophosphamide.,Carboplatin pharmacokinetics in young children with brain tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765431/),[mg] / [min·ml],6.5,57197,DB00773,Etoposide
,3020707,Overall objective response rate,"Overall objective response rate in 51 evaluable patients was 69% (95% confidence interval: range, 56% to 81%), with 16% sustaining complete remission (CR), 53% partial remission (PR), 17% stable disease (SD), and 14% progressive disease (PD).",A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3020707/),%,69,57393,DB00773,Etoposide
,3020707,Overall objective response rate,"Overall objective response rate in 51 evaluable patients was 69% (95% confidence interval: range, 56% to 81%), with 16% sustaining complete remission (CR), 53% partial remission (PR), 17% stable disease (SD), and 14% progressive disease (PD).",A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3020707/),,16,57394,DB00773,Etoposide
,3020707,Overall objective response rate,"Overall objective response rate in 51 evaluable patients was 69% (95% confidence interval: range, 56% to 81%), with 16% sustaining complete remission (CR), 53% partial remission (PR), 17% stable disease (SD), and 14% progressive disease (PD).",A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3020707/),%,53,57395,DB00773,Etoposide
,3020707,Overall objective response rate,"Overall objective response rate in 51 evaluable patients was 69% (95% confidence interval: range, 56% to 81%), with 16% sustaining complete remission (CR), 53% partial remission (PR), 17% stable disease (SD), and 14% progressive disease (PD).",A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3020707/),%,17,57396,DB00773,Etoposide
,3020707,Overall objective response rate,"Overall objective response rate in 51 evaluable patients was 69% (95% confidence interval: range, 56% to 81%), with 16% sustaining complete remission (CR), 53% partial remission (PR), 17% stable disease (SD), and 14% progressive disease (PD).",A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3020707/),,14,57397,DB00773,Etoposide
,3020707,survival,"Median survival of all evaluable patients was 52 weeks, greater than 75 weeks for CR patients, 52 weeks for PR patients, 42 weeks for SD patients, and 13 weeks for PD patients.",A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3020707/),weeks,52,57398,DB00773,Etoposide
,3020707,survival,"Median survival of all evaluable patients was 52 weeks, greater than 75 weeks for CR patients, 52 weeks for PR patients, 42 weeks for SD patients, and 13 weeks for PD patients.",A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3020707/),weeks,greater,57399,DB00773,Etoposide
,3020707,survival,"Median survival of all evaluable patients was 52 weeks, greater than 75 weeks for CR patients, 52 weeks for PR patients, 42 weeks for SD patients, and 13 weeks for PD patients.",A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3020707/),weeks,75,57400,DB00773,Etoposide
,3020707,survival,"Median survival of all evaluable patients was 52 weeks, greater than 75 weeks for CR patients, 52 weeks for PR patients, 42 weeks for SD patients, and 13 weeks for PD patients.",A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3020707/),weeks,42,57401,DB00773,Etoposide
,3020707,survival,"Median survival of all evaluable patients was 52 weeks, greater than 75 weeks for CR patients, 52 weeks for PR patients, 42 weeks for SD patients, and 13 weeks for PD patients.",A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3020707/),weeks,13,57402,DB00773,Etoposide
,16463061,AUC,"The patients intravenously received carboplatin with a target AUC of 4 or 5 mg min/ml (Chatelut formula) on day 1 and etoposide at 80-120 mg/m2 on days 1, 2 and 3.",A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16463061/),[mg·min] / [ml],4,58225,DB00773,Etoposide
,16463061,AUC,"The patients intravenously received carboplatin with a target AUC of 4 or 5 mg min/ml (Chatelut formula) on day 1 and etoposide at 80-120 mg/m2 on days 1, 2 and 3.",A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16463061/),[mg·min] / [ml],5,58226,DB00773,Etoposide
,16463061,AUC,A dose of carboplatin of AUC=4 and etoposide of 100 mg/m2 was recommended in this regimen.,A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16463061/),,4,58227,DB00773,Etoposide
,19834427,clearance,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),[l] / [h],23.1,59323,DB00773,Etoposide
,19834427,central,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,35.4,59324,DB00773,Etoposide
,19834427,peripheral volume of distribution,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,35.4,59325,DB00773,Etoposide
,19834427,peripheral volume of distribution,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,1090,59326,DB00773,Etoposide
,19834427,intercompartmental clearance,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,27.3,59327,DB00773,Etoposide
,19834427,mean transit time (tau),"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),d,3.8,59328,DB00773,Etoposide
,19834427,tau,"When patients had an early decrease in bilirubin at day 7, tau increased to 28.2 days.",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),d,28.2,59329,DB00773,Etoposide
,8070028,MTD,"Data from these trials show the rapid and complete conversion of EP to VP-16, a pharmacokinetic/pharmacodynamic relationship for myelosuppression and exposure to VP-16, and an MTD of 100 and 150 mg/m2 (molar equivalent to VP-16) when EP is given daily for 5 days and on days 1, 3, and 5, respectively.",Clinical and pharmacokinetic overview of parenteral etoposide phosphate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070028/),[mg] / [m2],100,59962,DB00773,Etoposide
,8070028,MTD,"Data from these trials show the rapid and complete conversion of EP to VP-16, a pharmacokinetic/pharmacodynamic relationship for myelosuppression and exposure to VP-16, and an MTD of 100 and 150 mg/m2 (molar equivalent to VP-16) when EP is given daily for 5 days and on days 1, 3, and 5, respectively.",Clinical and pharmacokinetic overview of parenteral etoposide phosphate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070028/),[mg] / [m2],150,59963,DB00773,Etoposide
,33560100,C0,"Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0-24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg.",Therapeutic Drug Monitoring and Pharmacokinetic Analysis of Cyclosporine in a Pediatric Patient with Hemophagocytic Lymphohistiocytosis Complicated by Diabetes Insipidus: A Grand Round. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33560100/),[mcg] / [l],50.2,61166,DB00773,Etoposide
,33560100,peak concentration (Cmax),"Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0-24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg.",Therapeutic Drug Monitoring and Pharmacokinetic Analysis of Cyclosporine in a Pediatric Patient with Hemophagocytic Lymphohistiocytosis Complicated by Diabetes Insipidus: A Grand Round. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33560100/),[mcg] / [l],723.4,61167,DB00773,Etoposide
,33560100,area under the curve0-24,"Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0-24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg.",Therapeutic Drug Monitoring and Pharmacokinetic Analysis of Cyclosporine in a Pediatric Patient with Hemophagocytic Lymphohistiocytosis Complicated by Diabetes Insipidus: A Grand Round. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33560100/),[h·mcg] / [l],7478.2,61168,DB00773,Etoposide
,33560100,clearance,"Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0-24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg.",Therapeutic Drug Monitoring and Pharmacokinetic Analysis of Cyclosporine in a Pediatric Patient with Hemophagocytic Lymphohistiocytosis Complicated by Diabetes Insipidus: A Grand Round. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33560100/),[l] / [h·kg],0.77,61169,DB00773,Etoposide
,33560100,elimination half-life,"Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0-24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg.",Therapeutic Drug Monitoring and Pharmacokinetic Analysis of Cyclosporine in a Pediatric Patient with Hemophagocytic Lymphohistiocytosis Complicated by Diabetes Insipidus: A Grand Round. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33560100/),h,5.3,61170,DB00773,Etoposide
,33560100,volume of distribution,"Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0-24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg.",Therapeutic Drug Monitoring and Pharmacokinetic Analysis of Cyclosporine in a Pediatric Patient with Hemophagocytic Lymphohistiocytosis Complicated by Diabetes Insipidus: A Grand Round. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33560100/),[l] / [kg],6.0,61171,DB00773,Etoposide
,8722343,clearance rate,The mean VP-16 clearance rate was 17.3 ml/min/m2 with continuous infusion.,Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[ml] / [m2·min],17.3,62274,DB00773,Etoposide
,8722343,steady-state plasma concentration,"A mean steady-state plasma concentration of 24.2 micrograms/ml (s.d. = 2) and 28.3 micrograms/ml (s.d. = 1.9) was achieved at the 1800 mg/ml and 2100 mg/m2 dose levels, respectively, GI toxicity is dose limiting when VP-16 at 2400 mg/m2/72 h, is associated with HDM.",Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[μg] / [ml],24.2,62275,DB00773,Etoposide
,8722343,steady-state plasma concentration,"A mean steady-state plasma concentration of 24.2 micrograms/ml (s.d. = 2) and 28.3 micrograms/ml (s.d. = 1.9) was achieved at the 1800 mg/ml and 2100 mg/m2 dose levels, respectively, GI toxicity is dose limiting when VP-16 at 2400 mg/m2/72 h, is associated with HDM.",Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[μg] / [ml],28.3,62276,DB00773,Etoposide
,2469544,area under the plasma concentration vs time curve (AUC),"The carboplatin dose was calculated so as to achieve a constant area under the plasma concentration vs time curve (AUC) of 4.5 mg carboplatin/ml x min by using the formula: dose = 4.5 x (GFR + 25), where GFR is the absolute glomerular filtration rate measured by 51Cr-EDTA clearance.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[carboplatin·mg] / [min·ml],4.5,62522,DB00773,Etoposide
,2469544,AUC,"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[mg] / [min·ml],4,62523,DB00773,Etoposide
,2469544,AUC,"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),min,94,62524,DB00773,Etoposide
,2469544,AUC,"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),min,129,62525,DB00773,Etoposide
,2469544,AUC,"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],20.1,62526,DB00773,Etoposide
,2469544,AUC,"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],155,62527,DB00773,Etoposide
,2469544,AUC,"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],102,62528,DB00773,Etoposide
,2469544,beta-phase half-life (t 1/2 beta),"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],102,62529,DB00773,Etoposide
,2469544,mean residence time (MRT,"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],102,62530,DB00773,Etoposide
,2469544,renal clearance,The renal clearance of carboplatin was not significantly different from the GFR (132 +/- 32 ml/min).,Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],132,62531,DB00773,Etoposide
,2469544,AUC,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[mg] / [min·ml],5.1,62532,DB00773,Etoposide
,2469544,t 1/2 alpha,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),min,40,62533,DB00773,Etoposide
,2469544,t 1/2 beta,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),min,257,62534,DB00773,Etoposide
,2469544,MRT,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),min,292,62535,DB00773,Etoposide
,2469544,Vd,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),,13.3,62536,DB00773,Etoposide
,2469544,TCLR,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],46,62537,DB00773,Etoposide
,2469544,RCLR,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],17.6,62538,DB00773,Etoposide
,2469544,AUC,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[mg] / [min·ml],5.3,62539,DB00773,Etoposide
,2469544,t 1/2 alpha,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),min,34,62540,DB00773,Etoposide
,2469544,t 1/2 beta,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),min,242,62541,DB00773,Etoposide
,2469544,Vd,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),,12.5,62542,DB00773,Etoposide
,2469544,TCLR,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],43,62543,DB00773,Etoposide
,2469544,RCLR,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],13.4,62544,DB00773,Etoposide
,7636539,MTD,"The MTD of dexverapamil was 150 mg/m2 every 4 hours (900 mg/m2/d), and hypotension was the principal dose-limiting toxicity.",Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636539/),[mg] / [m2],150,64149,DB00773,Etoposide
,12506184,t(1/2),"Free CPT accumulated slowly in plasma, with maximal plasma concentrations achieved at 23 +/- 12.3 hours; the harmonic mean half-life (t(1/2)) of free CPT was long (t(1/2), 77.46 +/- 36.77 hours).",A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506184/),h,77.46,64785,DB00773,Etoposide
,6690051,peak plasma etoposide concentrations,"Increasing the drug dosage produced proportionally higher peak plasma etoposide concentrations (27 to 114 micrograms/ml) and total areas under the concentration-time curve (9,200 to 48,000 micrograms/ml X min).",Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690051/),[μg] / [ml],27 to 114,65573,DB00773,Etoposide
,6690051,total areas under the concentration-time curve,"Increasing the drug dosage produced proportionally higher peak plasma etoposide concentrations (27 to 114 micrograms/ml) and total areas under the concentration-time curve (9,200 to 48,000 micrograms/ml X min).",Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690051/),[μg] / [min·ml],"9,200 to 48,000",65574,DB00773,Etoposide
,6690051,terminal half-life,"The etoposide mean (+/- S.D.) terminal half-life of 8.05 +/- 4.3 hr and plasma clearance of 28.0 +/- 9.7 ml/min/sq m, however, were independent of the dosage given.",Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690051/),h,8.05,65575,DB00773,Etoposide
,6690051,plasma clearance,"The etoposide mean (+/- S.D.) terminal half-life of 8.05 +/- 4.3 hr and plasma clearance of 28.0 +/- 9.7 ml/min/sq m, however, were independent of the dosage given.",Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690051/),[ml] / [m·min·sq],28.0,65576,DB00773,Etoposide
,6690051,renal clearance,"The mean etoposide renal clearance in 5 patients was 10.0 +/- 4.3 ml/min/sq m, representing from 35 to 40% of the total clearance of this drug from plasma.",Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690051/),[ml] / [m·min·sq],10.0,65577,DB00773,Etoposide
,7955814,systemic clearance,Etoposide systemic clearance decreased acutely when administered 2 days after cisplatin (median of 15.5 ml/min/m2) compared with both the first study (20.0 ml/min/m2) and the third study (19.7 ml/min/m2; p < 0.001).,Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955814/),[ml] / [m2·min],15.5,68342,DB00773,Etoposide
,7955814,systemic clearance,Etoposide systemic clearance decreased acutely when administered 2 days after cisplatin (median of 15.5 ml/min/m2) compared with both the first study (20.0 ml/min/m2) and the third study (19.7 ml/min/m2; p < 0.001).,Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955814/),[ml] / [m2·min],20.0,68343,DB00773,Etoposide
,7955814,systemic clearance,Etoposide systemic clearance decreased acutely when administered 2 days after cisplatin (median of 15.5 ml/min/m2) compared with both the first study (20.0 ml/min/m2) and the third study (19.7 ml/min/m2; p < 0.001).,Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955814/),[ml] / [m2·min],19.7,68344,DB00773,Etoposide
,9923536,AUC,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),[min·μg] / [ml],2227,69829,DB00773,Etoposide
,9923536,AUC,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),[min·μg] / [ml],245,69830,DB00773,Etoposide
,9923536,total clearance,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),[ml] / [min],0.8,69831,DB00773,Etoposide
,9923536,total clearance,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),[ml] / [min],7.0,69832,DB00773,Etoposide
,9923536,elimination half-life,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),min,92,69833,DB00773,Etoposide
,9923536,elimination half-life,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),min,18,69834,DB00773,Etoposide
,8445431,AUC,"Cohorts of at least three patients received carboplatin at an initial target AUC of 2 mg/mL x min, with escalations of 1 mg/mL x min in subsequent cohorts.",Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445431/),[mg] / [min·ml],2,70254,DB00773,Etoposide
,8445431,AUC,"At the target AUC of 8 mg/mL x min, 13 of 20 cycles were associated with febrile neutropenia.",Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445431/),[mg] / [min·ml],8,70255,DB00773,Etoposide
,8445431,AUC,"For phase II trials, we recommend a carboplatin target AUC of 6 mg/mL x min with three doses of IFOS and VP-16 for patients with prior craniospinal irradiation or high-dose cisplatin (CDDP)/VP-16, or 7 mg/mL x min for patients without such histories.",Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445431/),[mg] / [min·ml],6,70256,DB00773,Etoposide
,8445431,AUC,"For phase II trials, we recommend a carboplatin target AUC of 6 mg/mL x min with three doses of IFOS and VP-16 for patients with prior craniospinal irradiation or high-dose cisplatin (CDDP)/VP-16, or 7 mg/mL x min for patients without such histories.",Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445431/),[mg] / [min·ml],7,70257,DB00773,Etoposide
,9853980,CR rate,The CR rate after two courses with this regimen was 77%.,High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853980/),%,77,71027,DB00773,Etoposide
,20490798,clearance,"The population means for clearance and central volume of distribution were 2.05 l/h/70 kg and 9.21 l/70 kg with the corresponding between-subject variabilities, 0.26 and 0.28.",Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20490798/),[l] / [70·h·kg],2.05,73511,DB00773,Etoposide
,20490798,central volume of distribution,"The population means for clearance and central volume of distribution were 2.05 l/h/70 kg and 9.21 l/70 kg with the corresponding between-subject variabilities, 0.26 and 0.28.",Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20490798/),[l] / [70·kg],9.21,73512,DB00773,Etoposide
,8611379,area under the drug plasma concentration vs time curve (AUC),The target area under the drug plasma concentration vs time curve (AUC) was 6 mg ml-1 min for carboplatin and 18 and 21 mg ml-1 min for etoposide.,Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611379/),[mg·min] / [ml],6,73649,DB00773,Etoposide
,8611379,area under the drug plasma concentration vs time curve (AUC),The target area under the drug plasma concentration vs time curve (AUC) was 6 mg ml-1 min for carboplatin and 18 and 21 mg ml-1 min for etoposide.,Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611379/),[mg·min] / [ml],18,73650,DB00773,Etoposide
,8611379,area under the drug plasma concentration vs time curve (AUC),The target area under the drug plasma concentration vs time curve (AUC) was 6 mg ml-1 min for carboplatin and 18 and 21 mg ml-1 min for etoposide.,Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611379/),[mg·min] / [ml],21,73651,DB00773,Etoposide
,8611379,AUCs,On course 1 measured AUCs of carboplatin and etoposide were 6 and 20 mg ml-1 min for patient 1 and 6 and 21 mg ml-1 min for patient 2 respectively.,Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611379/),[mg·min] / [ml],6,73652,DB00773,Etoposide
,8611379,AUCs,On course 1 measured AUCs of carboplatin and etoposide were 6 and 20 mg ml-1 min for patient 1 and 6 and 21 mg ml-1 min for patient 2 respectively.,Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611379/),[mg·min] / [ml],20,73653,DB00773,Etoposide
,8611379,AUCs,On course 1 measured AUCs of carboplatin and etoposide were 6 and 20 mg ml-1 min for patient 1 and 6 and 21 mg ml-1 min for patient 2 respectively.,Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611379/),[mg·min] / [ml],21,73654,DB00773,Etoposide
,12439044,clearance rate,"The average clearance rate, reflecting systemic clearance and clearance by continuous venovenous hemofiltration and hemodialysis, was 12.4 L/hour per m for the first 3 days of 2-CdA therapy.",Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12439044/),[l] / [h·m],12.4,74076,DB00773,Etoposide
,25137530,gradient flow rate,"Chromatographic separation was conducted on a Shimadzu CLC-C8 column using a mobile phase consisting of water-acetonitrile (70:30; v/v) adjusted to pH 4.0 ± 0.1 with formic acid at a gradient flow rate of 1.0-0.6 mL/min, an injection volume of 30 μL and UV detection at 210 nm.",HPLC-UV method for quantifying etoposide in plasma and tumor interstitial fluid by microdialysis: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25137530/),[ml] / [min],1.0-0.6,74867,DB00773,Etoposide
,25137530,injection volume,"Chromatographic separation was conducted on a Shimadzu CLC-C8 column using a mobile phase consisting of water-acetonitrile (70:30; v/v) adjusted to pH 4.0 ± 0.1 with formic acid at a gradient flow rate of 1.0-0.6 mL/min, an injection volume of 30 μL and UV detection at 210 nm.",HPLC-UV method for quantifying etoposide in plasma and tumor interstitial fluid by microdialysis: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25137530/),μl,30,74868,DB00773,Etoposide
,16162976,AUC,"The second cohort (n=5) received VP-16 (120 mg/m) and CBDCA (AUC=5) followed 1 week later by a fixed daily oral dose of BAY (800 mg) b.i.d., to which VP-16 (120 mg/m) and CBDCA (AUC=5) were added.","A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16162976/),,5,75208,DB00773,Etoposide
,16418874,clearance,"Biliary etoposide clearance was approximately equal to the flow of bile, with an average clearance of 0.32 ml/min determined in patient 1.",Biliary excretion of etoposide in children with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418874/),[ml] / [min],0.32,80973,DB00773,Etoposide
,9649152,AUC,Target AUC values (4.6-8.2 mg ml(-1) x min) were achieved with a high degree of precision and with little bias (mean error 11% and root mean squared error 15% respectively).,A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649152/),[mg·min] / [ml],4.6-8.2,81053,DB00773,Etoposide
,9649152,plasma clearance,"Pharmacokinetic parameters were similar to those reported previously in children, although interpatient pharmacokinetic variability was less than that observed previously: plasma clearance, 23 (18-26) ml min(-1) m(-2); volume of distribution at steady state (Vdss), 6.0 (3.9-8.9) l m(-2); t(1/2) 254 (127-550) min (median and range).",A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649152/),[ml] / [(m)^2·min],23,81054,DB00773,Etoposide
,9649152,volume of distribution at steady state (Vdss),"Pharmacokinetic parameters were similar to those reported previously in children, although interpatient pharmacokinetic variability was less than that observed previously: plasma clearance, 23 (18-26) ml min(-1) m(-2); volume of distribution at steady state (Vdss), 6.0 (3.9-8.9) l m(-2); t(1/2) 254 (127-550) min (median and range).",A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649152/),[l] / [(m)^2],6.0,81055,DB00773,Etoposide
,9649152,t(1/2),"Pharmacokinetic parameters were similar to those reported previously in children, although interpatient pharmacokinetic variability was less than that observed previously: plasma clearance, 23 (18-26) ml min(-1) m(-2); volume of distribution at steady state (Vdss), 6.0 (3.9-8.9) l m(-2); t(1/2) 254 (127-550) min (median and range).",A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649152/),min,254,81056,DB00773,Etoposide
,17907289,response rate,"One patient showed complete response (CR) with disappearance of HCC and PVTT after treatment, and the two patients showed partial response (PR), response rate (CR + PR/All cases 30%).","Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17907289/),%,30,81438,DB00773,Etoposide
,17907289,survival time,The median survival time after the therapy was 457.2 d.,"Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17907289/),d,457.2,81439,DB00773,Etoposide
,3643849,volume of the central compartment,The volume of the central compartment varied from 7.4 to 20.1 l and the steady state volume of distribution from 3.1 to 7.8 l/m2.,Pharmacokinetics of high dose etoposide (VP 16-213). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643849/),l,7.4 to 20.1,82881,DB00773,Etoposide
,3643849,steady state volume of distribution,The volume of the central compartment varied from 7.4 to 20.1 l and the steady state volume of distribution from 3.1 to 7.8 l/m2.,Pharmacokinetics of high dose etoposide (VP 16-213). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643849/),[l] / [m2],3.1 to 7.8,82882,DB00773,Etoposide
,3643849,total body clearance,"The total body clearance varied from 12.0 to 26.8 ml/min/m2, and 26.2 to 53.4% was excreted as unchanged etoposide into the urine and 8.3 to 17.3% as glucuronide into the urine.",Pharmacokinetics of high dose etoposide (VP 16-213). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643849/),[ml] / [m2·min],12.0 to 26.8,82883,DB00773,Etoposide
,3643849,total body clearance,"The total body clearance varied from 12.0 to 26.8 ml/min/m2, and 26.2 to 53.4% was excreted as unchanged etoposide into the urine and 8.3 to 17.3% as glucuronide into the urine.",Pharmacokinetics of high dose etoposide (VP 16-213). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3643849/),,8,82884,DB00773,Etoposide
,19688296,DeltaAUC,"Statistically significant differences between fourth ventricle and lumbar AUC were noted at peaks (DeltaAUC = 3384196 ng h/ml with 95%CI: 1758625, 5009767, P = 0.0044) and at all collection time points (DeltaAUC = 1422977 ng h/ml with 95%CI: 732188, 2113766, P = 0.0046) but not at troughs (DeltaAUC = -29546 ng h/ml (95%CI: -147526, 88434.2, P = 0.5251).",Pharmacokinetic analysis of etoposide distribution after administration directly into the fourth ventricle in a piglet model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19688296/),[h·ng] / [ml],3384196,83199,DB00773,Etoposide
,19688296,DeltaAUC,"Statistically significant differences between fourth ventricle and lumbar AUC were noted at peaks (DeltaAUC = 3384196 ng h/ml with 95%CI: 1758625, 5009767, P = 0.0044) and at all collection time points (DeltaAUC = 1422977 ng h/ml with 95%CI: 732188, 2113766, P = 0.0046) but not at troughs (DeltaAUC = -29546 ng h/ml (95%CI: -147526, 88434.2, P = 0.5251).",Pharmacokinetic analysis of etoposide distribution after administration directly into the fourth ventricle in a piglet model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19688296/),[h·ng] / [ml],1422977,83200,DB00773,Etoposide
,19688296,DeltaAUC,"Statistically significant differences between fourth ventricle and lumbar AUC were noted at peaks (DeltaAUC = 3384196 ng h/ml with 95%CI: 1758625, 5009767, P = 0.0044) and at all collection time points (DeltaAUC = 1422977 ng h/ml with 95%CI: 732188, 2113766, P = 0.0046) but not at troughs (DeltaAUC = -29546 ng h/ml (95%CI: -147526, 88434.2, P = 0.5251).",Pharmacokinetic analysis of etoposide distribution after administration directly into the fourth ventricle in a piglet model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19688296/),[h·ng] / [ml],-,83201,DB00773,Etoposide
,11387367,clearance,"The clearance and terminal elimination half-lives for NSC 655649 averaged 7.57 (SD = 4.2) L/h/m(2) and 48.85 (SD = 23.65) hours, respectively.","Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11387367/),[h·l] / [m(2],7.57,84419,DB00773,Etoposide
,11387367,terminal elimination half-lives,"The clearance and terminal elimination half-lives for NSC 655649 averaged 7.57 (SD = 4.2) L/h/m(2) and 48.85 (SD = 23.65) hours, respectively.","Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11387367/),h,48.85,84420,DB00773,Etoposide
,1329670,peak plasma level (Cmax),"While the peak plasma level (Cmax) was 0.92 +/- 0.43 microgram/ml on the first day and 1.02 +/- 0.30 micrograms/ml on the seventh day of chemotherapy, AUC was 12.3 +/- 5.41 micrograms.hr/ml and 11.9 +/- 4.52 micrograms.hr/ml on the first and the seventh day, respectively.",[Pharmacokinetic study and side effects of chronic daily administration of oral etoposide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329670/),[μg] / [ml],0.92,87349,DB00773,Etoposide
,1329670,peak plasma level (Cmax),"While the peak plasma level (Cmax) was 0.92 +/- 0.43 microgram/ml on the first day and 1.02 +/- 0.30 micrograms/ml on the seventh day of chemotherapy, AUC was 12.3 +/- 5.41 micrograms.hr/ml and 11.9 +/- 4.52 micrograms.hr/ml on the first and the seventh day, respectively.",[Pharmacokinetic study and side effects of chronic daily administration of oral etoposide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329670/),[μg] / [ml],1.02,87350,DB00773,Etoposide
,1329670,AUC,"While the peak plasma level (Cmax) was 0.92 +/- 0.43 microgram/ml on the first day and 1.02 +/- 0.30 micrograms/ml on the seventh day of chemotherapy, AUC was 12.3 +/- 5.41 micrograms.hr/ml and 11.9 +/- 4.52 micrograms.hr/ml on the first and the seventh day, respectively.",[Pharmacokinetic study and side effects of chronic daily administration of oral etoposide]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329670/),[h·μg] / [ml],12.3,87351,DB00773,Etoposide
,1329670,AUC,"While the peak plasma level (Cmax) was 0.92 +/- 0.43 microgram/ml on the first day and 1.02 +/- 0.30 micrograms/ml on the seventh day of chemotherapy, AUC was 12.3 +/- 5.41 micrograms.hr/ml and 11.9 +/- 4.52 micrograms.hr/ml on the first and the seventh day, respectively.",[Pharmacokinetic study and side effects of chronic daily administration of oral etoposide]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1329670/),[h·μg] / [ml],11.9,87352,DB00773,Etoposide
,8402676,plasma clearance,"Median pharmacokinetic parameters were as follows: plasma clearance, 26 ml/min/m2; volume of distribution, 4.9 liters/m2; area under the etoposide plasma concentration-time curve (AUC), 3.9 mg/ml x min per 100 mg/m2.",Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402676/),[ml] / [m2·min],26,88279,DB00773,Etoposide
,8402676,volume of distribution,"Median pharmacokinetic parameters were as follows: plasma clearance, 26 ml/min/m2; volume of distribution, 4.9 liters/m2; area under the etoposide plasma concentration-time curve (AUC), 3.9 mg/ml x min per 100 mg/m2.",Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402676/),[l] / [m2],4.9,88280,DB00773,Etoposide
,8402676,area under the etoposide plasma concentration-time curve (AUC),"Median pharmacokinetic parameters were as follows: plasma clearance, 26 ml/min/m2; volume of distribution, 4.9 liters/m2; area under the etoposide plasma concentration-time curve (AUC), 3.9 mg/ml x min per 100 mg/m2.",Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402676/),[mg] / [100·m2·mg·min·ml],3.9,88281,DB00773,Etoposide
,8845473,Cmax,"The Cmax (25.3-42.5 micrograms/ml) increased linearly, while AUCinf (75.8-156 h micrograms/ml) of etoposide increased proportionately with dose (50-100 mg/m2 of etoposide equivalents).",Phase I and pharmacokinetic study of etoposide phosphate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845473/),[μg] / [ml],25.3-42.5,88421,DB00773,Etoposide
,8845473,AUCinf,"The Cmax (25.3-42.5 micrograms/ml) increased linearly, while AUCinf (75.8-156 h micrograms/ml) of etoposide increased proportionately with dose (50-100 mg/m2 of etoposide equivalents).",Phase I and pharmacokinetic study of etoposide phosphate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845473/),[h·μg] / [ml],75.8-156,88422,DB00773,Etoposide
,8845473,Cmax,"Mean etoposide phosphate/etoposide Cmax and AUCinf ratios were 0.08 or less and 0.003, respectively, indicating that the major circulating moiety in plasma was etoposide.",Phase I and pharmacokinetic study of etoposide phosphate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8845473/),,0,88423,DB00773,Etoposide
,671246,volume of the metabolite compartment,The volume of the metabolite compartment (27.5 liters) was calculated as a fraction of the extrapolated volume.,"Multicompartment pharmacokinetic model of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/671246/),l,27.5,89557,DB00773,Etoposide
,671246,body clearance,A larger body clearance (111.7 ml/min) of metabolite as compared to the renal clearance (31.3 ml/min) indicates that the metabolite is lost from the plasma equivalent space by another elimination route.,"Multicompartment pharmacokinetic model of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/671246/),[ml] / [min],111.7,89558,DB00773,Etoposide
,671246,renal clearance,A larger body clearance (111.7 ml/min) of metabolite as compared to the renal clearance (31.3 ml/min) indicates that the metabolite is lost from the plasma equivalent space by another elimination route.,"Multicompartment pharmacokinetic model of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) in humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/671246/),[ml] / [min],31.3,89559,DB00773,Etoposide
>,8640171,AUC,Eighteen of 51 (35.3%) evaluable patients had an AUC > 1500 mumol x min/l; 10 of whom received doses reduced proportionally to achieve an AUC = 1200 mumol x min/l starting with the 10th to 15th dose.,Association of busulfan area under the curve with veno-occlusive disease following BMT. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8640171/),[min·μM] / [l],1500,89824,DB00773,Etoposide
,8640171,AUC,Eighteen of 51 (35.3%) evaluable patients had an AUC > 1500 mumol x min/l; 10 of whom received doses reduced proportionally to achieve an AUC = 1200 mumol x min/l starting with the 10th to 15th dose.,Association of busulfan area under the curve with veno-occlusive disease following BMT. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8640171/),[min·μM] / [l],1200,89825,DB00773,Etoposide
>,8640171,AUC,Six of 18 (33.3%) patients with an initial AUC > 1500 mumol x min/l developed VOD vs one of 33 (3.0%) patients with an initial AUC < 1500 mumol x min/l (relative risk = 11.1; P = 0.0056).,Association of busulfan area under the curve with veno-occlusive disease following BMT. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8640171/),[min·μM] / [l],1500,89826,DB00773,Etoposide
<,8640171,AUC,Six of 18 (33.3%) patients with an initial AUC > 1500 mumol x min/l developed VOD vs one of 33 (3.0%) patients with an initial AUC < 1500 mumol x min/l (relative risk = 11.1; P = 0.0056).,Association of busulfan area under the curve with veno-occlusive disease following BMT. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8640171/),[min·μM] / [l],1500,89827,DB00773,Etoposide
,1611808,clearance,"Median pharmacokinetic parameters for ultrafilterable platinum were as follows: clearance 45.8 ml/min/m2 (range, 25.5 to 65.3 ml/min/m2) and a terminal half-life of 3.6 hours (range, 2.1 to 14.2 hours).",The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611808/),[ml] / [m2·min],45.8,89979,DB00773,Etoposide
,1611808,terminal half-life,"Median pharmacokinetic parameters for ultrafilterable platinum were as follows: clearance 45.8 ml/min/m2 (range, 25.5 to 65.3 ml/min/m2) and a terminal half-life of 3.6 hours (range, 2.1 to 14.2 hours).",The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611808/),h,3.6,89980,DB00773,Etoposide
,11384092,terminal half-life,"Pharmacokinetic data analysis in the CSF (11 courses, 4 patients) revealed a terminal half-life of 7.4+/-1.2 hours and an AUC of 25.0 +/- 9.5 microg h ml(-1)(mean +/- standard deviation).",Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11384092/),h,7.4,89984,DB00773,Etoposide
,11384092,AUC,"Pharmacokinetic data analysis in the CSF (11 courses, 4 patients) revealed a terminal half-life of 7.4+/-1.2 hours and an AUC of 25.0 +/- 9.5 microg h ml(-1)(mean +/- standard deviation).",Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11384092/),[h·μg] / [ml],25.0,89985,DB00773,Etoposide
,11384092,volume of distribution at steady state,The volume of distribution at steady state and total clearance exhibited a large interindividual variability with mean values of 0.16 l and 0.46 ml min(-1)respectively.,Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11384092/),l,0.16,89986,DB00773,Etoposide
,11384092,total clearance,The volume of distribution at steady state and total clearance exhibited a large interindividual variability with mean values of 0.16 l and 0.46 ml min(-1)respectively.,Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11384092/),[ml] / [min],0.46,89987,DB00773,Etoposide
,7083453,plasma elimination of half-life,At both doses the plasma elimination of half-life was around 30 min.,Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083453/),min,30,90259,DB00773,Etoposide
,8395871,overall response,"Among 25 evaluable pts, 60% (95% CI: 39%-79%) overall response, 144 and 217 days of median PFS and survival.",Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8395871/),,60,90635,DB00773,Etoposide
,2176133,half-lives,"In two patients, the pharmacokinetics of carboplatin were determined; the pre-dialysis half-lives, AUC, and total body clearances of free carboplatin-derived platinum were estimated to be 32 and 18.3 h, 4.93 and 6.17 mg ml-1 min, and 18.2 and 18.7 ml/min, respectively.",Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2176133/),h,32,91544,DB00773,Etoposide
,2176133,AUC,"In two patients, the pharmacokinetics of carboplatin were determined; the pre-dialysis half-lives, AUC, and total body clearances of free carboplatin-derived platinum were estimated to be 32 and 18.3 h, 4.93 and 6.17 mg ml-1 min, and 18.2 and 18.7 ml/min, respectively.",Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2176133/),[mg·min] / [ml],4.93,91545,DB00773,Etoposide
,2176133,total body clearances,"In two patients, the pharmacokinetics of carboplatin were determined; the pre-dialysis half-lives, AUC, and total body clearances of free carboplatin-derived platinum were estimated to be 32 and 18.3 h, 4.93 and 6.17 mg ml-1 min, and 18.2 and 18.7 ml/min, respectively.",Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2176133/),[mg·min] / [ml],6.17,91546,DB00773,Etoposide
,2176133,total body clearances,"In two patients, the pharmacokinetics of carboplatin were determined; the pre-dialysis half-lives, AUC, and total body clearances of free carboplatin-derived platinum were estimated to be 32 and 18.3 h, 4.93 and 6.17 mg ml-1 min, and 18.2 and 18.7 ml/min, respectively.",Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2176133/),[ml] / [min],18.2,91547,DB00773,Etoposide
,2176133,total body clearances,"In two patients, the pharmacokinetics of carboplatin were determined; the pre-dialysis half-lives, AUC, and total body clearances of free carboplatin-derived platinum were estimated to be 32 and 18.3 h, 4.93 and 6.17 mg ml-1 min, and 18.2 and 18.7 ml/min, respectively.",Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2176133/),[ml] / [min],18.7,91548,DB00773,Etoposide
,2176133,elimination half-lives (t1/2 beta),"The dialysis elimination half-lives (t1/2 beta) of 2 and 3 h, respectively, for these two patients were markedly lower than the predialysis values, indicating that carboplatin was dialyzed.",Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2176133/),h,2,91549,DB00773,Etoposide
,2176133,elimination half-lives (t1/2 beta),"The dialysis elimination half-lives (t1/2 beta) of 2 and 3 h, respectively, for these two patients were markedly lower than the predialysis values, indicating that carboplatin was dialyzed.",Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2176133/),h,3,91550,DB00773,Etoposide
,17944242,particle,"The mean particle size, zeta potential and entrapment efficiency of ESE were (189.9 +/- 54.6) nm, - 32.6 mV and 91.7%, respectively.",[Preparation and in vitro and in vivo evaluation of etoposide submicro-emulsion for intravenous injection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944242/),nm,189.9,91905,DB00773,Etoposide
,17944242,entrapment efficiency,"The mean particle size, zeta potential and entrapment efficiency of ESE were (189.9 +/- 54.6) nm, - 32.6 mV and 91.7%, respectively.",[Preparation and in vitro and in vivo evaluation of etoposide submicro-emulsion for intravenous injection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944242/),,91,91906,DB00773,Etoposide
,17944242,shelf life (T0.9),The shelf life (T0.9) of etoposide in lipid emulsion was estimated to be about 665 days at 4 degrees C.,[Preparation and in vitro and in vivo evaluation of etoposide submicro-emulsion for intravenous injection]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944242/),d,665,91907,DB00773,Etoposide
,17944242,area under the curve of concentration versus time from zero to the last time point,"The area under the curve of concentration versus time from zero to the last time point and the mean residence time of ESE and solution were (18.30 +/- 8.74) and (19.32 +/- 6.45) microg x h x mL(-1), and (1.46 +/- 0.32) and (1.71 +/- 0.52) h, respectively.",[Preparation and in vitro and in vivo evaluation of etoposide submicro-emulsion for intravenous injection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944242/),[h·μg] / [ml],18.30,91908,DB00773,Etoposide
,17944242,area under the curve of concentration versus time from zero to the last time point,"The area under the curve of concentration versus time from zero to the last time point and the mean residence time of ESE and solution were (18.30 +/- 8.74) and (19.32 +/- 6.45) microg x h x mL(-1), and (1.46 +/- 0.32) and (1.71 +/- 0.52) h, respectively.",[Preparation and in vitro and in vivo evaluation of etoposide submicro-emulsion for intravenous injection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944242/),[h·μg] / [ml],19.32,91909,DB00773,Etoposide
,17944242,area under the curve of concentration versus time from zero to the last time point,"The area under the curve of concentration versus time from zero to the last time point and the mean residence time of ESE and solution were (18.30 +/- 8.74) and (19.32 +/- 6.45) microg x h x mL(-1), and (1.46 +/- 0.32) and (1.71 +/- 0.52) h, respectively.",[Preparation and in vitro and in vivo evaluation of etoposide submicro-emulsion for intravenous injection]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944242/),h,1.46,91910,DB00773,Etoposide
,17944242,mean residence time,"The area under the curve of concentration versus time from zero to the last time point and the mean residence time of ESE and solution were (18.30 +/- 8.74) and (19.32 +/- 6.45) microg x h x mL(-1), and (1.46 +/- 0.32) and (1.71 +/- 0.52) h, respectively.",[Preparation and in vitro and in vivo evaluation of etoposide submicro-emulsion for intravenous injection]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944242/),[h·μg] / [ml],19.32,91911,DB00773,Etoposide
,17944242,mean residence time,"The area under the curve of concentration versus time from zero to the last time point and the mean residence time of ESE and solution were (18.30 +/- 8.74) and (19.32 +/- 6.45) microg x h x mL(-1), and (1.46 +/- 0.32) and (1.71 +/- 0.52) h, respectively.",[Preparation and in vitro and in vivo evaluation of etoposide submicro-emulsion for intravenous injection]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944242/),h,1.71,91912,DB00773,Etoposide
,3772420,Systemic clearance,"Systemic clearance, Vdss and t1/2 beta averaged (+/- SD) 21.4 (+/- 7.4) mL/min/m2, 10.7 (+/- 4.1) L/m2, and 8.1 (+/- 2.8) hours in the nine patients with bilirubin less than or equal to 1 mg/dL, and 22.4 (+/- 9.6) mL/min/m2, 13.6 (+/- 11.3) L/m2, and 8.4 (+/- 3.9) hours in the eight patients with bilirubin 1.9 to 23.0 mg/dL.",Etoposide pharmacokinetics in patients with normal and abnormal organ function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772420/),[ml] / [m2·min],21.4,92887,DB00773,Etoposide
,3772420,t1/2 beta,"Systemic clearance, Vdss and t1/2 beta averaged (+/- SD) 21.4 (+/- 7.4) mL/min/m2, 10.7 (+/- 4.1) L/m2, and 8.1 (+/- 2.8) hours in the nine patients with bilirubin less than or equal to 1 mg/dL, and 22.4 (+/- 9.6) mL/min/m2, 13.6 (+/- 11.3) L/m2, and 8.4 (+/- 3.9) hours in the eight patients with bilirubin 1.9 to 23.0 mg/dL.",Etoposide pharmacokinetics in patients with normal and abnormal organ function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772420/),h,8.1,92888,DB00773,Etoposide
,3772420,t1/2 beta,"Systemic clearance, Vdss and t1/2 beta averaged (+/- SD) 21.4 (+/- 7.4) mL/min/m2, 10.7 (+/- 4.1) L/m2, and 8.1 (+/- 2.8) hours in the nine patients with bilirubin less than or equal to 1 mg/dL, and 22.4 (+/- 9.6) mL/min/m2, 13.6 (+/- 11.3) L/m2, and 8.4 (+/- 3.9) hours in the eight patients with bilirubin 1.9 to 23.0 mg/dL.",Etoposide pharmacokinetics in patients with normal and abnormal organ function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772420/),h,8.4,92889,DB00773,Etoposide
,3772420,clearance,"Patients with total bilirubin 1.9 to 23 mg/dL, but creatinine clearance greater than 30 mL/min/m2 had etoposide clearance within the range for patients with normal liver function (16.8 to 35 mL/min/m2).",Etoposide pharmacokinetics in patients with normal and abnormal organ function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772420/),[ml] / [m2·min],16.8 to 35,92890,DB00773,Etoposide
>,11914910,AUC,"Short infusions (0.5 h and 4 h) resulted in extreme peak levels (factors of 17.6+/-1.5 and 8.7+/-0.4 compared to the standard LD schedule) and an AUC >10 mg/l (factors of 17.5+/-4.9 and 17.2+/-4.8, and 83+/-2.4% and 82+/-2.4% of the corresponding total AUC), and the 96-h infusion yielded a long duration of exposure to concentrations >10 mg/l (factor 7.9+/-2.6), whereas continuous i.v. infusion over 55+/-11 days was associated with a multiple increase in the duration of exposure to ""standard"" drug concentrations (1 mg/l ).",Low dose--high dose: what is the right dose? Pharmacokinetic modeling of etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914910/),[mg] / [l],10,93647,DB00773,Etoposide
,21050136,loading,"Moreover, the obtained loading of etoposide in the submicron emulsion was 3.0 mg/mL, which was three times higher than that of the previous liquid emulsions.","A lyophilized etoposide submicron emulsion with a high drug loading for intravenous injection: preparation, evaluation, and pharmacokinetics in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21050136/),[mg] / [ml],3.0,95081,DB00773,Etoposide
,21050136,diameter,"The median diameter, polydispersity index, and zeta potential of the optimum formulation of LEPE were 226.1 ± 5.1 nm, 0.107 ± 0.011, and -36.20 ± 1.13 mV, respectively.","A lyophilized etoposide submicron emulsion with a high drug loading for intravenous injection: preparation, evaluation, and pharmacokinetics in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21050136/),nm,226.1,95082,DB00773,Etoposide
,21050136,polydispersity index,"The median diameter, polydispersity index, and zeta potential of the optimum formulation of LEPE were 226.1 ± 5.1 nm, 0.107 ± 0.011, and -36.20 ± 1.13 mV, respectively.","A lyophilized etoposide submicron emulsion with a high drug loading for intravenous injection: preparation, evaluation, and pharmacokinetics in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21050136/),mv,0.107,95083,DB00773,Etoposide
,21050136,zeta potential,"The median diameter, polydispersity index, and zeta potential of the optimum formulation of LEPE were 226.1 ± 5.1 nm, 0.107 ± 0.011, and -36.20 ± 1.13 mV, respectively.","A lyophilized etoposide submicron emulsion with a high drug loading for intravenous injection: preparation, evaluation, and pharmacokinetics in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21050136/),mv,-,95084,DB00773,Etoposide
,21050136,zeta potential,"The median diameter, polydispersity index, and zeta potential of the optimum formulation of LEPE were 226.1 ± 5.1 nm, 0.107 ± 0.011, and -36.20 ± 1.13 mV, respectively.","A lyophilized etoposide submicron emulsion with a high drug loading for intravenous injection: preparation, evaluation, and pharmacokinetics in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21050136/),mv,36.20,95085,DB00773,Etoposide
>,12092743,terminal half-life,"The terminal half-life of total platinum > 5 days was fourfold longer than that of ultrafiltered platinum, indicating long-term retention.",Toxicity of high-dose carboplatin: ultrafiltered and not total plasma pharmacokinetics is of clinical relevance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12092743/),d,5,95823,DB00773,Etoposide
,7825963,area under the total plasma platinum concentrations versus time curve (AUC Pt 0-120),"CDDP doses were adjusted to achieve, during each 5 day infusion, an area under the total plasma platinum concentrations versus time curve (AUC Pt 0-120) ranging between 80,000 and 100,000 micrograms/l.h.","Dose optimization of gallium chloride, orally administered, in combination with platinum compounds. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825963/),[μg] / [h·l],"80,000 and 100,000",95887,DB00773,Etoposide
,7825963,AUC Pt 0-120,"The proposed methods of adaptation were successful from a pharmacokinetic point of view as AUC Pt 0-120 were respectively 81351 +/- 4788, 88268 +/- 8451 and 88331 +/- 8778 micrograms/l.h during the first 3 courses, and plasma Ga concentrations, determined during the 2nd and 3rd CDDP courses, 16 hours after the beginning of the CDDP infusion, were respectively 264 +/- 127 and 313 +/- 186 micrograms/l.","Dose optimization of gallium chloride, orally administered, in combination with platinum compounds. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825963/),[μg] / [h·l],81351,95888,DB00773,Etoposide
,7825963,AUC Pt 0-120,"The proposed methods of adaptation were successful from a pharmacokinetic point of view as AUC Pt 0-120 were respectively 81351 +/- 4788, 88268 +/- 8451 and 88331 +/- 8778 micrograms/l.h during the first 3 courses, and plasma Ga concentrations, determined during the 2nd and 3rd CDDP courses, 16 hours after the beginning of the CDDP infusion, were respectively 264 +/- 127 and 313 +/- 186 micrograms/l.","Dose optimization of gallium chloride, orally administered, in combination with platinum compounds. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825963/),[μg] / [h·l],88268,95889,DB00773,Etoposide
,7825963,AUC Pt 0-120,"The proposed methods of adaptation were successful from a pharmacokinetic point of view as AUC Pt 0-120 were respectively 81351 +/- 4788, 88268 +/- 8451 and 88331 +/- 8778 micrograms/l.h during the first 3 courses, and plasma Ga concentrations, determined during the 2nd and 3rd CDDP courses, 16 hours after the beginning of the CDDP infusion, were respectively 264 +/- 127 and 313 +/- 186 micrograms/l.","Dose optimization of gallium chloride, orally administered, in combination with platinum compounds. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825963/),[μg] / [h·l],88331,95890,DB00773,Etoposide
,7825963,plasma Ga concentrations,"The proposed methods of adaptation were successful from a pharmacokinetic point of view as AUC Pt 0-120 were respectively 81351 +/- 4788, 88268 +/- 8451 and 88331 +/- 8778 micrograms/l.h during the first 3 courses, and plasma Ga concentrations, determined during the 2nd and 3rd CDDP courses, 16 hours after the beginning of the CDDP infusion, were respectively 264 +/- 127 and 313 +/- 186 micrograms/l.","Dose optimization of gallium chloride, orally administered, in combination with platinum compounds. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825963/),[μg] / [l],264,95891,DB00773,Etoposide
,7825963,plasma Ga concentrations,"The proposed methods of adaptation were successful from a pharmacokinetic point of view as AUC Pt 0-120 were respectively 81351 +/- 4788, 88268 +/- 8451 and 88331 +/- 8778 micrograms/l.h during the first 3 courses, and plasma Ga concentrations, determined during the 2nd and 3rd CDDP courses, 16 hours after the beginning of the CDDP infusion, were respectively 264 +/- 127 and 313 +/- 186 micrograms/l.","Dose optimization of gallium chloride, orally administered, in combination with platinum compounds. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825963/),[μg] / [l],313,95892,DB00773,Etoposide
,8548877,bioavailabilities,"The mean etoposide bioavailabilities (+/- SD) of the 50-mg and 75-mg doses were 47 +/- 11% and 59 +/- 18%, respectively, and of the 100-mg dose in two patients were 51% and 33%, respectively.",Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8548877/),%,47,96128,DB00773,Etoposide
,8548877,bioavailabilities,"The mean etoposide bioavailabilities (+/- SD) of the 50-mg and 75-mg doses were 47 +/- 11% and 59 +/- 18%, respectively, and of the 100-mg dose in two patients were 51% and 33%, respectively.",Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8548877/),%,59,96129,DB00773,Etoposide
,8548877,bioavailabilities,"The mean etoposide bioavailabilities (+/- SD) of the 50-mg and 75-mg doses were 47 +/- 11% and 59 +/- 18%, respectively, and of the 100-mg dose in two patients were 51% and 33%, respectively.",Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8548877/),%,51,96130,DB00773,Etoposide
,8548877,bioavailabilities,"The mean etoposide bioavailabilities (+/- SD) of the 50-mg and 75-mg doses were 47 +/- 11% and 59 +/- 18%, respectively, and of the 100-mg dose in two patients were 51% and 33%, respectively.",Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8548877/),%,33,96131,DB00773,Etoposide
,10426664,terminal half-life (t1/2gamma),"Using an open 3-compartment model, the terminal half-life (t1/2gamma) was 14.7 +/- 3.7 h.",Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426664/),h,14.7,96412,DB00773,Etoposide
,10426664,AUC,"The AUC at 250 mg/m2 was determined to be 330 +/- 147 microg/mlh, the plasma clearance of NK611 was 16.2 +/- 8.2 ml/min x m2 and the V(ss) was 16.8 +/- 3.3 l/m2.",Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426664/),[μg] / [mlh],330,96413,DB00773,Etoposide
,10426664,plasma clearance,"The AUC at 250 mg/m2 was determined to be 330 +/- 147 microg/mlh, the plasma clearance of NK611 was 16.2 +/- 8.2 ml/min x m2 and the V(ss) was 16.8 +/- 3.3 l/m2.",Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426664/),[ml] / [m2·min],16.2,96414,DB00773,Etoposide
,10426664,V(ss),"The AUC at 250 mg/m2 was determined to be 330 +/- 147 microg/mlh, the plasma clearance of NK611 was 16.2 +/- 8.2 ml/min x m2 and the V(ss) was 16.8 +/- 3.3 l/m2.",Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426664/),[l] / [m2],16.8,96415,DB00773,Etoposide
,10426664,Protein binding,Protein binding of NK611 was 98.7%.,Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426664/),%,98.7,96416,DB00773,Etoposide
,1855278,terminal half-life,A terminal half-life of 3.4 +/- 0.7 h and a volume of distribution of 15.4 +/- 9.6 l were found (n = 8); the AUC was 764 +/- 302 micrograms h ml-1.,Unaltered pharmacokinetics after the administration of high-dose etoposide without prior dilution. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855278/),h,3.4,97662,DB00773,Etoposide
,1855278,volume of distribution,A terminal half-life of 3.4 +/- 0.7 h and a volume of distribution of 15.4 +/- 9.6 l were found (n = 8); the AUC was 764 +/- 302 micrograms h ml-1.,Unaltered pharmacokinetics after the administration of high-dose etoposide without prior dilution. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855278/),l,15.4,97663,DB00773,Etoposide
,1855278,AUC,A terminal half-life of 3.4 +/- 0.7 h and a volume of distribution of 15.4 +/- 9.6 l were found (n = 8); the AUC was 764 +/- 302 micrograms h ml-1.,Unaltered pharmacokinetics after the administration of high-dose etoposide without prior dilution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855278/),[h·μg] / [ml],764,97664,DB00773,Etoposide
,19342996,concentration,The median TGN concentration in non-DS children above 2 years of age was 2.30 micromol/mmol Hb (range 0.57-25.3).,Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19342996/),[μM] / [hb·mM],2.30,97683,DB00773,Etoposide
,7964955,clearance (Cl),"The median values for clearance (Cl) and terminal half-life (T1/2 beta) of etoposide were 14.3 mL/min/m2 (range, 6.8 to 29.6) and 5.9 hours (range, 3.7 to 39).",Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7964955/),[ml] / [m2·min],14.3,97732,DB00773,Etoposide
,7964955,terminal half-life (T1/2 beta),"The median values for clearance (Cl) and terminal half-life (T1/2 beta) of etoposide were 14.3 mL/min/m2 (range, 6.8 to 29.6) and 5.9 hours (range, 3.7 to 39).",Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7964955/),h,5.9,97733,DB00773,Etoposide
,7964955,Cl,"However, seven patients who received concomitant anticonvulsant therapy had significantly higher (P < .01) average etoposide Cl values (23.7 mL/min/m2) than 22 patients who did not receive drugs known to alter hepatic metabolism (13.4 mL/min/m2).",Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7964955/),[ml] / [m2·min],23.7,97734,DB00773,Etoposide
,7964955,Cl,"However, seven patients who received concomitant anticonvulsant therapy had significantly higher (P < .01) average etoposide Cl values (23.7 mL/min/m2) than 22 patients who did not receive drugs known to alter hepatic metabolism (13.4 mL/min/m2).",Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7964955/),[ml] / [m2·min],13.4,97735,DB00773,Etoposide
,24368401,DLT rates,"Cycle 1 DLT rates were 50.0%, 22.2%, and 16.7% in cohorts A, B, and C, respectively.",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,50.0,98403,DB00773,Etoposide
,24368401,DLT rates,"Cycle 1 DLT rates were 50.0%, 22.2%, and 16.7% in cohorts A, B, and C, respectively.",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,22.2,98404,DB00773,Etoposide
,24368401,DLT rates,"Cycle 1 DLT rates were 50.0%, 22.2%, and 16.7% in cohorts A, B, and C, respectively.",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,16.7,98405,DB00773,Etoposide
,24368401,overall response,"Best overall response was partial response (40.0%, 61.1%, and 58.3% in cohorts A, B, and C, respectively).",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,40.0,98406,DB00773,Etoposide
,24368401,overall response,"Best overall response was partial response (40.0%, 61.1%, and 58.3% in cohorts A, B, and C, respectively).",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,61.1,98407,DB00773,Etoposide
,24368401,overall response,"Best overall response was partial response (40.0%, 61.1%, and 58.3% in cohorts A, B, and C, respectively).",A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368401/),%,58.3,98408,DB00773,Etoposide
,19920107,apparent clearance,Pegfilgrastim apparent clearance (11 mL/h/kg) was similar to that reported in adults.,Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19920107/),[ml] / [h·kg],11,98475,DB00773,Etoposide
<,8996572,area under the plasma concentration-time curve ratio,"The individual area under the plasma concentration-time curve ratio of etoposide phosphate/etoposide was < or = 0.0324, indicating that etoposide was the major circulating moiety after infusion of etoposide phosphate.","Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996572/),,0.0324,100183,DB00773,Etoposide
,2453234,area under the concentration curve,"In this patient, melphalan pharmacokinetics was different from that of patients without important renal dysfunction for the area under the concentration curve (1,324 mg.l-1.min).",[Pharmacokinetics of high-dose melphalan (200 mg/m2) in a case of total renal insufficiency]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453234/),[mg·min] / [l],"1,324",100874,DB00773,Etoposide
,2453234,elimination half-life,"However, with a melphalan elimination half-life of 80 min, ABMG could be performed, as usually, 24 h after melphalan administration.",[Pharmacokinetics of high-dose melphalan (200 mg/m2) in a case of total renal insufficiency]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453234/),min,80,100875,DB00773,Etoposide
,8019466,maximal concentration,The major difference was the maximal concentration in the case of 6-h infusions (122 +/- 35 micrograms/ml) and in the case of 34-h infusions (23.2 +/- 4.9 micrograms/ml) and the duration of VP-16 concentrations with > 10 and > 1 microgram/ml.,Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8019466/),[μg] / [ml],122,101521,DB00773,Etoposide
,8019466,maximal concentration,The major difference was the maximal concentration in the case of 6-h infusions (122 +/- 35 micrograms/ml) and in the case of 34-h infusions (23.2 +/- 4.9 micrograms/ml) and the duration of VP-16 concentrations with > 10 and > 1 microgram/ml.,Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8019466/),[μg] / [ml],23.2,101522,DB00773,Etoposide
,11695718,tmax,"Peak serum concentrations occurred from 0.04 to 4.0 days after infusion (mean tmax = 1.79 +/- 1.55 d) with a mean cmax of 4,595 +/- 2,849 ng/ml.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),d,1.79,102175,DB00773,Etoposide
,11695718,cmax,"Peak serum concentrations occurred from 0.04 to 4.0 days after infusion (mean tmax = 1.79 +/- 1.55 d) with a mean cmax of 4,595 +/- 2,849 ng/ml.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ng] / [ml],"4,595",102176,DB00773,Etoposide
,11695718,Vp,"A total amount of 12.84 +/- 2.47 mg liposomal DOXO in the plasma volume (Vp = 2,794 + 537 ml) could be estimated at tmax (= 27 % of the mean dose of 47.6 mg).","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),ml,"2,794",102177,DB00773,Etoposide
,11695718,t 1/2el,Stealth liposomes were eliminated slowly from the blood with a mean t 1/2el of 1.9 + 0.5 days (MRT was 4.6 + 2.5 days).,"Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),d,1.9,102178,DB00773,Etoposide
,11695718,MRT,Stealth liposomes were eliminated slowly from the blood with a mean t 1/2el of 1.9 + 0.5 days (MRT was 4.6 + 2.5 days).,"Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),d,4.6,102179,DB00773,Etoposide
,11695718,AUClast,"AUClast values ranged from 8,070 to 33,446 ng/ml*d (mean 10,987 +/- 9,339 ng/ml*d).","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ng] / [d·ml],"8,070 to 33,446",102180,DB00773,Etoposide
,11695718,AUClast,"AUClast values ranged from 8,070 to 33,446 ng/ml*d (mean 10,987 +/- 9,339 ng/ml*d).","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ng] / [d·ml],"10,987",102181,DB00773,Etoposide
,11695718,plasma clearance (Cltot,"The low plasma clearance (Cltot = 4,681 +/- 2,835 ml/day) and the small volume of distribution (Vz = 11.7 +/- 6.31) suggested that stealth-liposomes were stable in the blood at least for 14 days.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ml] / [d],"4,681",102182,DB00773,Etoposide
,11695718,volume of distribution (Vz,"The low plasma clearance (Cltot = 4,681 +/- 2,835 ml/day) and the small volume of distribution (Vz = 11.7 +/- 6.31) suggested that stealth-liposomes were stable in the blood at least for 14 days.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),,11.7,102183,DB00773,Etoposide
less,3884152,Absorption,Absorption was less than 40% for only one patient.,"Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884152/),%,40,102954,DB00773,Etoposide
,3884152,peak plasma VP-16 concentrations,"For oral and iv preparations, mean peak plasma VP-16 concentrations were 9.6 and 13.0 micrograms/ml, mean alpha-half-lives were 0.96 and 0.82 hour, mean beta-half-lives were 7.2 and 6.8 hours, mean C X t values were 75.9 and 75.3 mg/L/hour, mean plasma clearances were 1.44 and 1.45 L/hour/m2, and mean extrapolated volumes of distribution were 15.2 and 16.9 L/m2, respectively.","Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884152/),[μg] / [ml],9.6,102955,DB00773,Etoposide
,3884152,peak plasma VP-16 concentrations,"For oral and iv preparations, mean peak plasma VP-16 concentrations were 9.6 and 13.0 micrograms/ml, mean alpha-half-lives were 0.96 and 0.82 hour, mean beta-half-lives were 7.2 and 6.8 hours, mean C X t values were 75.9 and 75.3 mg/L/hour, mean plasma clearances were 1.44 and 1.45 L/hour/m2, and mean extrapolated volumes of distribution were 15.2 and 16.9 L/m2, respectively.","Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884152/),[μg] / [ml],13.0,102956,DB00773,Etoposide
,3884152,alpha-half-lives,"For oral and iv preparations, mean peak plasma VP-16 concentrations were 9.6 and 13.0 micrograms/ml, mean alpha-half-lives were 0.96 and 0.82 hour, mean beta-half-lives were 7.2 and 6.8 hours, mean C X t values were 75.9 and 75.3 mg/L/hour, mean plasma clearances were 1.44 and 1.45 L/hour/m2, and mean extrapolated volumes of distribution were 15.2 and 16.9 L/m2, respectively.","Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884152/),h,0.96,102957,DB00773,Etoposide
,3884152,alpha-half-lives,"For oral and iv preparations, mean peak plasma VP-16 concentrations were 9.6 and 13.0 micrograms/ml, mean alpha-half-lives were 0.96 and 0.82 hour, mean beta-half-lives were 7.2 and 6.8 hours, mean C X t values were 75.9 and 75.3 mg/L/hour, mean plasma clearances were 1.44 and 1.45 L/hour/m2, and mean extrapolated volumes of distribution were 15.2 and 16.9 L/m2, respectively.","Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884152/),h,0.82,102958,DB00773,Etoposide
,3884152,beta-half-lives,"For oral and iv preparations, mean peak plasma VP-16 concentrations were 9.6 and 13.0 micrograms/ml, mean alpha-half-lives were 0.96 and 0.82 hour, mean beta-half-lives were 7.2 and 6.8 hours, mean C X t values were 75.9 and 75.3 mg/L/hour, mean plasma clearances were 1.44 and 1.45 L/hour/m2, and mean extrapolated volumes of distribution were 15.2 and 16.9 L/m2, respectively.","Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884152/),h,7.2,102959,DB00773,Etoposide
,3884152,beta-half-lives,"For oral and iv preparations, mean peak plasma VP-16 concentrations were 9.6 and 13.0 micrograms/ml, mean alpha-half-lives were 0.96 and 0.82 hour, mean beta-half-lives were 7.2 and 6.8 hours, mean C X t values were 75.9 and 75.3 mg/L/hour, mean plasma clearances were 1.44 and 1.45 L/hour/m2, and mean extrapolated volumes of distribution were 15.2 and 16.9 L/m2, respectively.","Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884152/),h,6.8,102960,DB00773,Etoposide
,3884152,C X t,"For oral and iv preparations, mean peak plasma VP-16 concentrations were 9.6 and 13.0 micrograms/ml, mean alpha-half-lives were 0.96 and 0.82 hour, mean beta-half-lives were 7.2 and 6.8 hours, mean C X t values were 75.9 and 75.3 mg/L/hour, mean plasma clearances were 1.44 and 1.45 L/hour/m2, and mean extrapolated volumes of distribution were 15.2 and 16.9 L/m2, respectively.","Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884152/),[mg] / [h·l],75.9,102961,DB00773,Etoposide
,3884152,C X t,"For oral and iv preparations, mean peak plasma VP-16 concentrations were 9.6 and 13.0 micrograms/ml, mean alpha-half-lives were 0.96 and 0.82 hour, mean beta-half-lives were 7.2 and 6.8 hours, mean C X t values were 75.9 and 75.3 mg/L/hour, mean plasma clearances were 1.44 and 1.45 L/hour/m2, and mean extrapolated volumes of distribution were 15.2 and 16.9 L/m2, respectively.","Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884152/),[mg] / [h·l],75.3,102962,DB00773,Etoposide
,3884152,plasma clearances,"For oral and iv preparations, mean peak plasma VP-16 concentrations were 9.6 and 13.0 micrograms/ml, mean alpha-half-lives were 0.96 and 0.82 hour, mean beta-half-lives were 7.2 and 6.8 hours, mean C X t values were 75.9 and 75.3 mg/L/hour, mean plasma clearances were 1.44 and 1.45 L/hour/m2, and mean extrapolated volumes of distribution were 15.2 and 16.9 L/m2, respectively.","Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884152/),[l] / [h·m2],1.44,102963,DB00773,Etoposide
,3884152,plasma clearances,"For oral and iv preparations, mean peak plasma VP-16 concentrations were 9.6 and 13.0 micrograms/ml, mean alpha-half-lives were 0.96 and 0.82 hour, mean beta-half-lives were 7.2 and 6.8 hours, mean C X t values were 75.9 and 75.3 mg/L/hour, mean plasma clearances were 1.44 and 1.45 L/hour/m2, and mean extrapolated volumes of distribution were 15.2 and 16.9 L/m2, respectively.","Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884152/),[l] / [h·m2],1.45,102964,DB00773,Etoposide
,3884152,volumes of distribution,"For oral and iv preparations, mean peak plasma VP-16 concentrations were 9.6 and 13.0 micrograms/ml, mean alpha-half-lives were 0.96 and 0.82 hour, mean beta-half-lives were 7.2 and 6.8 hours, mean C X t values were 75.9 and 75.3 mg/L/hour, mean plasma clearances were 1.44 and 1.45 L/hour/m2, and mean extrapolated volumes of distribution were 15.2 and 16.9 L/m2, respectively.","Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884152/),[l] / [m2],15.2,102965,DB00773,Etoposide
,3884152,volumes of distribution,"For oral and iv preparations, mean peak plasma VP-16 concentrations were 9.6 and 13.0 micrograms/ml, mean alpha-half-lives were 0.96 and 0.82 hour, mean beta-half-lives were 7.2 and 6.8 hours, mean C X t values were 75.9 and 75.3 mg/L/hour, mean plasma clearances were 1.44 and 1.45 L/hour/m2, and mean extrapolated volumes of distribution were 15.2 and 16.9 L/m2, respectively.","Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884152/),[l] / [m2],16.9,102966,DB00773,Etoposide
,3884152,half-life for oral absorption,The half-life for oral absorption was 0.44 hour and peak plasma concentrations were noted 0.5-3 hours after oral drug administration.,"Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3884152/),h,0.44,102967,DB00773,Etoposide
,30089585,MTD,The MTD of roniciclib was 5 mg BID with CARBO-ETOP or CIS-ETOP.,Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30089585/),mg,5,104372,DB00773,Etoposide
,30089585,tmax,"Roniciclib was readily absorbed following oral administration at the MTD (median tmax 0.5-1 h), with a 30-40% reduction in exposure when co-administered with CARBO-ETOP or CIS-ETOP; administration of roniciclib had no effect on etoposide or platinum pharmacokinetics.",Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30089585/),h,0.5-1,104373,DB00773,Etoposide
,30089585,response rate,The response rate was 81.4% (35/43) overall and 86.1% (31/36) in the pooled roniciclib 5 mg BID population (all partial responses).,Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30089585/),%,81.4,104374,DB00773,Etoposide
,30089585,response rate,The response rate was 81.4% (35/43) overall and 86.1% (31/36) in the pooled roniciclib 5 mg BID population (all partial responses).,Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30089585/),%,86,104375,DB00773,Etoposide
,10587291,total systemic exposure,"When VP-16 was administered in association with TAM, the median total systemic exposure was not significantly (p = NS) different from that observed when VP-16 was administered alone [33.74 (range 11.19-56.58) versus 32.97 (range 20.23-119.28) mg/l/h].",Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587291/),[mg] / [h·l],33.74,104456,DB00773,Etoposide
,10587291,total systemic exposure,"When VP-16 was administered in association with TAM, the median total systemic exposure was not significantly (p = NS) different from that observed when VP-16 was administered alone [33.74 (range 11.19-56.58) versus 32.97 (range 20.23-119.28) mg/l/h].",Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587291/),[mg] / [h·l],32.97,104457,DB00773,Etoposide
,10587291,protein binding,"Moreover, TAM did not affect significantly (p = NS) the levels of protein binding of VP-16 [median 94.6 (range 87.7-98.2) versus median 94.9 (range 91.6-98.0)% for VP-16+TAM and VP-16 alone, respectively] and the systemic exposure of the free drug (free AUC) [1.86 (range 0.21-4.57) versus median 1.78 (range 0.59-3.73) mg/l/h for VP-16+TAM and VP = 16 alone, respectively].",Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587291/),%,94.6,104458,DB00773,Etoposide
,10587291,protein binding,"Moreover, TAM did not affect significantly (p = NS) the levels of protein binding of VP-16 [median 94.6 (range 87.7-98.2) versus median 94.9 (range 91.6-98.0)% for VP-16+TAM and VP-16 alone, respectively] and the systemic exposure of the free drug (free AUC) [1.86 (range 0.21-4.57) versus median 1.78 (range 0.59-3.73) mg/l/h for VP-16+TAM and VP = 16 alone, respectively].",Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587291/),%,94.9,104459,DB00773,Etoposide
,10587291,systemic exposure of,"Moreover, TAM did not affect significantly (p = NS) the levels of protein binding of VP-16 [median 94.6 (range 87.7-98.2) versus median 94.9 (range 91.6-98.0)% for VP-16+TAM and VP-16 alone, respectively] and the systemic exposure of the free drug (free AUC) [1.86 (range 0.21-4.57) versus median 1.78 (range 0.59-3.73) mg/l/h for VP-16+TAM and VP = 16 alone, respectively].",Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587291/),[mg] / [h·l],1.86,104460,DB00773,Etoposide
,10587291,systemic exposure of,"Moreover, TAM did not affect significantly (p = NS) the levels of protein binding of VP-16 [median 94.6 (range 87.7-98.2) versus median 94.9 (range 91.6-98.0)% for VP-16+TAM and VP-16 alone, respectively] and the systemic exposure of the free drug (free AUC) [1.86 (range 0.21-4.57) versus median 1.78 (range 0.59-3.73) mg/l/h for VP-16+TAM and VP = 16 alone, respectively].",Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587291/),[mg] / [h·l],1.78,104461,DB00773,Etoposide
,10587291,free AUC),"Moreover, TAM did not affect significantly (p = NS) the levels of protein binding of VP-16 [median 94.6 (range 87.7-98.2) versus median 94.9 (range 91.6-98.0)% for VP-16+TAM and VP-16 alone, respectively] and the systemic exposure of the free drug (free AUC) [1.86 (range 0.21-4.57) versus median 1.78 (range 0.59-3.73) mg/l/h for VP-16+TAM and VP = 16 alone, respectively].",Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587291/),[mg] / [h·l],1.86,104462,DB00773,Etoposide
,10587291,free AUC),"Moreover, TAM did not affect significantly (p = NS) the levels of protein binding of VP-16 [median 94.6 (range 87.7-98.2) versus median 94.9 (range 91.6-98.0)% for VP-16+TAM and VP-16 alone, respectively] and the systemic exposure of the free drug (free AUC) [1.86 (range 0.21-4.57) versus median 1.78 (range 0.59-3.73) mg/l/h for VP-16+TAM and VP = 16 alone, respectively].",Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10587291/),[mg] / [h·l],1.78,104463,DB00773,Etoposide
,26696583,elimination half-life,The median MTX elimination half-life was 21.7 h (range 9.4-204.4).,The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696583/),h,21.7,105605,DB00773,Etoposide
,3698170,t1/2 beta,"VP-16 disappeared biphasically, with a t1/2 beta of 6.1 +/- 1.4 h; the total clearance was 26.8 +/- 2.8 ml/min/m2, and the Vss was 8.8 +/- 1.6 l/m2.",Clinical pharmacology of intracarotid etoposide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698170/),h,6.1,106046,DB00773,Etoposide
,3698170,total clearance,"VP-16 disappeared biphasically, with a t1/2 beta of 6.1 +/- 1.4 h; the total clearance was 26.8 +/- 2.8 ml/min/m2, and the Vss was 8.8 +/- 1.6 l/m2.",Clinical pharmacology of intracarotid etoposide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698170/),[ml] / [m2·min],26.8,106047,DB00773,Etoposide
,3698170,Vss,"VP-16 disappeared biphasically, with a t1/2 beta of 6.1 +/- 1.4 h; the total clearance was 26.8 +/- 2.8 ml/min/m2, and the Vss was 8.8 +/- 1.6 l/m2.",Clinical pharmacology of intracarotid etoposide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698170/),[l] / [m2],8.8,106048,DB00773,Etoposide
,27016067,absorptive transport,"The absorptive transport from mucosal-to-serosal (M → S) and secretory transport from serosal-to-mucosal (S → M) for VP-16 solution over 90 min were found to be (3.58 ± 0.32) × 10-6 and (14.63 ± 3.11) × 10-6 cm/s, respectively, with a net efflux of 4.08.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),[cm] / [s],3.58,107284,DB00773,Etoposide
,27016067,secretory transport,"The absorptive transport from mucosal-to-serosal (M → S) and secretory transport from serosal-to-mucosal (S → M) for VP-16 solution over 90 min were found to be (3.58 ± 0.32) × 10-6 and (14.63 ± 3.11) × 10-6 cm/s, respectively, with a net efflux of 4.08.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),[cm] / [s],3.58,107285,DB00773,Etoposide
,27016067,secretory transport,"The absorptive transport from mucosal-to-serosal (M → S) and secretory transport from serosal-to-mucosal (S → M) for VP-16 solution over 90 min were found to be (3.58 ± 0.32) × 10-6 and (14.63 ± 3.11) × 10-6 cm/s, respectively, with a net efflux of 4.08.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),[cm] / [s],14.63,107286,DB00773,Etoposide
,27016067,net efflux,"The absorptive transport from mucosal-to-serosal (M → S) and secretory transport from serosal-to-mucosal (S → M) for VP-16 solution over 90 min were found to be (3.58 ± 0.32) × 10-6 and (14.63 ± 3.11) × 10-6 cm/s, respectively, with a net efflux of 4.08.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),,4.08,107287,DB00773,Etoposide
,27016067,Papp,"Addition of verapamil (200 µM), a P-glycoprotein inhibitor, elevated the transport from M → S [Papp from (3.58 ± 0.32) to (9.66 ± 1.55) × 10-6 cm/s, p < 0.05] and lowered the S → M [Papp from (14.63 ± 3.11) to (13.35 ± 2.01) × 10-6 cm/s, p < 0.01], with a net efflux of 1.38.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),[cm] / [s],3.58,107288,DB00773,Etoposide
,27016067,Papp,"Addition of verapamil (200 µM), a P-glycoprotein inhibitor, elevated the transport from M → S [Papp from (3.58 ± 0.32) to (9.66 ± 1.55) × 10-6 cm/s, p < 0.05] and lowered the S → M [Papp from (14.63 ± 3.11) to (13.35 ± 2.01) × 10-6 cm/s, p < 0.01], with a net efflux of 1.38.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),[cm] / [s],9.66,107289,DB00773,Etoposide
,27016067,Papp,"Addition of verapamil (200 µM), a P-glycoprotein inhibitor, elevated the transport from M → S [Papp from (3.58 ± 0.32) to (9.66 ± 1.55) × 10-6 cm/s, p < 0.05] and lowered the S → M [Papp from (14.63 ± 3.11) to (13.35 ± 2.01) × 10-6 cm/s, p < 0.01], with a net efflux of 1.38.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),[cm] / [s],14.63,107290,DB00773,Etoposide
,27016067,Papp,"Addition of verapamil (200 µM), a P-glycoprotein inhibitor, elevated the transport from M → S [Papp from (3.58 ± 0.32) to (9.66 ± 1.55) × 10-6 cm/s, p < 0.05] and lowered the S → M [Papp from (14.63 ± 3.11) to (13.35 ± 2.01) × 10-6 cm/s, p < 0.01], with a net efflux of 1.38.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),[cm] / [s],13.35,107291,DB00773,Etoposide
,27016067,net efflux,"Addition of verapamil (200 µM), a P-glycoprotein inhibitor, elevated the transport from M → S [Papp from (3.58 ± 0.32) to (9.66 ± 1.55) × 10-6 cm/s, p < 0.05] and lowered the S → M [Papp from (14.63 ± 3.11) to (13.35 ± 2.01) × 10-6 cm/s, p < 0.01], with a net efflux of 1.38.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),,1.38,107292,DB00773,Etoposide
,9164226,overall response rate,"The overall response rate was 32% (two complete and six partial responses), and the median progression-free survival was 8 weeks (range, 4 to 27).",Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164226/),%,32,107904,DB00773,Etoposide
,9164226,progression-free survival,"The overall response rate was 32% (two complete and six partial responses), and the median progression-free survival was 8 weeks (range, 4 to 27).",Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164226/),weeks,8,107905,DB00773,Etoposide
,12451286,CL,The mean VP16 pharmacokinetic parameters of the reference population calculated from 14 patients following the two-stage method were CL = 1.92 +/- 0.512 L/h and t(1/2) = 6.7 +/- 2 hours.,Population pharmacokinetics of etoposide: application to therapeutic drug monitoring. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451286/),[l] / [h],1.92,108238,DB00773,Etoposide
,12451286,t(1/2),The mean VP16 pharmacokinetic parameters of the reference population calculated from 14 patients following the two-stage method were CL = 1.92 +/- 0.512 L/h and t(1/2) = 6.7 +/- 2 hours.,Population pharmacokinetics of etoposide: application to therapeutic drug monitoring. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451286/),h,6.7,108239,DB00773,Etoposide
,10388001,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 µmol/l and 1.58 µmol/l, respectively.",Clinical Reversal of Multidrug Resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388001/),[μM] / [l],1.66,108553,DB00773,Etoposide
,10388001,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 µmol/l and 1.58 µmol/l, respectively.",Clinical Reversal of Multidrug Resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388001/),[μM] / [l],1.58,108554,DB00773,Etoposide
,10388001,peak total reversing concentration,"Since both are comparable antagonists, a median peak total reversing concentration of 3.24 µmol/l was achieved.",Clinical Reversal of Multidrug Resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388001/),[μM] / [l],3.24,108555,DB00773,Etoposide
,11976838,peak GL331 concentration,"This patient's peak GL331 concentration was 16.8 microg/ml, which was high compared to the mean peak drug concentration of 6+/-4.1 microg/ml.",Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976838/),[μg] / [ml],16.8,111410,DB00773,Etoposide
,11976838,peak drug concentration,"This patient's peak GL331 concentration was 16.8 microg/ml, which was high compared to the mean peak drug concentration of 6+/-4.1 microg/ml.",Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976838/),[μg] / [ml],6,111411,DB00773,Etoposide
,11976838,systemic,"The mean systemic GL331 clearance was 12.1+/-7.2 l/h per m(2), much lower than 23.3+/-8.2 l/h per m(2) found in the phase I trial.",Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976838/),[h·l] / [m(2],12.1,111412,DB00773,Etoposide
,11976838,systemic,"The mean systemic GL331 clearance was 12.1+/-7.2 l/h per m(2), much lower than 23.3+/-8.2 l/h per m(2) found in the phase I trial.",Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976838/),[h·l] / [m(2],23.3,111413,DB00773,Etoposide
,2910453,oral bioavailability,The oral bioavailability of an ACRO solution in VPD was only 50% but both i.p. and p.o. regimens achieved plasma levels greater than 1.0 micrograms/ml.,Antitumor activity and murine pharmacokinetics of parenteral acronycine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2910453/),%,50,111856,DB00773,Etoposide
under,2910453,plasma half-life,The plasma half-life was just under 2 h.,Antitumor activity and murine pharmacokinetics of parenteral acronycine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2910453/),h,2,111857,DB00773,Etoposide
,9815787,Max,3.76+/-0.68 4.10+/-0.86 7.86+/-1.43 Range 2.01-5.03 2. 29-5.72 4.30-10.68 Max/min 2.50 2.45 2.48 High interpatient variability was observed in the AUC.,Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815787/),,2.50,113003,DB00773,Etoposide
within,8485379,recoveries,The mean recoveries were within 100 +/- 5%.,"Simultaneous determination of NK611, a novel water-soluble derivative of etoposide, and its metabolite (DeNK611) in dog plasma by column-switching high performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485379/),%,100,113896,DB00773,Etoposide
,11699396,elimination half-life,"Following a 1 hour i.v. infusion of 50 mg/m2 etoposide, the elimination half-life ranged from 49.8 min to 509.4 min (mean +/- SD = 218.6 +/- 134.7 min), the MRT ranged from 71.8 to 734.9 min (mean +/- SD = 315.4 +/- 194.3 min) and the systemic clearance of etoposide ranged from 15.7 to 38.0 ml/min/m2 (mean +/- SD = 24.1 +/- 7.0 ml/min/m2).",Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),min,49.8,114521,DB00773,Etoposide
,11699396,elimination half-life,"Following a 1 hour i.v. infusion of 50 mg/m2 etoposide, the elimination half-life ranged from 49.8 min to 509.4 min (mean +/- SD = 218.6 +/- 134.7 min), the MRT ranged from 71.8 to 734.9 min (mean +/- SD = 315.4 +/- 194.3 min) and the systemic clearance of etoposide ranged from 15.7 to 38.0 ml/min/m2 (mean +/- SD = 24.1 +/- 7.0 ml/min/m2).",Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),min,509.4,114522,DB00773,Etoposide
,11699396,elimination half-life,"Following a 1 hour i.v. infusion of 50 mg/m2 etoposide, the elimination half-life ranged from 49.8 min to 509.4 min (mean +/- SD = 218.6 +/- 134.7 min), the MRT ranged from 71.8 to 734.9 min (mean +/- SD = 315.4 +/- 194.3 min) and the systemic clearance of etoposide ranged from 15.7 to 38.0 ml/min/m2 (mean +/- SD = 24.1 +/- 7.0 ml/min/m2).",Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),min,218.6,114523,DB00773,Etoposide
,11699396,MRT,"Following a 1 hour i.v. infusion of 50 mg/m2 etoposide, the elimination half-life ranged from 49.8 min to 509.4 min (mean +/- SD = 218.6 +/- 134.7 min), the MRT ranged from 71.8 to 734.9 min (mean +/- SD = 315.4 +/- 194.3 min) and the systemic clearance of etoposide ranged from 15.7 to 38.0 ml/min/m2 (mean +/- SD = 24.1 +/- 7.0 ml/min/m2).",Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),min,71.8 to 734.9,114524,DB00773,Etoposide
,11699396,MRT,"Following a 1 hour i.v. infusion of 50 mg/m2 etoposide, the elimination half-life ranged from 49.8 min to 509.4 min (mean +/- SD = 218.6 +/- 134.7 min), the MRT ranged from 71.8 to 734.9 min (mean +/- SD = 315.4 +/- 194.3 min) and the systemic clearance of etoposide ranged from 15.7 to 38.0 ml/min/m2 (mean +/- SD = 24.1 +/- 7.0 ml/min/m2).",Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),min,315.4,114525,DB00773,Etoposide
,11699396,systemic clearance,"Following a 1 hour i.v. infusion of 50 mg/m2 etoposide, the elimination half-life ranged from 49.8 min to 509.4 min (mean +/- SD = 218.6 +/- 134.7 min), the MRT ranged from 71.8 to 734.9 min (mean +/- SD = 315.4 +/- 194.3 min) and the systemic clearance of etoposide ranged from 15.7 to 38.0 ml/min/m2 (mean +/- SD = 24.1 +/- 7.0 ml/min/m2).",Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),[ml] / [m2·min],15.7 to 38.0,114526,DB00773,Etoposide
,11699396,systemic clearance,"Following a 1 hour i.v. infusion of 50 mg/m2 etoposide, the elimination half-life ranged from 49.8 min to 509.4 min (mean +/- SD = 218.6 +/- 134.7 min), the MRT ranged from 71.8 to 734.9 min (mean +/- SD = 315.4 +/- 194.3 min) and the systemic clearance of etoposide ranged from 15.7 to 38.0 ml/min/m2 (mean +/- SD = 24.1 +/- 7.0 ml/min/m2).",Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),[ml] / [m2·min],24.1,114527,DB00773,Etoposide
,11699396,AUC,"The AUC ranged from 2234.9 to 5427.0 microM.min) (mean +/- SD = 3827.8 +/- 1069.5 microM.min) and Vc ranged from 2026.9 to 13,505.2 ml/m2 (mean +/- SD = 6825.4 +/- 3278.5 ml/m2).",Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),min)·μM,2234.9 to 5427.0,114528,DB00773,Etoposide
,11699396,AUC,"The AUC ranged from 2234.9 to 5427.0 microM.min) (mean +/- SD = 3827.8 +/- 1069.5 microM.min) and Vc ranged from 2026.9 to 13,505.2 ml/m2 (mean +/- SD = 6825.4 +/- 3278.5 ml/m2).",Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),min·μM,3827.8,114529,DB00773,Etoposide
,11699396,Vc,"The AUC ranged from 2234.9 to 5427.0 microM.min) (mean +/- SD = 3827.8 +/- 1069.5 microM.min) and Vc ranged from 2026.9 to 13,505.2 ml/m2 (mean +/- SD = 6825.4 +/- 3278.5 ml/m2).",Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),[ml] / [m2],"2026.9 to 13,505.2",114530,DB00773,Etoposide
,11699396,Vc,"The AUC ranged from 2234.9 to 5427.0 microM.min) (mean +/- SD = 3827.8 +/- 1069.5 microM.min) and Vc ranged from 2026.9 to 13,505.2 ml/m2 (mean +/- SD = 6825.4 +/- 3278.5 ml/m2).",Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),[ml] / [m2],6825.4,114531,DB00773,Etoposide
,11699396,maximum plasma etoposide levels,The maximum plasma etoposide levels ranged from 6.0 to 28.4 microM (mean +/- SD = 13.6 +/- 6.3 microM).,Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),μM,13.6,114532,DB00773,Etoposide
,11699396,overall bioavailability,The overall bioavailability (mean +/- SD) was 60.6 +/- 22.4% (ranged from 17.6% to 91.2%).,Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),%,60.6,114533,DB00773,Etoposide
,11699396,overall bioavailability,The overall bioavailability (mean +/- SD) was 60.6 +/- 22.4% (ranged from 17.6% to 91.2%).,Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),%,91.2,114534,DB00773,Etoposide
,11699396,elimination half-life,The elimination half-life following oral administration (mean +/- SD) was 209.8 +/- 196.3 min (ranged from 51.0 to 794.2 min).,Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),min,209.8,114535,DB00773,Etoposide
,11699396,time required to reach the maximum plasma etoposide concentration,The time required to reach the maximum plasma etoposide concentration was 145.4 +/- 118.7 min (ranged from 23.7 to 396.9 min).,Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699396/),min,145.4,114536,DB00773,Etoposide
,8426216,bioavailability,"The mean (+/- SD) bioavailability following a 100-mg dose of oral etoposide was 76% +/- 22%, which was significantly greater (P < .01) than the mean bioavailability of 48% +/- 18% following a 400-mg oral dose.",Bioavailability of low-dose oral etoposide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8426216/),%,76,116594,DB00773,Etoposide
,8426216,bioavailability,"The mean (+/- SD) bioavailability following a 100-mg dose of oral etoposide was 76% +/- 22%, which was significantly greater (P < .01) than the mean bioavailability of 48% +/- 18% following a 400-mg oral dose.",Bioavailability of low-dose oral etoposide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8426216/),%,48,116595,DB00773,Etoposide
,8426216,bioavailability,The coefficient of variation in oral etoposide bioavailability was significant: 29% with a 100-mg oral dose and 37% with a 400-mg dose.,Bioavailability of low-dose oral etoposide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8426216/),%,29,116596,DB00773,Etoposide
,8426216,bioavailability,The coefficient of variation in oral etoposide bioavailability was significant: 29% with a 100-mg oral dose and 37% with a 400-mg dose.,Bioavailability of low-dose oral etoposide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8426216/),%,37,116597,DB00773,Etoposide
,12663724,area under concentration-time curve (AUC),"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],24,117533,DB00773,Etoposide
,12663724,area under concentration-time curve (AUC),"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],522,117534,DB00773,Etoposide
,12663724,area under concentration-time curve (AUC),"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],14,117535,DB00773,Etoposide
,12663724,cumulative AUC,"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],14,117536,DB00773,Etoposide
,12663724,cumulative AUC,"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],303,117537,DB00773,Etoposide
,8083713,MTD,The MTD due to leukopenia was determined to be between 175 and 200 mg/m2/d.,"Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083713/),[mg] / [d·m2],175 and 200,118128,DB00773,Etoposide
,8083713,terminal half-life (t1/2),"Etoposide phosphate had peak plasma concentrations at 5 minutes, with a terminal half-life (t1/2) of 7 minutes.","Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083713/),min,7,118129,DB00773,Etoposide
,8083713,t1/2,"Etoposide reached peak concentrations at 7 to 8 minutes, with a t1/2 of 6 to 9 hours.","Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083713/),h,6 to 9,118130,DB00773,Etoposide
,22370160,area under the curve (AUC),"PK-directed dosing was performed to achieve a predefined target area under the curve (AUC) of 20,000 μM-min (range: 18,400-21,600 μM-min).",Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22370160/),μM-min,"20,000",118498,DB00773,Etoposide
,2305718,Peak plasma melphalan concentrations,Peak plasma melphalan concentrations in the three patients ranged from 0.354 (patient 2) to 1.768 micrograms/ml (patient 1).,Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),[μg] / [ml],0.354,119352,DB00773,Etoposide
,2305718,Peak plasma melphalan concentrations,Peak plasma melphalan concentrations in the three patients ranged from 0.354 (patient 2) to 1.768 micrograms/ml (patient 1).,Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),[μg] / [ml],1.768,119353,DB00773,Etoposide
,2305718,concentration X time products (C x Ts),"Plasma melphalan concentration X time products (C x Ts) showed extreme variability in one patient (patient 2), ranging from 0.76 to 4.48 micrograms.h/ml.",Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),[h·μg] / [ml],0.76 to 4.48,119354,DB00773,Etoposide
,2305718,plasma C X T ratios,The p.o.:i.v. plasma C X T ratios for high-dose melphalan ranged between 0.09 (patient 3) and 0.58 (patient 2).,Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),,0.09,119355,DB00773,Etoposide
,2305718,plasma C X T ratios,The p.o.:i.v. plasma C X T ratios for high-dose melphalan ranged between 0.09 (patient 3) and 0.58 (patient 2).,Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),,0.58,119356,DB00773,Etoposide
,9816174,peritoneal fluid:plasma AUC ratio,"The pharmacokinetics of 5-fluorouracil were not altered by vasopressin; however, vasopressin increased the peritoneal fluid:plasma AUC ratio for CBDCA from 30.6 +/- 5.6 to 70. 6 +/- 7.4 (P < 0.01) and increased the lymph:plasma AUC ratio from 1.1 +/- 0.4 to 2.6 +/- 0.22 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,30.6,120412,DB00773,Etoposide
,9816174,peritoneal fluid:plasma AUC ratio,"The pharmacokinetics of 5-fluorouracil were not altered by vasopressin; however, vasopressin increased the peritoneal fluid:plasma AUC ratio for CBDCA from 30.6 +/- 5.6 to 70. 6 +/- 7.4 (P < 0.01) and increased the lymph:plasma AUC ratio from 1.1 +/- 0.4 to 2.6 +/- 0.22 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,70. 6,120413,DB00773,Etoposide
,9816174,lymph:plasma AUC ratio,"The pharmacokinetics of 5-fluorouracil were not altered by vasopressin; however, vasopressin increased the peritoneal fluid:plasma AUC ratio for CBDCA from 30.6 +/- 5.6 to 70. 6 +/- 7.4 (P < 0.01) and increased the lymph:plasma AUC ratio from 1.1 +/- 0.4 to 2.6 +/- 0.22 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,1.1,120414,DB00773,Etoposide
,9816174,lymph:plasma AUC ratio,"The pharmacokinetics of 5-fluorouracil were not altered by vasopressin; however, vasopressin increased the peritoneal fluid:plasma AUC ratio for CBDCA from 30.6 +/- 5.6 to 70. 6 +/- 7.4 (P < 0.01) and increased the lymph:plasma AUC ratio from 1.1 +/- 0.4 to 2.6 +/- 0.22 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,2.6,120415,DB00773,Etoposide
,9816174,peritoneal fluid:plasma AUC ratio,"In the case of VP-16, vasopressin increased the peritoneal fluid:plasma AUC ratio from 129 +/- 35 to 350 +/- 76 (P < 0.05) and the lymph:plasma AUC ratio from 2.1 +/- 0.6 to 10.6 +/- 3.5 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,129,120416,DB00773,Etoposide
,9816174,peritoneal fluid:plasma AUC ratio,"In the case of VP-16, vasopressin increased the peritoneal fluid:plasma AUC ratio from 129 +/- 35 to 350 +/- 76 (P < 0.05) and the lymph:plasma AUC ratio from 2.1 +/- 0.6 to 10.6 +/- 3.5 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,350,120417,DB00773,Etoposide
,9816174,lymph:plasma AUC ratio,"In the case of VP-16, vasopressin increased the peritoneal fluid:plasma AUC ratio from 129 +/- 35 to 350 +/- 76 (P < 0.05) and the lymph:plasma AUC ratio from 2.1 +/- 0.6 to 10.6 +/- 3.5 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,2.1,120418,DB00773,Etoposide
,9816174,lymph:plasma AUC ratio,"In the case of VP-16, vasopressin increased the peritoneal fluid:plasma AUC ratio from 129 +/- 35 to 350 +/- 76 (P < 0.05) and the lymph:plasma AUC ratio from 2.1 +/- 0.6 to 10.6 +/- 3.5 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,10.6,120419,DB00773,Etoposide
,1333371,overall objective response rate,"Six patients achieved a complete response as confirmed by repeat bronchoscopy and five patients showed a partial response, for an overall objective response rate of 65% (95% confidence interval, 38%-87%).",Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1333371/),%,65,120663,DB00773,Etoposide
,27816627,k2max,"The PK/PD model was capable of describing the tumor growth inhibition using total plasma or free tumor concentrations, resulting in higher k2max (maximal potency) for free concentrations (25.8mL·μg-1·day-1 - intratumoral vs. 12.6mL·μg-1·day-1 total plasma).",Pharmacokinetic/pharmacodynamic modeling of etoposide tumor growth inhibitory effect in Walker-256 tumor-bearing rat model using free intratumoral drug concentrations. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27816627/),[ml] / [d·μg],25.8,121362,DB00773,Etoposide
,27816627,k2max,"The PK/PD model was capable of describing the tumor growth inhibition using total plasma or free tumor concentrations, resulting in higher k2max (maximal potency) for free concentrations (25.8mL·μg-1·day-1 - intratumoral vs. 12.6mL·μg-1·day-1 total plasma).",Pharmacokinetic/pharmacodynamic modeling of etoposide tumor growth inhibitory effect in Walker-256 tumor-bearing rat model using free intratumoral drug concentrations. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27816627/),[ml] / [d·μg],12.6,121363,DB00773,Etoposide
,25776193,area under the curve (AUC),"In this single-center, phase I study, adult AML patients received I.V. busulfan targeted to either an area under the curve (AUC) of 1250 (cohort 1) or 1400 (cohort 2) μmol/min over 16 doses.","A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776193/),[μM] / [min],1250,121969,DB00773,Etoposide
,25776193,area under the curve (AUC),"In this single-center, phase I study, adult AML patients received I.V. busulfan targeted to either an area under the curve (AUC) of 1250 (cohort 1) or 1400 (cohort 2) μmol/min over 16 doses.","A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776193/),[μM] / [min],1400,121970,DB00773,Etoposide
,25776193,re,Two-year relapse-free survival was 33% in cohort 1 versus 67% in cohort 2 (P = .08).,"A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776193/),%,33,121971,DB00773,Etoposide
,25776193,re,Two-year relapse-free survival was 33% in cohort 1 versus 67% in cohort 2 (P = .08).,"A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776193/),%,67,121972,DB00773,Etoposide
,25776193,AUC,A phase II study is warranted to further evaluate the activity and safety of busulfan targeted to AUC 1400 μmol/min.,"A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776193/),[μM] / [min],1400,121973,DB00773,Etoposide
,9053503,maximum-tolerated dose (MTD),The maximum-tolerated dose (MTD) of EP was 20 mg/m2/d.,Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9053503/),mg,20,122768,DB00773,Etoposide
,9053503,Css,"The mean Css (+/- SD) of etoposide were 0.67 +/- 0.25, 1.14 +/- 0.24, 1.38 +/- 0.64, and 2.19 +/- 0.52 microg/mL at daily EP doses of 10, 20, 25, and 30 mg/m2, respectively.",Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9053503/),[μg] / [ml],0.67,122769,DB00773,Etoposide
,9053503,Css,"The mean Css (+/- SD) of etoposide were 0.67 +/- 0.25, 1.14 +/- 0.24, 1.38 +/- 0.64, and 2.19 +/- 0.52 microg/mL at daily EP doses of 10, 20, 25, and 30 mg/m2, respectively.",Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9053503/),[μg] / [ml],1.14,122770,DB00773,Etoposide
,9053503,Css,"The mean Css (+/- SD) of etoposide were 0.67 +/- 0.25, 1.14 +/- 0.24, 1.38 +/- 0.64, and 2.19 +/- 0.52 microg/mL at daily EP doses of 10, 20, 25, and 30 mg/m2, respectively.",Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9053503/),[μg] / [ml],1.38,122771,DB00773,Etoposide
,9053503,Css,"The mean Css (+/- SD) of etoposide were 0.67 +/- 0.25, 1.14 +/- 0.24, 1.38 +/- 0.64, and 2.19 +/- 0.52 microg/mL at daily EP doses of 10, 20, 25, and 30 mg/m2, respectively.",Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9053503/),[μg] / [ml],2.19,122772,DB00773,Etoposide
,3349461,clearance,"The clearance of etoposide was 3.56 ml/min indicating that, in the rat, it is not highly extracted.",Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349461/),[ml] / [min],3.56,123680,DB00773,Etoposide
,3975657,absolute bioavailability,The absolute bioavailability based on plasma concentrations or urinary excretion of etoposide was 48% to 57%.,Bioavailability and pharmacokinetics of etoposide (VP-16). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975657/),%,48,125155,DB00773,Etoposide
,3975657,absolute bioavailability,The absolute bioavailability based on plasma concentrations or urinary excretion of etoposide was 48% to 57%.,Bioavailability and pharmacokinetics of etoposide (VP-16). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975657/),%,57,125156,DB00773,Etoposide
,3975657,plasma elimination half-life,"The plasma elimination half-life was 5.3 hours, total body clearance 21.4 mL/min/m2, and renal clearance 7.7 mL/min/m2.",Bioavailability and pharmacokinetics of etoposide (VP-16). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975657/),h,5.3,125157,DB00773,Etoposide
,3975657,total body clearance,"The plasma elimination half-life was 5.3 hours, total body clearance 21.4 mL/min/m2, and renal clearance 7.7 mL/min/m2.",Bioavailability and pharmacokinetics of etoposide (VP-16). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975657/),[ml] / [m2·min],21.4,125158,DB00773,Etoposide
,3975657,renal clearance,"The plasma elimination half-life was 5.3 hours, total body clearance 21.4 mL/min/m2, and renal clearance 7.7 mL/min/m2.",Bioavailability and pharmacokinetics of etoposide (VP-16). ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975657/),[ml] / [m2·min],7.7,125159,DB00773,Etoposide
,11914647,t1/2alpha,"Data were best described by a three-compartment model with t1/2alpha = 0.28 h +/- 3.2%, t1/2beta = 3.6 h +/- 16.9% and t1/2gamma = 44.2 h +/- 56.5%, respectively (mean(geom) +/- CV(geom)).",Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914647/),h,0.28,125978,DB00773,Etoposide
,11914647,t1/2beta,"Data were best described by a three-compartment model with t1/2alpha = 0.28 h +/- 3.2%, t1/2beta = 3.6 h +/- 16.9% and t1/2gamma = 44.2 h +/- 56.5%, respectively (mean(geom) +/- CV(geom)).",Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914647/),h,3.6,125979,DB00773,Etoposide
,11914647,t1/2gamma,"Data were best described by a three-compartment model with t1/2alpha = 0.28 h +/- 3.2%, t1/2beta = 3.6 h +/- 16.9% and t1/2gamma = 44.2 h +/- 56.5%, respectively (mean(geom) +/- CV(geom)).",Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914647/),h,44.2,125980,DB00773,Etoposide
,11914647,Clearance (CL),Clearance (CL) was 15.5 ml/min/m2 +/- 30.6% (mean(geom) +/- CV(geom)) and thus at the lower range of data reported in the literature.,Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914647/),[ml] / [m2·min],15.5,125981,DB00773,Etoposide
,11914647,fraction of unbound Eto (fu),"The fraction of unbound Eto (fu) was 7.0% (4.3-11.9%) [median (range)], with high intra-individual variability.",Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914647/),%,7.0,125982,DB00773,Etoposide
,27233686,"AUC, Cmax","There was strong correlation between the in vitro % permeated across porcine skin and in vivo absorption (AUC, Cmax) in the range 100-300 μA/cm(2).",Transdermal Delivery of Etoposide Phosphate II: In Vitro In Vivo Correlations (IVIVC). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27233686/),[μa] / [cm(2],100-300,126028,DB00773,Etoposide
,9649150,area under the concentration time for etoposide curve,Cyclosporin levels ranged from 1359 to 4835 ng ml(-1) and cyclosporin increased the median area under the concentration time for etoposide curve from 7.2 to 12.5 mg ml(-1) min.,High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649150/),[mg·min] / [ml],7,126710,DB00773,Etoposide
,9815892,half-life,The mean half-life of etoposide at the different dose levels ranged from 5.5 to 9.3 h.,"Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815892/),h,5.5 to 9.3,127964,DB00773,Etoposide
,9869217,time to progression,Median time to progression and survival were 13 and 14 months respectively.,"Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869217/),month,13,128008,DB00773,Etoposide
,9869217,survival,Median time to progression and survival were 13 and 14 months respectively.,"Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869217/),month,14,128009,DB00773,Etoposide
,9869217,plasma concentrations,"The mean +/- SD 2 hr and 6 hr plasma concentrations were 0.92 +/- 0.43 microg/ml and 0.36 +/- 0.12 microg/ml, respectively.","Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869217/),[μg] / [ml],0.92,128010,DB00773,Etoposide
,9869217,plasma concentrations,"The mean +/- SD 2 hr and 6 hr plasma concentrations were 0.92 +/- 0.43 microg/ml and 0.36 +/- 0.12 microg/ml, respectively.","Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869217/),[μg] / [ml],0.36,128011,DB00773,Etoposide
,3004725,Peak plasma levels,"Peak plasma levels were 7.96, 10.84, 18.24, 21.0, and 24.0 micrograms/ml for dosages of etoposide of 75, 100, 150, 200, and 250 mg, respectively.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),[μg] / [ml],7.96,129400,DB00773,Etoposide
,3004725,Peak plasma levels,"Peak plasma levels were 7.96, 10.84, 18.24, 21.0, and 24.0 micrograms/ml for dosages of etoposide of 75, 100, 150, 200, and 250 mg, respectively.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),[μg] / [ml],10.84,129401,DB00773,Etoposide
,3004725,Peak plasma levels,"Peak plasma levels were 7.96, 10.84, 18.24, 21.0, and 24.0 micrograms/ml for dosages of etoposide of 75, 100, 150, 200, and 250 mg, respectively.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),[μg] / [ml],18.24,129402,DB00773,Etoposide
,3004725,Peak plasma levels,"Peak plasma levels were 7.96, 10.84, 18.24, 21.0, and 24.0 micrograms/ml for dosages of etoposide of 75, 100, 150, 200, and 250 mg, respectively.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),[μg] / [ml],21.0,129403,DB00773,Etoposide
,3004725,Peak plasma levels,"Peak plasma levels were 7.96, 10.84, 18.24, 21.0, and 24.0 micrograms/ml for dosages of etoposide of 75, 100, 150, 200, and 250 mg, respectively.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),[μg] / [ml],24.0,129404,DB00773,Etoposide
,3004725,half-life times of the elimination phase,"No accumulation occurred, half-life times of the elimination phase were between 8.7 and 23.0 hours, apparent distribution volumes of the central compartment were between 9.2 and 14.5 L, and the total-body clearances were between 2.1 and 2.8 L/hour.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),h,8.7 and 23.0,129405,DB00773,Etoposide
,3004725,apparent distribution volumes of the central compartment,"No accumulation occurred, half-life times of the elimination phase were between 8.7 and 23.0 hours, apparent distribution volumes of the central compartment were between 9.2 and 14.5 L, and the total-body clearances were between 2.1 and 2.8 L/hour.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),l,9.2 and 14.5,129406,DB00773,Etoposide
,3004725,total-body clearances,"No accumulation occurred, half-life times of the elimination phase were between 8.7 and 23.0 hours, apparent distribution volumes of the central compartment were between 9.2 and 14.5 L, and the total-body clearances were between 2.1 and 2.8 L/hour.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),[l] / [h],2.1 and 2.8,129407,DB00773,Etoposide
,2828072,saliva to plasma ratios,In four of these patients we also monitored etoposide salivary excretion and found saliva to plasma ratios in the range 0.003-0.25.,Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2828072/),,0.003-0.25,129686,DB00773,Etoposide
,8996574,AUC,Patients with histologically or cytologically proven small cell lung cancer were treated with etoposide phosphate by continuous 120-hour infusion and carboplatin at a dose calculated by the Calvert formula to give an AUC of 5 mg/ mL.min.,Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996574/),[mg] / [min·ml],5,129787,DB00773,Etoposide
,2189591,Clearance,Clearance of VP-16 from the pleural cavity was low at 2 ml/min m2.,Intrapleural etoposide for malignant effusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189591/),[ml] / [m2·min],2,130980,DB00773,Etoposide
exceeded,2189591,Peak pleural-fluid drug levels,"Peak pleural-fluid drug levels in patients receiving 225 mg/m2 exceeded 300 micrograms/ml, whereas peak drug concentrations in corresponding plasma samples obtained at the same time amounted to less than 10 micrograms/ml.",Intrapleural etoposide for malignant effusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189591/),[μg] / [ml],300,130981,DB00773,Etoposide
less,2189591,peak drug concentrations,"Peak pleural-fluid drug levels in patients receiving 225 mg/m2 exceeded 300 micrograms/ml, whereas peak drug concentrations in corresponding plasma samples obtained at the same time amounted to less than 10 micrograms/ml.",Intrapleural etoposide for malignant effusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189591/),[μg] / [ml],10,130982,DB00773,Etoposide
,7492822,bioavailability,The pharmacokinetic results confirmed the low bioavailability of this formulation (14% +/- 10%) and its large interindividual variability.,[Relations between hematological toxicity and total and free plasma levels of etoposide in daily oral administration]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7492822/),%,14,131942,DB00773,Etoposide
,15956976,response rate (RR),The response rate (RR) was 28% in 18 evaluable patients.,Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15956976/),%,28,132862,DB00773,Etoposide
,8646796,50% inhibitory concentrations (IC50,"Both agents were very potent inhibitors of cell growth, with dolastatin 10 being an average of 9.1-fold more potent than dolastatin 15 [mean 50% inhibitory concentrations (IC50 values) 2.3 x 10(-10) and 2.1 x 10(-9) M, respectively; P < 0.05] and more potent than paclitaxel or vinblastine.",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),M,2.3 x 10(-10),133271,DB00773,Etoposide
,8646796,50% inhibitory concentrations (IC50,"Both agents were very potent inhibitors of cell growth, with dolastatin 10 being an average of 9.1-fold more potent than dolastatin 15 [mean 50% inhibitory concentrations (IC50 values) 2.3 x 10(-10) and 2.1 x 10(-9) M, respectively; P < 0.05] and more potent than paclitaxel or vinblastine.",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),M,2.1 x 10(-9),133272,DB00773,Etoposide
,8646796,limit of detection,A radioimmunoassay for dolastatin 10 (limit of detection in mouse plasma 5 ng/ml) was developed.,Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),[ng] / [ml],5,133273,DB00773,Etoposide
,8646796,areas under the plasma concentration-time curve (AUC values),"In addition, areas under the plasma concentration-time curve (AUC values) were 1.6-fold higher for dolastatin 10 (333 versus 208 ng ml-1 h).",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),[h·ng] / [ml],333,133274,DB00773,Etoposide
,8646796,areas under the plasma concentration-time curve (AUC values),"In addition, areas under the plasma concentration-time curve (AUC values) were 1.6-fold higher for dolastatin 10 (333 versus 208 ng ml-1 h).",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),[h·ng] / [ml],208,133275,DB00773,Etoposide
exceeded,8646796,Plasma binding,Plasma binding of dolastatin 10 exceeded 90%.,Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),%,90,133276,DB00773,Etoposide
,8751809,Recovery,Recovery of the unchanged drug from the hepatic bile in the present series was 2.7-3.0% during the period of 3.5 hrs.,[Biliary and pancreatic excretion of etoposide]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751809/),%,2.7-3.0,133465,DB00773,Etoposide
,8751809,total recovery,And total recovery was estimated as 3.5-4.0% from AUC of the further extended concentration curve.,[Biliary and pancreatic excretion of etoposide]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751809/),%,3.5-4.0,133466,DB00773,Etoposide
,8751809,Recovery,Recovery for 3.5 hrs. was less than 0.02%.,[Biliary and pancreatic excretion of etoposide]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751809/),h,3.5,133467,DB00773,Etoposide
less,8751809,Recovery,Recovery for 3.5 hrs. was less than 0.02%.,[Biliary and pancreatic excretion of etoposide]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751809/),%,0.02,133468,DB00773,Etoposide
,2378980,duration of complete response (CR),Median duration of complete response (CR) was 3.5 months (range 1.1 to 20+).,High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378980/),month,3.5,134486,DB00773,Etoposide
greater,25720462,AUC ratios,"The AUC ratios of omeprazole and erythromycin, which are administered orally to humans, as enteric-coated tablets, were greater than 1.9 in the rats and dogs controlled for gastric acid secretion.",Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25720462/),,1.9,135783,DB00773,Etoposide
less,25720462,AUC ratios,"On the contrary, the AUC ratios of clarithromycin, azithromycin, and etoposide (commercially available as a standard immediate-release form) were less than 1.3 each.",Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25720462/),,1.3,135784,DB00773,Etoposide
,1666659,area under the curve (AUC),"The area under the curve (AUC), elimination half-life, steady state concentration, systemic clearance, renal clearance of etoposide and distribution volume at steady state were 225.4 +/- 39.2 micrograms x h/ml, 8.1 +/- 3.4 h, 3.1 +/- 0.6 micrograms/ml, 18.8 +/- 3.1 ml/min/m2, 3.1 +/- 1.4 ml/min/m2, 9.6 +/- 3.8 l/m2, respectively, which were in accordance with those reported previously in patients treated with etoposide alone.",Pharmacokinetics of an etoposide infused over three days: concomitant infusion with cisplatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1666659/),[h·μg] / [ml],225.4,136880,DB00773,Etoposide
,1666659,distribution volume at steady state,"The area under the curve (AUC), elimination half-life, steady state concentration, systemic clearance, renal clearance of etoposide and distribution volume at steady state were 225.4 +/- 39.2 micrograms x h/ml, 8.1 +/- 3.4 h, 3.1 +/- 0.6 micrograms/ml, 18.8 +/- 3.1 ml/min/m2, 3.1 +/- 1.4 ml/min/m2, 9.6 +/- 3.8 l/m2, respectively, which were in accordance with those reported previously in patients treated with etoposide alone.",Pharmacokinetics of an etoposide infused over three days: concomitant infusion with cisplatin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1666659/),[l] / [m2],9.6,136881,DB00773,Etoposide
less,3000790,Urinary excretion,Urinary excretion was less than 25% and showed no increase over the 3 days.,Variable bioavailability following repeated oral doses of etoposide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3000790/),%,25,137119,DB00773,Etoposide
,1503923,clearance,"Median methotrexate clearance tended to be lower in four infants (0.26-0.99 years) vs 108 children (1-19 years): 80 vs 103 ml min-1 m-2, respectively (P = 0.01).",Disposition of antineoplastic agents in the very young child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503923/),[ml] / [(m)^2·min],80,139441,DB00773,Etoposide
,1503923,clearance,"Median methotrexate clearance tended to be lower in four infants (0.26-0.99 years) vs 108 children (1-19 years): 80 vs 103 ml min-1 m-2, respectively (P = 0.01).",Disposition of antineoplastic agents in the very young child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503923/),[ml] / [(m)^2·min],103,139442,DB00773,Etoposide
not exceed,15139794,peak plasma concentrations,"Pharmacokinetic-pharmacodynamic relationships indicate that severe toxicity is avoided when peak plasma concentrations do not exceed 3-5 mg/L and C(24,trough) is under the threshold limit of 0.3 mg/L.",Pharmacokinetic optimisation of treatment with oral etoposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139794/),[mg] / [l],3-5,139859,DB00773,Etoposide
under,15139794,"C(24,trough)","Pharmacokinetic-pharmacodynamic relationships indicate that severe toxicity is avoided when peak plasma concentrations do not exceed 3-5 mg/L and C(24,trough) is under the threshold limit of 0.3 mg/L.",Pharmacokinetic optimisation of treatment with oral etoposide. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139794/),[mg] / [l],0.3,139860,DB00773,Etoposide
,8398708,peritoneal/plasma peak ratio,The mean peritoneal/plasma peak ratio was 18.3 for CBDCA and 12.7 for VP-16.,A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398708/),,18.3,139878,DB00773,Etoposide
,8398708,peritoneal/plasma peak ratio,The mean peritoneal/plasma peak ratio was 18.3 for CBDCA and 12.7 for VP-16.,A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398708/),,12.7,139879,DB00773,Etoposide
,8398708,peritoneal/plasma AUC ratio,The pharmacologic advantage (peritoneal/plasma AUC ratio) was 14.9 for CBDCA and 8.8 for VP-16.,A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398708/),,14.9,139880,DB00773,Etoposide
,8398708,peritoneal/plasma AUC ratio,The pharmacologic advantage (peritoneal/plasma AUC ratio) was 14.9 for CBDCA and 8.8 for VP-16.,A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398708/),,8.8,139881,DB00773,Etoposide
,8398708,response rate,Although measurable disease was not a requirement for entrance into this study a response rate of 27% was noted in 15 patients with evaluable disease who had ovarian cancer.,A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398708/),%,27,139882,DB00773,Etoposide
,9402748,overall response rate,Thirty-five patients (53%) achieved CR and 9 PR for an overall response rate of 67%.,Idarubicin in induction treatment of acute myeloid leukemia in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402748/),%,67,142609,DB00773,Etoposide
,9402748,Overall survival,"Overall survival and disease free survival were 14 and 13 months, respectively.",Idarubicin in induction treatment of acute myeloid leukemia in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402748/),month,14,142610,DB00773,Etoposide
,9402748,disease free survival,"Overall survival and disease free survival were 14 and 13 months, respectively.",Idarubicin in induction treatment of acute myeloid leukemia in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402748/),month,13,142611,DB00773,Etoposide
,7902243,apparent Ki,Their estimated apparent Ki values ranged from 0.3 mM for navelbine to 9.8 mM for methotrexate.,Effect of anticancer drugs on the glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902243/),mM,0.3,142868,DB00773,Etoposide
,7902243,apparent Ki,Their estimated apparent Ki values ranged from 0.3 mM for navelbine to 9.8 mM for methotrexate.,Effect of anticancer drugs on the glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902243/),mM,9.8,142869,DB00773,Etoposide
,16390815,percentage of tumor growth suppression rate (%T/C),"The percentage of tumor growth suppression rate (%T/C) in Lewis lung carcinoma bearing mice was 63.23, 62.83 and 33.78% in EPE, PEG-EPE and ETP treated mice, respectively.",Pharmacokinetics and tissue distribution of etoposide delivered in long circulating parenteral emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390815/),%,63.23,143794,DB00773,Etoposide
,16390815,percentage of tumor growth suppression rate (%T/C),"The percentage of tumor growth suppression rate (%T/C) in Lewis lung carcinoma bearing mice was 63.23, 62.83 and 33.78% in EPE, PEG-EPE and ETP treated mice, respectively.",Pharmacokinetics and tissue distribution of etoposide delivered in long circulating parenteral emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390815/),%,62.83,143795,DB00773,Etoposide
,16390815,percentage of tumor growth suppression rate (%T/C),"The percentage of tumor growth suppression rate (%T/C) in Lewis lung carcinoma bearing mice was 63.23, 62.83 and 33.78% in EPE, PEG-EPE and ETP treated mice, respectively.",Pharmacokinetics and tissue distribution of etoposide delivered in long circulating parenteral emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390815/),%,33.78,143796,DB00773,Etoposide
,12738720,maximum tolerated dose,"For the 21-day cycle, the maximum tolerated dose was 75 mg/m(2) for i.v. etoposide and 85 mg/m(2) for oral etoposide.",Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12738720/),[mg] / [m(2],75,144785,DB00773,Etoposide
,12738720,maximum tolerated dose,"For the 21-day cycle, the maximum tolerated dose was 75 mg/m(2) for i.v. etoposide and 85 mg/m(2) for oral etoposide.",Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12738720/),[mg] / [m],85,144786,DB00773,Etoposide
,8797893,Cbefore,"Among 5 courses with dose reduction, the Cbefore of 1.7 +/- 0.1 (microgram/ml, mean +/- SE) was decreased to 1.3 +/- 0.2 after day 5 (Cafter).",Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797893/),[μg] / [ml],1.7,145197,DB00773,Etoposide
,8797893,Cbefore,"Among 5 courses with dose reduction, the Cbefore of 1.7 +/- 0.1 (microgram/ml, mean +/- SE) was decreased to 1.3 +/- 0.2 after day 5 (Cafter).",Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797893/),[μg] / [ml],1.3,145198,DB00773,Etoposide
,8797893,Cbefore,"Among 7 courses with dose escalation, the Cbefore of 0.9 +/- 0.0 was increased to the Cafter of 1.2 +/- 0.1.",Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797893/),,0.9,145199,DB00773,Etoposide
,8797893,Cafter,"Among 7 courses with dose escalation, the Cbefore of 0.9 +/- 0.0 was increased to the Cafter of 1.2 +/- 0.1.",Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797893/),,1.2,145200,DB00773,Etoposide
,8797893,Cbefore,"Among the remaining 12 courses without dose modification, the Cbefore and the Cafter were 1.2 +/- 0.0 and 1.3 +/- 0.1, respectively.",Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797893/),,1.2,145201,DB00773,Etoposide
,8797893,Cafter,"Among the remaining 12 courses without dose modification, the Cbefore and the Cafter were 1.2 +/- 0.0 and 1.3 +/- 0.1, respectively.",Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797893/),,1.3,145202,DB00773,Etoposide
,19414395,absolute bioavailability (AB),"Consequently, compared to the control group (8.87%), the presence of quercetin significantly (5 mg/kg, p<0.05; 15 mg/kg, p<0.01) increased the absolute bioavailability (AB) of etoposide to 12.7 or 13.6% .",Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414395/),%,12.7,145331,DB00773,Etoposide
,19414395,absolute bioavailability (AB),"Consequently, compared to the control group (8.87%), the presence of quercetin significantly (5 mg/kg, p<0.05; 15 mg/kg, p<0.01) increased the absolute bioavailability (AB) of etoposide to 12.7 or 13.6% .",Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414395/),%,13.6,145332,DB00773,Etoposide
,27068281,penetration,"ETO penetration was higher in the periphery (61 ± 15% and 61 ± 29%) than in tumor center (34 ± 6% and 28 ± 11%) following 10 and 20 mg/kg doses, respectively (ANOVA, α = 0.05).",Population Pharmacokinetic Modeling of Etoposide Free Concentrations in Solid Tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27068281/),%,61,146316,DB00773,Etoposide
,27068281,penetration,"ETO penetration was higher in the periphery (61 ± 15% and 61 ± 29%) than in tumor center (34 ± 6% and 28 ± 11%) following 10 and 20 mg/kg doses, respectively (ANOVA, α = 0.05).",Population Pharmacokinetic Modeling of Etoposide Free Concentrations in Solid Tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27068281/),%,61,146317,DB00773,Etoposide
,27068281,penetration,"ETO penetration was higher in the periphery (61 ± 15% and 61 ± 29%) than in tumor center (34 ± 6% and 28 ± 11%) following 10 and 20 mg/kg doses, respectively (ANOVA, α = 0.05).",Population Pharmacokinetic Modeling of Etoposide Free Concentrations in Solid Tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27068281/),%,34,146318,DB00773,Etoposide
,27068281,penetration,"ETO penetration was higher in the periphery (61 ± 15% and 61 ± 29%) than in tumor center (34 ± 6% and 28 ± 11%) following 10 and 20 mg/kg doses, respectively (ANOVA, α = 0.05).",Population Pharmacokinetic Modeling of Etoposide Free Concentrations in Solid Tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27068281/),%,28,146319,DB00773,Etoposide
,7577097,plasma protein binding,Docetaxel exhibited linear pharmacokinetics and long tumour retention in tumour-bearing mice; plasma protein binding ranged from 76 to 89%.,Preclinical pharmacology of docetaxel. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7577097/),%,76 to 89,147082,DB00773,Etoposide
,7497581,AUC (AUC,"Specifically, metoclopramide had little effect on the etoposide absorption profile and did not significantly alter the AUC (AUC with etoposide alone, 68.4 +/- 20.3 micrograms ml-1 h, versus 74.3 +/- 25.9 micrograms ml-1 h with metoclopramide), suggesting that in most patients the drug is already emptied rapidly from the stomach.",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],68.4,148763,DB00773,Etoposide
,7497581,AUC (AUC,"Specifically, metoclopramide had little effect on the etoposide absorption profile and did not significantly alter the AUC (AUC with etoposide alone, 68.4 +/- 20.3 micrograms ml-1 h, versus 74.3 +/- 25.9 micrograms ml-1 h with metoclopramide), suggesting that in most patients the drug is already emptied rapidly from the stomach.",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],74.3,148764,DB00773,Etoposide
,7497581,time of maximal concentration tmax,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),h,1.1,148765,DB00773,Etoposide
,7497581,time of maximal concentration tmax,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),h,3.5,148766,DB00773,Etoposide
,7497581,AUC,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],78.3,148767,DB00773,Etoposide
,7497581,AUC,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],88.1,148768,DB00773,Etoposide
,14744945,total clearance (CL),"At a dose of 20 mg/kg, the total clearance (CL), hepatic clearance (CLH), and renal clearance (CLR=CL-CLH), which were almost constant, were 2.82 +/- 0.24, 0.742 +/- 0.214, and 2.09 +/- 0.34 l/h/kg, respectively.",An evaluation method for nonlinear local disposition in rat liver and kidney. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744945/),[l] / [h·kg],2.82,150236,DB00773,Etoposide
,14744945,hepatic clearance (CLH),"At a dose of 20 mg/kg, the total clearance (CL), hepatic clearance (CLH), and renal clearance (CLR=CL-CLH), which were almost constant, were 2.82 +/- 0.24, 0.742 +/- 0.214, and 2.09 +/- 0.34 l/h/kg, respectively.",An evaluation method for nonlinear local disposition in rat liver and kidney. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744945/),[l] / [h·kg],0.742,150237,DB00773,Etoposide
,14744945,renal clearance (CLR=CL-CLH),"At a dose of 20 mg/kg, the total clearance (CL), hepatic clearance (CLH), and renal clearance (CLR=CL-CLH), which were almost constant, were 2.82 +/- 0.24, 0.742 +/- 0.214, and 2.09 +/- 0.34 l/h/kg, respectively.",An evaluation method for nonlinear local disposition in rat liver and kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744945/),[l] / [h·kg],2.09,150238,DB00773,Etoposide
,2549204,overall response rate,"In the 24-hour arm, two patients achieved a partial remission, resulting in an overall response rate of 10%.",A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),%,10,151311,DB00773,Etoposide
,2549204,overall response rate,"In the 5-day schedule, 16 patients had a partial response and one had a complete remission, producing an overall response rate of 89%, which was significantly superior to that in the 24-hour arm (P less than .001).",A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),%,89,151312,DB00773,Etoposide
,2549204,duration of remission,The median duration of remission to etoposide in the 5-day arm was 4.5 months.,A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),month,4.5,151313,DB00773,Etoposide
excess,2549204,response rate,The response rate to single-agent etoposide using an efficacious schedule in extensive small-cell lung cancer has been determined to be in excess of 80%.,A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),%,80,151314,DB00773,Etoposide
,10715285,AUC,"The dose of etoposide was 1, 200 mg/m(2), and the carboplatin target AUC ranged among cohorts from 12 to 32 (mg/mL) x min.","Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10715285/),[mg] / [min·ml)],12 to 32,152320,DB00773,Etoposide
,8674162,T1/2 alpha,"For etoposide, plasma disposition demonstrated biphasic clearance, with mean T1/2 alpha of 2.09 +/- 0.61 h, and T1/2 beta of 5.83 +/- 1.71 h.",Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674162/),h,2.09,154181,DB00773,Etoposide
,8674162,T1/2 beta,"For etoposide, plasma disposition demonstrated biphasic clearance, with mean T1/2 alpha of 2.09 +/- 0.61 h, and T1/2 beta of 5.83 +/- 1.71 h.",Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674162/),h,5.83,154182,DB00773,Etoposide
high,8674162,AUC,An AUC as high as 1768.50 micrograms.h/ml was observed at a dose of 1200 mg/m2.,Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674162/),[h·μg] / [ml],1768.50,154183,DB00773,Etoposide
,8674162,total body clearance (TBC),"The total body clearance (TBC) showed an overall mean of 15.72 +/- 4.25 ml/min per m2, and mean volume of distribution (VDss) of 5.64 +/- 1.06 l/m2.",Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674162/),[ml] / [m2·min],15.72,154184,DB00773,Etoposide
,8674162,volume of distribution (VDss),"The total body clearance (TBC) showed an overall mean of 15.72 +/- 4.25 ml/min per m2, and mean volume of distribution (VDss) of 5.64 +/- 1.06 l/m2.",Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674162/),[l] / [m2],5.64,154185,DB00773,Etoposide
,8674162,residual time (MRT),The mean residual time (MRT) for etoposide was 6.24 +/- 1.61 h.,Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674162/),h,6.24,154186,DB00773,Etoposide
,8402672,total body clearance,The plasma pharmacokinetics of mitoxantrone was linear between 15 and 90 mg/m2: total body clearance (19.3 +/- 6.2 liter/h/m2) and volume of distribution at steady state (486 +/- 254 liter/m2) were not altered by increasing the dose.,Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402672/),[l] / [h·m2],19.3,155501,DB00773,Etoposide
,8402672,volume of distribution at steady state,The plasma pharmacokinetics of mitoxantrone was linear between 15 and 90 mg/m2: total body clearance (19.3 +/- 6.2 liter/h/m2) and volume of distribution at steady state (486 +/- 254 liter/m2) were not altered by increasing the dose.,Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402672/),[l] / [m2],486,155502,DB00773,Etoposide
,8402672,area under the concentration +/- time curve ratio,"Whereas cellular versus plasma maximum concentration ratio was near 1, the area under the concentration +/- time curve ratio reached 100, suggesting a long elimination half-life from cells.",Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402672/),,100,155503,DB00773,Etoposide
,20855828,AUC,"For example, an AUC of 5 mg/mL · min is associated with a risk of grade 3 or 4 thrombocytopenia of 2% in combination with paclitaxel versus 38% with gemcitabine in a non-pretreated patient.",Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20855828/),[mg] / [min·ml],5,157411,DB00773,Etoposide
,26000396,zeta potential,The entrapment efficiency of both ETP and CUR in nanoemulsion was more than 98% while the globule size was less than 150 nm with zeta potential - 29.8 mV.,Nanoemulsion based concomitant delivery of curcumin and etoposide: impact on cross talk between prostate cancer cells and osteoblast during metastasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26000396/),m,29.8,157596,DB00773,Etoposide
,26000396,percent inhibition,The percent inhibition in case of ETP and ETP: CUR (1:3 w/w) was 55.92 ± 1.2 and 41.13 ± 2.4% (at 5 μM) respectively when tested in PC3 cells.,Nanoemulsion based concomitant delivery of curcumin and etoposide: impact on cross talk between prostate cancer cells and osteoblast during metastasis. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26000396/),%,55.92,157597,DB00773,Etoposide
,26000396,percent inhibition,The percent inhibition in case of ETP and ETP: CUR (1:3 w/w) was 55.92 ± 1.2 and 41.13 ± 2.4% (at 5 μM) respectively when tested in PC3 cells.,Nanoemulsion based concomitant delivery of curcumin and etoposide: impact on cross talk between prostate cancer cells and osteoblast during metastasis. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26000396/),%,41.13,157598,DB00773,Etoposide
,8133538,AUC,Cohorts of at least three patients received carboplatin at an initial target AUC of 6 mg.,Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8133538/),mg,6,158337,DB00773,Etoposide
,8133538,AUC,Neutropenia was dose limiting at the carboplatin target AUC of 12 mg.min/mL.,Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8133538/),[mg·min] / [ml],12,158338,DB00773,Etoposide
,8133538,AUC,"ICE chemotherapy, with the carboplatin dose based on a target AUC of 10 mg.",Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8133538/),mg,10,158339,DB00773,Etoposide
,11459198,apparent Ki,"Using uptake of 3H-vinblastine in L-MDR1 cells, atovaquone was shown to inhibit P-glycoprotein with an apparent Ki of 95.6 microM.",The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459198/),μM,95.6,159828,DB00773,Etoposide
,10537337,bioavailability,"Mean etoposide bioavailability at a dose of 50 mg was 64.6%, again with greater interpatient than intrapatient variability (34.8 versus 22.6%).",Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10537337/),%,64.6,160579,DB00773,Etoposide
,10537337,bioavailability,"Mean etoposide bioavailability at a dose of 50 mg was 64.6%, again with greater interpatient than intrapatient variability (34.8 versus 22.6%).",Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10537337/),%,34.8,160580,DB00773,Etoposide
,10537337,bioavailability,"Mean etoposide bioavailability at a dose of 50 mg was 64.6%, again with greater interpatient than intrapatient variability (34.8 versus 22.6%).",Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10537337/),%,22.6,160581,DB00773,Etoposide
,11368437,maximum tolerated dose,The maximum tolerated dose of mitoxantrone was defined as 4.5 mg/m2/day.,"Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368437/),[mg] / [d·m2],4.5,161135,DB00773,Etoposide
,11368437,overall survival,The median overall survival was 4 months.,"Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368437/),month,4,161136,DB00773,Etoposide
,10427872,Cmax,"Oral IVES yielded an adequate bioavailability profile because Cmax was 2.38 +/- 0.30 micrograms/mL, AUC was 12.87 +/- 2.02 micrograms/mL and half-life was 6.72 +/- 0.97 h.",Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10427872/),[μg] / [ml],2.38,162411,DB00773,Etoposide
,10427872,AUC,"Oral IVES yielded an adequate bioavailability profile because Cmax was 2.38 +/- 0.30 micrograms/mL, AUC was 12.87 +/- 2.02 micrograms/mL and half-life was 6.72 +/- 0.97 h.",Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10427872/),[μg] / [ml],12.87,162412,DB00773,Etoposide
,10427872,half-life,"Oral IVES yielded an adequate bioavailability profile because Cmax was 2.38 +/- 0.30 micrograms/mL, AUC was 12.87 +/- 2.02 micrograms/mL and half-life was 6.72 +/- 0.97 h.",Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10427872/),h,6.72,162413,DB00773,Etoposide
,8083566,Steady state levels,"Steady state levels averaged 89 ng/mg in the conjunctiva and sclera, 195 ng/ml in the vitreous, and 29 ng/ml in serum.",Pharmacokinetics of etoposide delivery by a bioerodible drug carrier implanted at glaucoma surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083566/),[ng] / [mg],89,162660,DB00773,Etoposide
,8083566,Steady state levels,"Steady state levels averaged 89 ng/mg in the conjunctiva and sclera, 195 ng/ml in the vitreous, and 29 ng/ml in serum.",Pharmacokinetics of etoposide delivery by a bioerodible drug carrier implanted at glaucoma surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083566/),[ng] / [ml],195,162661,DB00773,Etoposide
,8083566,Steady state levels,"Steady state levels averaged 89 ng/mg in the conjunctiva and sclera, 195 ng/ml in the vitreous, and 29 ng/ml in serum.",Pharmacokinetics of etoposide delivery by a bioerodible drug carrier implanted at glaucoma surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083566/),[ng] / [ml],29,162662,DB00773,Etoposide
,10944128,area under the curve,Paclitaxel at 175 mg/m(2) given over 3 hours and carboplatin at an area under the curve of 5 were administered on day 1 followed by oral etoposide 50 mg/m(2)/d beginning on day 2.,"Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10944128/),,5,162889,DB00773,Etoposide
,7786781,half-life,"The apparent terminal half-life of IDAol was significantly longer in the elderly than in the younger patients (mean half-life 59.7 h versus 41.4 h, P < 0.05).",Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786781/),h,59.7,164234,DB00773,Etoposide
,7786781,half-life,"The apparent terminal half-life of IDAol was significantly longer in the elderly than in the younger patients (mean half-life 59.7 h versus 41.4 h, P < 0.05).",Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7786781/),h,41.4,164235,DB00773,Etoposide
,11205919,maximum concentration,The maximum concentration of IL-6 (2.5 microg/kg/day) was 0.799 +/- 1.055 ng/ml (mean +/- SD).,"A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11205919/),[ng] / [ml],0.799,164876,DB00773,Etoposide
,11205919,time to absolute neutrophil count,"During the first course, the median time to absolute neutrophil count > or = 1,000/mm3 and platelets > or = 100,000 mm3 was estimated at 19 and 23 days, respectively.","A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11205919/),d,19,164877,DB00773,Etoposide
,11205919,time to absolute neutrophil count,"During the first course, the median time to absolute neutrophil count > or = 1,000/mm3 and platelets > or = 100,000 mm3 was estimated at 19 and 23 days, respectively.","A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11205919/),d,23,164878,DB00773,Etoposide
,8820952,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 mumol/l and 1.58 mumol/l, respectively.",Clinical reversal of multidrug resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],1.66,165049,DB00773,Etoposide
,8820952,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 mumol/l and 1.58 mumol/l, respectively.",Clinical reversal of multidrug resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],1.58,165050,DB00773,Etoposide
,8820952,peak total reversing concentration,"Since both are comparable antagonists, a median peak total reversing concentration of 3.24 mumol/l was achieved.",Clinical reversal of multidrug resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],3.24,165051,DB00773,Etoposide
,12218955,maximum plasma etoposide concentration,"In patients at dose-level I and II the maximum plasma etoposide concentration was 2.97 and 8.59 mg/ml, respectively.",Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12218955/),[mg] / [ml],2.97,166956,DB00773,Etoposide
,12218955,maximum plasma etoposide concentration,"In patients at dose-level I and II the maximum plasma etoposide concentration was 2.97 and 8.59 mg/ml, respectively.",Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12218955/),[mg] / [ml],8.59,166957,DB00773,Etoposide
,8221713,duration of response,"Median duration of response was 16 weeks (range, 7 to 46).",Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8221713/),weeks,16,168432,DB00773,Etoposide
,22821149,IC(50),"BAY 1000394 inhibits the activity of cell-cycle CDKs CDK1, CDK2, CDK3, CDK4, and of transcriptional CDKs CDK7 and CDK9 with IC(50) values in the range between 5 and 25 nmol/L.","BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22821149/),[nM] / [l],5 and 25,169104,DB00773,Etoposide
,8683232,absorption rate constant (Ka),"After oral administration of EP, the pharmacokinetics of E were as follows: mean absorption rate constant (Ka), 1.7 +/- 1.7 h-1 (mean +/- SD); lag time, 0.3 +/- 0.2 hours; time of maximum concentration (t(max)), 1.6 +/- 0.8 hours; and mean half-lives (t1/2), 1.6 +/- 0.2 (first) and 10.3 +/- 5.8 hours (terminal); the increase in the area under the plasma concentration-versus-time curve (AUC) of E was proportional to the EP dose.",Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8683232/),1/[h],1.7,169266,DB00773,Etoposide
,8683232,lag time,"After oral administration of EP, the pharmacokinetics of E were as follows: mean absorption rate constant (Ka), 1.7 +/- 1.7 h-1 (mean +/- SD); lag time, 0.3 +/- 0.2 hours; time of maximum concentration (t(max)), 1.6 +/- 0.8 hours; and mean half-lives (t1/2), 1.6 +/- 0.2 (first) and 10.3 +/- 5.8 hours (terminal); the increase in the area under the plasma concentration-versus-time curve (AUC) of E was proportional to the EP dose.",Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8683232/),h,0.3,169267,DB00773,Etoposide
,8683232,time of maximum concentration (t(max)),"After oral administration of EP, the pharmacokinetics of E were as follows: mean absorption rate constant (Ka), 1.7 +/- 1.7 h-1 (mean +/- SD); lag time, 0.3 +/- 0.2 hours; time of maximum concentration (t(max)), 1.6 +/- 0.8 hours; and mean half-lives (t1/2), 1.6 +/- 0.2 (first) and 10.3 +/- 5.8 hours (terminal); the increase in the area under the plasma concentration-versus-time curve (AUC) of E was proportional to the EP dose.",Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8683232/),h,1.6,169268,DB00773,Etoposide
,8683232,half-lives (t1/2),"After oral administration of EP, the pharmacokinetics of E were as follows: mean absorption rate constant (Ka), 1.7 +/- 1.7 h-1 (mean +/- SD); lag time, 0.3 +/- 0.2 hours; time of maximum concentration (t(max)), 1.6 +/- 0.8 hours; and mean half-lives (t1/2), 1.6 +/- 0.2 (first) and 10.3 +/- 5.8 hours (terminal); the increase in the area under the plasma concentration-versus-time curve (AUC) of E was proportional to the EP dose.",Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8683232/),h,1.6,169269,DB00773,Etoposide
,8683232,half-lives (t1/2),"After oral administration of EP, the pharmacokinetics of E were as follows: mean absorption rate constant (Ka), 1.7 +/- 1.7 h-1 (mean +/- SD); lag time, 0.3 +/- 0.2 hours; time of maximum concentration (t(max)), 1.6 +/- 0.8 hours; and mean half-lives (t1/2), 1.6 +/- 0.2 (first) and 10.3 +/- 5.8 hours (terminal); the increase in the area under the plasma concentration-versus-time curve (AUC) of E was proportional to the EP dose.",Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8683232/),h,10.3,169270,DB00773,Etoposide
,8683232,maximum concentration (C(max)),"After the 1-hour i.v. infusion of E, maximum concentration (C(max)) was 15 +/- 3 micrograms/mL; mean AUC, 88.0 +/- 22.0 micrograms.h/mL; mean total-body clearance (CL), 0.97 +/- 0.24 L/h/m2 (16.2 mL/min/m2); and mean t1/2, 0.9 +/- 0.6 (first) and 8.1 +/- 4.1 hours (terminal).",Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8683232/),[μg] / [ml],15,169271,DB00773,Etoposide
,8683232,AUC,"After the 1-hour i.v. infusion of E, maximum concentration (C(max)) was 15 +/- 3 micrograms/mL; mean AUC, 88.0 +/- 22.0 micrograms.h/mL; mean total-body clearance (CL), 0.97 +/- 0.24 L/h/m2 (16.2 mL/min/m2); and mean t1/2, 0.9 +/- 0.6 (first) and 8.1 +/- 4.1 hours (terminal).",Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8683232/),[h·μg] / [ml],88.0,169272,DB00773,Etoposide
,8683232,total-body clearance (CL),"After the 1-hour i.v. infusion of E, maximum concentration (C(max)) was 15 +/- 3 micrograms/mL; mean AUC, 88.0 +/- 22.0 micrograms.h/mL; mean total-body clearance (CL), 0.97 +/- 0.24 L/h/m2 (16.2 mL/min/m2); and mean t1/2, 0.9 +/- 0.6 (first) and 8.1 +/- 4.1 hours (terminal).",Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8683232/),[l] / [h·m2],0.97,169273,DB00773,Etoposide
,8683232,total-body clearance (CL),"After the 1-hour i.v. infusion of E, maximum concentration (C(max)) was 15 +/- 3 micrograms/mL; mean AUC, 88.0 +/- 22.0 micrograms.h/mL; mean total-body clearance (CL), 0.97 +/- 0.24 L/h/m2 (16.2 mL/min/m2); and mean t1/2, 0.9 +/- 0.6 (first) and 8.1 +/- 4.1 hours (terminal).",Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8683232/),[ml] / [m2·min],16.2,169274,DB00773,Etoposide
,8683232,t1/2,"After the 1-hour i.v. infusion of E, maximum concentration (C(max)) was 15 +/- 3 micrograms/mL; mean AUC, 88.0 +/- 22.0 micrograms.h/mL; mean total-body clearance (CL), 0.97 +/- 0.24 L/h/m2 (16.2 mL/min/m2); and mean t1/2, 0.9 +/- 0.6 (first) and 8.1 +/- 4.1 hours (terminal).",Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8683232/),h,0.9,169275,DB00773,Etoposide
,8683232,t1/2,"After the 1-hour i.v. infusion of E, maximum concentration (C(max)) was 15 +/- 3 micrograms/mL; mean AUC, 88.0 +/- 22.0 micrograms.h/mL; mean total-body clearance (CL), 0.97 +/- 0.24 L/h/m2 (16.2 mL/min/m2); and mean t1/2, 0.9 +/- 0.6 (first) and 8.1 +/- 4.1 hours (terminal).",Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8683232/),h,8.1,169276,DB00773,Etoposide
,8683232,urinary excretion,The 24-hour urinary excretion of E after i.v. E was significantly higher (33%) compared with that of oral EP (17%) (P < .001).,Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8683232/),%,33,169277,DB00773,Etoposide
,8683232,urinary excretion,The 24-hour urinary excretion of E after i.v. E was significantly higher (33%) compared with that of oral EP (17%) (P < .001).,Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8683232/),%,17,169278,DB00773,Etoposide
,2852947,peak plasma levels (PPL),"When given as a 6-h infusion of 600 mg/m2 on each of 3 consecutive days, the peak plasma levels (PPL) were 45.6 +/- SD 10.5 micrograms/ml, and the area under the curve (AUC) values were 1379.6 +/- SD 332.4 micrograms/ml/h.",Pharmacokinetic study of high dose etoposide infusion in patients with small cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2852947/),[μg] / [ml],45.6,173717,DB00773,Etoposide
,2852947,area under the curve (AUC),"When given as a 6-h infusion of 600 mg/m2 on each of 3 consecutive days, the peak plasma levels (PPL) were 45.6 +/- SD 10.5 micrograms/ml, and the area under the curve (AUC) values were 1379.6 +/- SD 332.4 micrograms/ml/h.",Pharmacokinetic study of high dose etoposide infusion in patients with small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2852947/),[μg] / [h·ml],1379.6,173718,DB00773,Etoposide
,2852947,PPL,"In 2 patients a second cycle 28 days later as a 72-h infusion at a total dose of 1,800 mg/m2 was given, and in these cases the mean PPL was 30 micrograms/ml compared to 63 micrograms/ml for the 6-h infusion in the same patients, and the mean AUC was 1,239 micrograms/ml/h compared to 1,952.5 micrograms/ml/h.",Pharmacokinetic study of high dose etoposide infusion in patients with small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2852947/),[μg] / [ml],30,173719,DB00773,Etoposide
,2852947,PPL,"In 2 patients a second cycle 28 days later as a 72-h infusion at a total dose of 1,800 mg/m2 was given, and in these cases the mean PPL was 30 micrograms/ml compared to 63 micrograms/ml for the 6-h infusion in the same patients, and the mean AUC was 1,239 micrograms/ml/h compared to 1,952.5 micrograms/ml/h.",Pharmacokinetic study of high dose etoposide infusion in patients with small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2852947/),[μg] / [ml],63,173720,DB00773,Etoposide
,2852947,AUC,"In 2 patients a second cycle 28 days later as a 72-h infusion at a total dose of 1,800 mg/m2 was given, and in these cases the mean PPL was 30 micrograms/ml compared to 63 micrograms/ml for the 6-h infusion in the same patients, and the mean AUC was 1,239 micrograms/ml/h compared to 1,952.5 micrograms/ml/h.",Pharmacokinetic study of high dose etoposide infusion in patients with small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2852947/),[μg] / [h·ml],"1,239",173721,DB00773,Etoposide
,2852947,AUC,"In 2 patients a second cycle 28 days later as a 72-h infusion at a total dose of 1,800 mg/m2 was given, and in these cases the mean PPL was 30 micrograms/ml compared to 63 micrograms/ml for the 6-h infusion in the same patients, and the mean AUC was 1,239 micrograms/ml/h compared to 1,952.5 micrograms/ml/h.",Pharmacokinetic study of high dose etoposide infusion in patients with small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2852947/),[μg] / [h·ml],"1,952.5",173722,DB00773,Etoposide
,20209646,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) of valspodar was 12.5 mg/kg/day, combined with 50% dose-reduced mitoxantrone and etoposide.",Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20209646/),[mg] / [d·kg],12.5,173804,DB00773,Etoposide
,18442869,CL,"Ifosfamide (IFO) coadministration increased etoposide clearance by 28% (median CL(VP16): 2.42L/h vs. 1.89L/h, p<0.0005) leading to a reduced systemic exposure (median AUC(VP16): 260mgh/L vs. 339mgh/L).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),[l] / [h],2.42,174976,DB00773,Etoposide
,18442869,CL,"Ifosfamide (IFO) coadministration increased etoposide clearance by 28% (median CL(VP16): 2.42L/h vs. 1.89L/h, p<0.0005) leading to a reduced systemic exposure (median AUC(VP16): 260mgh/L vs. 339mgh/L).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),[l] / [h],1.89,174977,DB00773,Etoposide
,18442869,AUC,"Ifosfamide (IFO) coadministration increased etoposide clearance by 28% (median CL(VP16): 2.42L/h vs. 1.89L/h, p<0.0005) leading to a reduced systemic exposure (median AUC(VP16): 260mgh/L vs. 339mgh/L).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),[mgh] / [l],260,174978,DB00773,Etoposide
,18442869,AUC,"Ifosfamide (IFO) coadministration increased etoposide clearance by 28% (median CL(VP16): 2.42L/h vs. 1.89L/h, p<0.0005) leading to a reduced systemic exposure (median AUC(VP16): 260mgh/L vs. 339mgh/L).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),[mgh] / [l],339,174979,DB00773,Etoposide
,18442869,OS,"Median OS was significantly longer in patients treated without ifosfamide (11.0 months vs. 7.0 months, p=0.049) and in patients with CL(VP16)<2.22L/h (14 months vs. 7 months, p=0.013) and AUC(VP16)>254.8mgh/L (11 months vs. 7 months, p=0.048).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),month,11.0,174980,DB00773,Etoposide
,18442869,OS,"Median OS was significantly longer in patients treated without ifosfamide (11.0 months vs. 7.0 months, p=0.049) and in patients with CL(VP16)<2.22L/h (14 months vs. 7 months, p=0.013) and AUC(VP16)>254.8mgh/L (11 months vs. 7 months, p=0.048).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),month,7.0,174981,DB00773,Etoposide
,18442869,OS,"Median OS was significantly longer in patients treated without ifosfamide (11.0 months vs. 7.0 months, p=0.049) and in patients with CL(VP16)<2.22L/h (14 months vs. 7 months, p=0.013) and AUC(VP16)>254.8mgh/L (11 months vs. 7 months, p=0.048).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),month,7,174982,DB00773,Etoposide
<,18442869,CL,"Median OS was significantly longer in patients treated without ifosfamide (11.0 months vs. 7.0 months, p=0.049) and in patients with CL(VP16)<2.22L/h (14 months vs. 7 months, p=0.013) and AUC(VP16)>254.8mgh/L (11 months vs. 7 months, p=0.048).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),[l] / [h],2.22,174983,DB00773,Etoposide
>,18442869,AUC(,"Median OS was significantly longer in patients treated without ifosfamide (11.0 months vs. 7.0 months, p=0.049) and in patients with CL(VP16)<2.22L/h (14 months vs. 7 months, p=0.013) and AUC(VP16)>254.8mgh/L (11 months vs. 7 months, p=0.048).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),[mgh] / [l],254.8,174984,DB00773,Etoposide
,18442869,AUC(,"Median OS was significantly longer in patients treated without ifosfamide (11.0 months vs. 7.0 months, p=0.049) and in patients with CL(VP16)<2.22L/h (14 months vs. 7 months, p=0.013) and AUC(VP16)>254.8mgh/L (11 months vs. 7 months, p=0.048).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),month,7,174985,DB00773,Etoposide
,2849466,clearance,A daily dose of 60 mg/m2 of cisplatin in a person with a body surface of 1.7 m2 and EDTA clearance of 100 ml/min was equivalent to 0.69 mg cisplatin/l EDTA clearance/24 h.,EDTA clearance in monitoring cisplatin dose escalation in patients with bulky metastatic germ cell tumors of the testis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849466/),[ml] / [min],100,175510,DB00773,Etoposide
,2849466,clearance,A daily dose of 60 mg/m2 of cisplatin in a person with a body surface of 1.7 m2 and EDTA clearance of 100 ml/min was equivalent to 0.69 mg cisplatin/l EDTA clearance/24 h.,EDTA clearance in monitoring cisplatin dose escalation in patients with bulky metastatic germ cell tumors of the testis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849466/),c·mg,0.69,175511,DB00773,Etoposide
,2849466,clearance,The mean daily cisplatin dose (mean) in the whole group was 0.86 mg/l EDTA clearance/24 h (range 0.35-2.00).,EDTA clearance in monitoring cisplatin dose escalation in patients with bulky metastatic germ cell tumors of the testis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849466/),[mg] / [l],0.86,175512,DB00773,Etoposide
,2849466,clearance,Patients with PD received a significantly lower cisplatin dose than the whole group (0.61 versus 0.86 mg cisplatin/l EDTA clearance/24 h x 4.),EDTA clearance in monitoring cisplatin dose escalation in patients with bulky metastatic germ cell tumors of the testis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849466/),,0.86,175513,DB00773,Etoposide
,10550152,survival time,"The median survival time was 10.8 months (LD, 11.6 months; ED, 10.1 months), and the 1-year survival rate was 47%.",Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550152/),month,10.8,178830,DB00773,Etoposide
,10550152,survival time,"The median survival time was 10.8 months (LD, 11.6 months; ED, 10.1 months), and the 1-year survival rate was 47%.",Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550152/),month,11.6,178831,DB00773,Etoposide
,10550152,survival time,"The median survival time was 10.8 months (LD, 11.6 months; ED, 10.1 months), and the 1-year survival rate was 47%.",Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550152/),month,10.1,178832,DB00773,Etoposide
,9923567,unbound fraction (fu),"On day 1, the mean value (with coefficient of variation for interindividual variability) for the unbound fraction (fu), area under the concentration versus time curve (AUC), and unbound AUC was 9.8% (59%), 34 mg x h/l (39%), and 3.5 mg x h/l (92%), respectively.",Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923567/),,9.8,178846,DB00773,Etoposide
,9923567,area under the concentration versus time curve (AUC),"On day 1, the mean value (with coefficient of variation for interindividual variability) for the unbound fraction (fu), area under the concentration versus time curve (AUC), and unbound AUC was 9.8% (59%), 34 mg x h/l (39%), and 3.5 mg x h/l (92%), respectively.",Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923567/),[h·mg] / [l],34,178847,DB00773,Etoposide
,9923567,unbound AUC,"On day 1, the mean value (with coefficient of variation for interindividual variability) for the unbound fraction (fu), area under the concentration versus time curve (AUC), and unbound AUC was 9.8% (59%), 34 mg x h/l (39%), and 3.5 mg x h/l (92%), respectively.",Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923567/),[h·mg] / [l],3.5,178848,DB00773,Etoposide
,3815383,steady-state VP-16 concentrations,"At a VP-16 dosage of 150 mg/m2/day, steady-state VP-16 concentrations were in the range of 2.1 to 7.0 micrograms/ml in all patients.",Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3815383/),[μg] / [ml],2.1 to 7.0,179368,DB00773,Etoposide
,3815383,plasma clearance,Further pharmacokinetic analysis revealed that the plasma clearance of VP-16 was consistently near 25 ml/min/m2 (independent of dosage) and that renal clearance accounted for only 15% of VP-16 total plasma clearance.,Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3815383/),[ml] / [m2·min],25,179369,DB00773,Etoposide
,8398279,bioavailability,The median bioavailability was 48% and beyond 30 min after either oral or intravenous injection there was little difference in the plasma profile.,24-hour plasma etoposide profile after oral and intravenous administration in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398279/),%,48,179946,DB00773,Etoposide
greater,11146899,Cpeek (peak plasma concentration),"On the one-dose schedule, Cpeek (peak plasma concentration) was greater than 2 micrograms/ml in five patients and greater than 3 micrograms/ml in three patients, while in none of the patients on the three-dose schedule did the peak exceed 2 micrograms/ml.",Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11146899/),[μg] / [ml],2,181336,DB00773,Etoposide
greater,11146899,Cpeek (peak plasma concentration),"On the one-dose schedule, Cpeek (peak plasma concentration) was greater than 2 micrograms/ml in five patients and greater than 3 micrograms/ml in three patients, while in none of the patients on the three-dose schedule did the peak exceed 2 micrograms/ml.",Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11146899/),[μg] / [ml],3,181337,DB00773,Etoposide
exceed,11146899,Cpeek (peak plasma concentration),"On the one-dose schedule, Cpeek (peak plasma concentration) was greater than 2 micrograms/ml in five patients and greater than 3 micrograms/ml in three patients, while in none of the patients on the three-dose schedule did the peak exceed 2 micrograms/ml.",Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11146899/),[μg] / [ml],2,181338,DB00773,Etoposide
exceed,11146899,peak,"On the one-dose schedule, Cpeek (peak plasma concentration) was greater than 2 micrograms/ml in five patients and greater than 3 micrograms/ml in three patients, while in none of the patients on the three-dose schedule did the peak exceed 2 micrograms/ml.",Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11146899/),[μg] / [ml],2,181339,DB00773,Etoposide
,8324869,clearance (CL),"The mean (+/- SD) parameters for total etoposide included: clearance (CL), 31.8 +/- 17.7 ml min-1 m-2; volume of distribution (Vss), 11.5 +/- 5.9 l/m2, and terminal half-life (t1/2 beta), 7.2 +/- 3.7 h.",Disposition of total and unbound etoposide following high-dose therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324869/),[ml] / [(m)^2·min],31.8,182076,DB00773,Etoposide
,8324869,volume of distribution (Vss),"The mean (+/- SD) parameters for total etoposide included: clearance (CL), 31.8 +/- 17.7 ml min-1 m-2; volume of distribution (Vss), 11.5 +/- 5.9 l/m2, and terminal half-life (t1/2 beta), 7.2 +/- 3.7 h.",Disposition of total and unbound etoposide following high-dose therapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324869/),[l] / [m2],11.5,182077,DB00773,Etoposide
,8324869,terminal half-life (t1/2 beta),"The mean (+/- SD) parameters for total etoposide included: clearance (CL), 31.8 +/- 17.7 ml min-1 m-2; volume of distribution (Vss), 11.5 +/- 5.9 l/m2, and terminal half-life (t1/2 beta), 7.2 +/- 3.7 h.",Disposition of total and unbound etoposide following high-dose therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324869/),h,7.2,182078,DB00773,Etoposide
,8324869,unbound CL,Mean unbound CL was 209.6 +/- 62.7 ml min-1 m-2 and %unbound was 16% +/- 5%.,Disposition of total and unbound etoposide following high-dose therapy. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324869/),[ml] / [(m)^2·min],209.6,182079,DB00773,Etoposide
,8324869,%unbound,Mean unbound CL was 209.6 +/- 62.7 ml min-1 m-2 and %unbound was 16% +/- 5%.,Disposition of total and unbound etoposide following high-dose therapy. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324869/),%,16,182080,DB00773,Etoposide
,8324869,%unbound,"The mean %unbound at the end of the etoposide infusion was higher than that at the lowest measured concentration (21% vs 13%, respectively; P = 0.017), suggesting that concentration-dependent binding may occur after high etoposide doses.",Disposition of total and unbound etoposide following high-dose therapy. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324869/),%,21,182081,DB00773,Etoposide
,8324869,%unbound,"The mean %unbound at the end of the etoposide infusion was higher than that at the lowest measured concentration (21% vs 13%, respectively; P = 0.017), suggesting that concentration-dependent binding may occur after high etoposide doses.",Disposition of total and unbound etoposide following high-dose therapy. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324869/),%,13,182082,DB00773,Etoposide
,8324869,total CL,"The median total CL was higher in patients with serum albumin concentrations of < or = 3.0 g/dl than in those with levels of > 3.0 g/dl (34.6 vs 23.5 ml min-1 m-2, P = 0.05).",Disposition of total and unbound etoposide following high-dose therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324869/),[ml] / [(m)^2·min],34.6,182083,DB00773,Etoposide
,8324869,total CL,"The median total CL was higher in patients with serum albumin concentrations of < or = 3.0 g/dl than in those with levels of > 3.0 g/dl (34.6 vs 23.5 ml min-1 m-2, P = 0.05).",Disposition of total and unbound etoposide following high-dose therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324869/),[ml] / [(m)^2·min],23.5,182084,DB00773,Etoposide
,8646795,mean residence time (MRT),"The overall median pharmacokinetic values were as follows (ranges are given in parentheses): mean residence time (MRT) 16.5 (5.4-42.3)h, terminal half-life 14.0 (8.2-30.5)h, volume of distribution at steady state (V(ss)) 11.4 (7.9-18.1) l/m2 and plasma clearance (Cl(p)) 15.1 (3.6-36.4) ml min-1 m-2.",Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646795/),h,16.5,182219,DB00773,Etoposide
,8646795,terminal half-life,"The overall median pharmacokinetic values were as follows (ranges are given in parentheses): mean residence time (MRT) 16.5 (5.4-42.3)h, terminal half-life 14.0 (8.2-30.5)h, volume of distribution at steady state (V(ss)) 11.4 (7.9-18.1) l/m2 and plasma clearance (Cl(p)) 15.1 (3.6-36.4) ml min-1 m-2.",Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646795/),h,14.0,182220,DB00773,Etoposide
,8646795,volume of distribution at steady state (V(ss)),"The overall median pharmacokinetic values were as follows (ranges are given in parentheses): mean residence time (MRT) 16.5 (5.4-42.3)h, terminal half-life 14.0 (8.2-30.5)h, volume of distribution at steady state (V(ss)) 11.4 (7.9-18.1) l/m2 and plasma clearance (Cl(p)) 15.1 (3.6-36.4) ml min-1 m-2.",Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646795/),[l] / [m2],11.4,182221,DB00773,Etoposide
,8646795,plasma clearance (Cl(p)),"The overall median pharmacokinetic values were as follows (ranges are given in parentheses): mean residence time (MRT) 16.5 (5.4-42.3)h, terminal half-life 14.0 (8.2-30.5)h, volume of distribution at steady state (V(ss)) 11.4 (7.9-18.1) l/m2 and plasma clearance (Cl(p)) 15.1 (3.6-36.4) ml min-1 m-2.",Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646795/),[ml] / [(m)^2·min],15.1,182222,DB00773,Etoposide
,8646795,area under the curve (AUC),"The total systemic drug exposure, represented by the area under the curve (AUC), varied between 53.4 and 532.0 micrograms ml-1 h.",Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646795/),[h·μg] / [ml],53.4 and 532.0,182223,DB00773,Etoposide
,8646795,AUC,The mean AUC (+/- SD) increased with the dose from 78.7 +/- 3.7 micrograms ml-1 h at 60 mg/m2 up to 202.8 +/- 157.2 micrograms ml-1 h at 120 mg/m2.,Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646795/),[h·μg] / [ml],78.7,182224,DB00773,Etoposide
,8646795,AUC,The mean AUC (+/- SD) increased with the dose from 78.7 +/- 3.7 micrograms ml-1 h at 60 mg/m2 up to 202.8 +/- 157.2 micrograms ml-1 h at 120 mg/m2.,Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646795/),[h·μg] / [ml],202.8,182225,DB00773,Etoposide
,8646795,urinary excretion (UE) fraction of unchanged,The mean urinary excretion (UE) fraction of unchanged drug at 48 h after the end of the infusion varied between 3.0% and 25.8% of the total dose delivered.,Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646795/),%,3.0,182226,DB00773,Etoposide
,8646795,urinary excretion (UE) fraction of unchanged,The mean urinary excretion (UE) fraction of unchanged drug at 48 h after the end of the infusion varied between 3.0% and 25.8% of the total dose delivered.,Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646795/),%,25.,182227,DB00773,Etoposide
,8646795,protein binding,Analysis of ultrafiltrate samples showed a protein binding of approx.. 99%.,Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646795/),%,99,182228,DB00773,Etoposide
,10898537,terminal half-life time,The terminal half-life time was 4.1 h (median value; range 2.0-7.8 h).,Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10898537/),h,4.1,182651,DB00773,Etoposide
,17325899,Overall response rate,"Overall response rate was 58%, with 37% complete and 21% partial responses.","A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17325899/),%,58,184793,DB00773,Etoposide
,17325899,time to progression,"Median time to progression and overall median survival were 5.7 months and 14.5 months, respectively.","A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17325899/),month,5.7,184794,DB00773,Etoposide
,17325899,overall median survival,"Median time to progression and overall median survival were 5.7 months and 14.5 months, respectively.","A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17325899/),month,14.5,184795,DB00773,Etoposide
,33675184,AUC,Carboplatin dose was adapted on day 3 based on carboplatin clearance (CL) at day 1 in order to reach a target AUC of 24 mg.,Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675184/),mg,24,185771,DB00773,Etoposide
,33675184,AUC,Measured mean AUC was 24.4 mg.min/mL per cycle (22.4 and 26.8 mg.min/mL for 10th and 90th percentiles).,Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675184/),[mg·min] / [cycle·ml],24.4,185772,DB00773,Etoposide
,33675184,AUC,Measured mean AUC was 24.4 mg.min/mL per cycle (22.4 and 26.8 mg.min/mL for 10th and 90th percentiles).,Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675184/),[mg·min] / [ml],26.8,185773,DB00773,Etoposide
,33675184,PFS,"With a median follow-up of 44 months (m), median PFS was 12.3 m (95% CI: 7.5-25.9) and OS was 46.3 m (95% CI: 18.6-not reached).",Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675184/),m,12.3,185774,DB00773,Etoposide
,33675184,OS,"With a median follow-up of 44 months (m), median PFS was 12.3 m (95% CI: 7.5-25.9) and OS was 46.3 m (95% CI: 18.6-not reached).",Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675184/),m,46.3,185775,DB00773,Etoposide
,30261554,AUC,"The final model was used to simulate whether target carboplatin AUC (16.4 mg ml-1 ·min) would be achieved using the paediatric Newell formula, modified Calvert formula and weight-based dosing.","Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30261554/),[mg·min] / [ml],16.4,185909,DB00773,Etoposide
above,10755319,AUC,"The fitted parameter-estimates suggested that at equivalent unbound etoposide AUC values above 10 microg x h/ml, the sigmoid Emax model predicted a 5% greater WBC count suppression when CsA was added to the treatment regimen.",Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755319/),[h·μg] / [ml],10,186323,DB00773,Etoposide
,9649162,Response rates,Response rates in the literature range from 12% to 26% and median survival from 5 to 7 months.,A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649162/),%,12,186890,DB00773,Etoposide
,9649162,Response rates,Response rates in the literature range from 12% to 26% and median survival from 5 to 7 months.,A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649162/),%,26,186891,DB00773,Etoposide
,9649162,response rate,"For the 26 patients evaluable for response, the response rate was 23% with responses lasting a median of 11 months (range 7-13 months), with one patient still responding at 12 months.",A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649162/),%,23,186892,DB00773,Etoposide
,9649162,survival,Median survival for all patients was 5.6 months (range 2 weeks to 33 months).,A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649162/),month,5.,186893,DB00773,Etoposide
,9649162,AUC,Dosing according to estimated creatinine clearance to achieve a carboplatin AUC of 6.0 mg ml(-1) min might have decreased the incidence of severe myelotoxicity without compromising the regimen's efficacy.,A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649162/),[mg·min] / [ml],6.0,186894,DB00773,Etoposide
,15114410,plasma clearance,"Infusion of CyA (1 mg/h) in rats treated with an i.v. bolus of etoposide caused a decrease in the plasma clearance (5.4+/-2.1 vs 9.3+/-2.4 ml/min), and an increase in plasma and tissue concentrations of etoposide, but the tissue-to-plasma concentration ratios of etoposide were not affected.",Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114410/),[ml] / [min],5.4,186964,DB00773,Etoposide
,15114410,plasma clearance,"Infusion of CyA (1 mg/h) in rats treated with an i.v. bolus of etoposide caused a decrease in the plasma clearance (5.4+/-2.1 vs 9.3+/-2.4 ml/min), and an increase in plasma and tissue concentrations of etoposide, but the tissue-to-plasma concentration ratios of etoposide were not affected.",Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114410/),[ml] / [min],9.3,186965,DB00773,Etoposide
,15114410,plasma clearance,"When etoposide was infused at a constant rate to reach a steady-state plasma level, coinfusion of CyA (10 mg/h) also caused a decrease in the plasma clearance (4.8+/-1.5 vs 9.8+/-4.7 ml/min), and an increase in plasma and tissue concentrations of etoposide.",Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114410/),[ml] / [min],4.8,186966,DB00773,Etoposide
,15114410,plasma clearance,"When etoposide was infused at a constant rate to reach a steady-state plasma level, coinfusion of CyA (10 mg/h) also caused a decrease in the plasma clearance (4.8+/-1.5 vs 9.8+/-4.7 ml/min), and an increase in plasma and tissue concentrations of etoposide.",Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114410/),[ml] / [min],9.8,186967,DB00773,Etoposide
,8558207,clearance,"Patients with renal impairment (serum creatinine level > 130 mumol/L) had a lower plasma etoposide clearance (13.6 v 18.5 mL/min/m2; P = .016), resulting in an increased total-drug and free-drug AUC (total etoposide AUC 615 v 452 micrograms/mL.hr; P = .016; free etoposide AUC 26.0 v 17.6 micrograms/mL.hr; P = .026) and increased hematologic toxicity (nadir neutrophil count 0.3 v 1.9 x 10(9)/L; P = .005).",Predicting etoposide toxicity: relationship to organ function and protein binding. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558207/),[ml] / [m2·min],13.6,188767,DB00773,Etoposide
,8558207,clearance,"Patients with renal impairment (serum creatinine level > 130 mumol/L) had a lower plasma etoposide clearance (13.6 v 18.5 mL/min/m2; P = .016), resulting in an increased total-drug and free-drug AUC (total etoposide AUC 615 v 452 micrograms/mL.hr; P = .016; free etoposide AUC 26.0 v 17.6 micrograms/mL.hr; P = .026) and increased hematologic toxicity (nadir neutrophil count 0.3 v 1.9 x 10(9)/L; P = .005).",Predicting etoposide toxicity: relationship to organ function and protein binding. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558207/),[ml] / [m2·min],18.5,188768,DB00773,Etoposide
,8558207,AUC,"Patients with renal impairment (serum creatinine level > 130 mumol/L) had a lower plasma etoposide clearance (13.6 v 18.5 mL/min/m2; P = .016), resulting in an increased total-drug and free-drug AUC (total etoposide AUC 615 v 452 micrograms/mL.hr; P = .016; free etoposide AUC 26.0 v 17.6 micrograms/mL.hr; P = .026) and increased hematologic toxicity (nadir neutrophil count 0.3 v 1.9 x 10(9)/L; P = .005).",Predicting etoposide toxicity: relationship to organ function and protein binding. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558207/),[μg] / [h·ml],615,188769,DB00773,Etoposide
,8558207,AUC,"Patients with renal impairment (serum creatinine level > 130 mumol/L) had a lower plasma etoposide clearance (13.6 v 18.5 mL/min/m2; P = .016), resulting in an increased total-drug and free-drug AUC (total etoposide AUC 615 v 452 micrograms/mL.hr; P = .016; free etoposide AUC 26.0 v 17.6 micrograms/mL.hr; P = .026) and increased hematologic toxicity (nadir neutrophil count 0.3 v 1.9 x 10(9)/L; P = .005).",Predicting etoposide toxicity: relationship to organ function and protein binding. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558207/),[μg] / [h·ml],452,188770,DB00773,Etoposide
,8558207,AUC,"Patients with renal impairment (serum creatinine level > 130 mumol/L) had a lower plasma etoposide clearance (13.6 v 18.5 mL/min/m2; P = .016), resulting in an increased total-drug and free-drug AUC (total etoposide AUC 615 v 452 micrograms/mL.hr; P = .016; free etoposide AUC 26.0 v 17.6 micrograms/mL.hr; P = .026) and increased hematologic toxicity (nadir neutrophil count 0.3 v 1.9 x 10(9)/L; P = .005).",Predicting etoposide toxicity: relationship to organ function and protein binding. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558207/),[μg] / [h·ml],26.0,188771,DB00773,Etoposide
,8558207,AUC,"Patients with renal impairment (serum creatinine level > 130 mumol/L) had a lower plasma etoposide clearance (13.6 v 18.5 mL/min/m2; P = .016), resulting in an increased total-drug and free-drug AUC (total etoposide AUC 615 v 452 micrograms/mL.hr; P = .016; free etoposide AUC 26.0 v 17.6 micrograms/mL.hr; P = .026) and increased hematologic toxicity (nadir neutrophil count 0.3 v 1.9 x 10(9)/L; P = .005).",Predicting etoposide toxicity: relationship to organ function and protein binding. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558207/),[μg] / [h·ml],17.6,188772,DB00773,Etoposide
,8558207,AUC,"Patients with albumin levels less than 35 g/L had no change in total etoposide kinetics but had an increase in unbound etoposide (5.2% v 4.1%; P = .01), resulting in an increase in free etoposide AUC (27.5 v 16.5 micrograms/mL.hr; P = .003) and more profound toxicity (nadir neutrophil count 0.6 v 1.9 x 10(9)/L; P = .004).",Predicting etoposide toxicity: relationship to organ function and protein binding. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558207/),[μg] / [h·ml],27.5,188773,DB00773,Etoposide
,8558207,AUC,"Patients with albumin levels less than 35 g/L had no change in total etoposide kinetics but had an increase in unbound etoposide (5.2% v 4.1%; P = .01), resulting in an increase in free etoposide AUC (27.5 v 16.5 micrograms/mL.hr; P = .003) and more profound toxicity (nadir neutrophil count 0.6 v 1.9 x 10(9)/L; P = .004).",Predicting etoposide toxicity: relationship to organ function and protein binding. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558207/),[μg] / [h·ml],16.5,188774,DB00773,Etoposide
,8558207,nadir neutrophil count,"Patients with albumin levels less than 35 g/L had no change in total etoposide kinetics but had an increase in unbound etoposide (5.2% v 4.1%; P = .01), resulting in an increase in free etoposide AUC (27.5 v 16.5 micrograms/mL.hr; P = .003) and more profound toxicity (nadir neutrophil count 0.6 v 1.9 x 10(9)/L; P = .004).",Predicting etoposide toxicity: relationship to organ function and protein binding. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558207/),,0.6,188775,DB00773,Etoposide
,8558207,nadir neutrophil count,"Patients with albumin levels less than 35 g/L had no change in total etoposide kinetics but had an increase in unbound etoposide (5.2% v 4.1%; P = .01), resulting in an increase in free etoposide AUC (27.5 v 16.5 micrograms/mL.hr; P = .003) and more profound toxicity (nadir neutrophil count 0.6 v 1.9 x 10(9)/L; P = .004).",Predicting etoposide toxicity: relationship to organ function and protein binding. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558207/),,1,188776,DB00773,Etoposide
,7961128,Vc,"The population mean values (CV%) of Vc, CL, K12, and K21 were, respectively, 31.8 (15.7%) liter/m2, 14.1 (27.8%) liter/h/m2, 1.1 (8.4%)/h, and 0.41 (30.3%)/h.",CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7961128/),,31.8,191376,DB00773,Etoposide
,7961128,CL,"The population mean values (CV%) of Vc, CL, K12, and K21 were, respectively, 31.8 (15.7%) liter/m2, 14.1 (27.8%) liter/h/m2, 1.1 (8.4%)/h, and 0.41 (30.3%)/h.",CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7961128/),,14.1,191377,DB00773,Etoposide
,7961128,K12,"The population mean values (CV%) of Vc, CL, K12, and K21 were, respectively, 31.8 (15.7%) liter/m2, 14.1 (27.8%) liter/h/m2, 1.1 (8.4%)/h, and 0.41 (30.3%)/h.",CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7961128/),,14.1,191378,DB00773,Etoposide
,7961128,K21,"The population mean values (CV%) of Vc, CL, K12, and K21 were, respectively, 31.8 (15.7%) liter/m2, 14.1 (27.8%) liter/h/m2, 1.1 (8.4%)/h, and 0.41 (30.3%)/h.",CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7961128/),,0.41,191379,DB00773,Etoposide
,27287856,disease control rate,"In the etoposide arm, 2 patients (16.7 %) demonstrated partial responses, 1 (8.3 %) patient demonstrated a minor response, and 2 (16.7 %) showed prolonged stable disease, for a prolonged disease control rate of 41.7 %.",Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27287856/),,41,191902,DB00773,Etoposide
,2019667,terminal half-life,Plasma etoposide concentrations reached a peak at 4.2 +/- 2.5 hours and declined exponentially with a terminal half-life of 9.5 +/- 3.6 hours.,Pharmacologic study of etoposide and cisplatin by the intraperitoneal route. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2019667/),h,9.5,192086,DB00773,Etoposide
,2019667,half-life,Peritoneal etoposide concentrations declined monoexponentially with a half-life of 3.7 +/- 2.6 hour.,Pharmacologic study of etoposide and cisplatin by the intraperitoneal route. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2019667/),h,3.7,192087,DB00773,Etoposide
,2019667,peritoneal-to-plasma ratio of unbound,The calculated peritoneal-to-plasma ratio of unbound etoposide was 35.,Pharmacologic study of etoposide and cisplatin by the intraperitoneal route. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2019667/),,35,192088,DB00773,Etoposide
,2019667,plasma,"The plasma and peritoneal half-lives of ultrafilterable cisplatin were 21.7 +/- 14.1 hours and 1.8 +/- 0.7 hours, respectively.",Pharmacologic study of etoposide and cisplatin by the intraperitoneal route. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2019667/),h,21.7,192089,DB00773,Etoposide
,2019667,peritoneal half-lives,"The plasma and peritoneal half-lives of ultrafilterable cisplatin were 21.7 +/- 14.1 hours and 1.8 +/- 0.7 hours, respectively.",Pharmacologic study of etoposide and cisplatin by the intraperitoneal route. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2019667/),h,1.8,192090,DB00773,Etoposide
,2019667,peritoneal/plasma area under curve AUC ratio,The peritoneal/plasma area under curve AUC ratio was 18.3.,Pharmacologic study of etoposide and cisplatin by the intraperitoneal route. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2019667/),,18.3,192091,DB00773,Etoposide
,8664132,AUC,"The AUC was highly variable (mean +/- s.d. = 2.48 +/- 0.51 micrograms h-1 ml-1; range 1.10-3.82) and was closely correlated with the AUA (r = 0.78, P < 0.0001) and A(max) (r = 0.73, P < 0.0001).","Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8664132/),[μg] / [h·ml],2.48,193342,DB00773,Etoposide
,18828689,Oral bioavailability,"Oral bioavailability of etoposide was low (median, 13.4%) and highly variable among dogs (range, 5.7% to 57.3%).",Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18828689/),%,13.4,194969,DB00773,Etoposide
,18828689,Oral bioavailability,"Oral bioavailability of etoposide was low (median, 13.4%) and highly variable among dogs (range, 5.7% to 57.3%).",Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18828689/),%,5.7,194970,DB00773,Etoposide
,18828689,Oral bioavailability,"Oral bioavailability of etoposide was low (median, 13.4%) and highly variable among dogs (range, 5.7% to 57.3%).",Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18828689/),%,57.3,194971,DB00773,Etoposide
,22028494,MTD,The topotecan MTD in this regimen was 64 mg/m(2) (21.3 mg/m(2)/d).,"Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028494/),[mg] / [m(2],64,195022,DB00773,Etoposide
,22028494,MTD,The topotecan MTD in this regimen was 64 mg/m(2) (21.3 mg/m(2)/d).,"Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028494/),mg,21.3,195023,DB00773,Etoposide
,17708397,overall survival time,Both the median overall survival time and the median disease-free interval in dogs treated with LDC were 178 days.,Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17708397/),d,178,195038,DB00773,Etoposide
,17708397,overall survival time,"By comparison, the overall survival time and disease-free interval in dogs treated with DOX were 133 and 126 days, respectively.",Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17708397/),d,133,195039,DB00773,Etoposide
,17708397,disease-free interval,"By comparison, the overall survival time and disease-free interval in dogs treated with DOX were 133 and 126 days, respectively.",Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17708397/),d,126,195040,DB00773,Etoposide
,8233302,overall response rate,"The overall response rate to this high-dose chemotherapy was 55%, with a complete response (CR) rate of 45% (9 patients).",Escalating high-dose carboplatin and autologous bone marrow transplantation in solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8233302/),%,55,195318,DB00773,Etoposide
,8233302,complete response (CR) rate,"The overall response rate to this high-dose chemotherapy was 55%, with a complete response (CR) rate of 45% (9 patients).",Escalating high-dose carboplatin and autologous bone marrow transplantation in solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8233302/),%,45,195319,DB00773,Etoposide
,15032307,zeta potential,"Following 1:10 aqueous dilution of optimal paclitaxel SMEDDS, the droplet size of resulting microemulsions was 2.0 +/- 0.4 nm, and the zeta potential was -45.5 +/- 0.5 mV.",Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),m,-,195658,DB00773,Etoposide
,15032307,zeta potential,"Following 1:10 aqueous dilution of optimal paclitaxel SMEDDS, the droplet size of resulting microemulsions was 2.0 +/- 0.4 nm, and the zeta potential was -45.5 +/- 0.5 mV.",Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),m,45.5,195659,DB00773,Etoposide
,15032307,oral bioavailability,"Compared to Taxol, the oral bioavailability of paclitaxel SMEDDS increased by 28.6% to 52.7% at various doses.",Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),,52,195660,DB00773,Etoposide
,15032307,time above therapeutic level,There was a significant improvement in area under the curve (AUC) and time above therapeutic level (0.1 microM) of paclitaxel SMEDDS as compared to those of Taxol following coadministration of both formulations with 40 mg cyclosporin A (CsA)/kg.,Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),,0,195661,DB00773,Etoposide
,30948132,PDI,"The particle size, PDI and EE obtained for the optimized formulation (Z15) were 239.43 ± 2.35 nm, 0.261 ± 0.001 and 80.96 ± 2.21% respectively.","Optimization by design of etoposide loaded solid lipid nanoparticles for ocular delivery: Characterization, pharmacokinetic and deposition study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30948132/),%,0.261,195777,DB00773,Etoposide
,30948132,EE,"The particle size, PDI and EE obtained for the optimized formulation (Z15) were 239.43 ± 2.35 nm, 0.261 ± 0.001 and 80.96 ± 2.21% respectively.","Optimization by design of etoposide loaded solid lipid nanoparticles for ocular delivery: Characterization, pharmacokinetic and deposition study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30948132/),%,80.96,195778,DB00773,Etoposide
,16203659,maximum topotecan lactone AUC,"When the administration sequence was changed (topotecan, carboplatin, etoposide), Cycle 1 hematologic toxicity decreased; however, the maximum topotecan lactone AUC of 24-36 ng/mL*hr (median dose 0.82 mg/m2) had significant cumulative hematologic toxicity.",A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203659/),[ng] / [h·ml],24-36,196180,DB00773,Etoposide
,16203659,maximum topotecan lactone AUC,"The number of topotecan doses were reduced from 5 to 3, which resulted in a maximum topotecan lactone AUC of 37 to 53 ng/mL*hr with only 1 of 6 patients having Cycle 1 DLT.",A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203659/),[ng] / [h·ml],37 to 53,196181,DB00773,Etoposide
,16203659,Overall response rate,Overall response rate was 71 percent with median survival of 10.8 months.,A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203659/),%,71,196182,DB00773,Etoposide
,2908850,peak plasma ara-C concentration,"The peak plasma ara-C concentration of ara-C ranged from 57 to 199 microM with an average concentration of 103 +/- 49 microM; the half-lives of distribution (t1/2, alpha) and elimination (t1/2, beta) averaged 17 +/- 7 min and 4.04 +/- 3.1 h, respectively.",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),μM,57 to 199,198955,DB00773,Etoposide
,2908850,"half-lives of distribution (t1/2, alpha)","The peak plasma ara-C concentration of ara-C ranged from 57 to 199 microM with an average concentration of 103 +/- 49 microM; the half-lives of distribution (t1/2, alpha) and elimination (t1/2, beta) averaged 17 +/- 7 min and 4.04 +/- 3.1 h, respectively.",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),min,17,198956,DB00773,Etoposide
,2908850,"elimination (t1/2, beta)","The peak plasma ara-C concentration of ara-C ranged from 57 to 199 microM with an average concentration of 103 +/- 49 microM; the half-lives of distribution (t1/2, alpha) and elimination (t1/2, beta) averaged 17 +/- 7 min and 4.04 +/- 3.1 h, respectively.",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),h,4.04,198957,DB00773,Etoposide
,2908850,area under the plasma concentration time curve from 0 to 12 h (AUC0----12 h),"The mean area under the plasma concentration time curve from 0 to 12 h (AUC0----12 h) of ara-C averaged 386.8 +/- 328.0 microMh (mean, +/- SD, n = 8).",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),μMh,386.8,198958,DB00773,Etoposide
,2908850,peak concentration,"The peak concentration of uracil arabinoside averaged 501 +/- 123 microM, and it was eliminated with a t1/2, el of 2.3 +/- 0.6 h.",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),μM,501,198959,DB00773,Etoposide
,2908850,"t1/2, el","The peak concentration of uracil arabinoside averaged 501 +/- 123 microM, and it was eliminated with a t1/2, el of 2.3 +/- 0.6 h.",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),h,2.3,198960,DB00773,Etoposide
,2908850,Css,"The patients then received an individualized loading bolus (mean = 0.5 g/m2) followed by a continuous infusion regimen of ara-C (mean = 130 mg/m2/h), to achieve a Css in the range of 20 to 35 microM.",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),μM,20 to 35,198961,DB00773,Etoposide
,2908850,AUC,"The percentage of variation of correlation of the AUC following the loading bolus plus the continuous infusion from 12 to 72 h was only 12.4% (mean = 2158 microMh, n = 8), whereas the percentage of variation of correlation of the AUC after the test dose of ara-C in the same patients was 84.8%.(ABSTRACT TRUNCATED AT 400 WORDS)",Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908850/),μMh,2158,198962,DB00773,Etoposide
,1537079,t1/2 beta,"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),min,256,199424,DB00773,Etoposide
,1537079,mean residence time (MRT),"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),min,346,199425,DB00773,Etoposide
,1537079,AUC,"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),[min·μg] / [ml],"4,972",199426,DB00773,Etoposide
,1537079,volume of distribution at steady state (Vdss),"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),[l] / [m2],6.6,199427,DB00773,Etoposide
,1537079,clearance (CL),"The mean values for the calculated pharmacokinetic parameters were: t1/2 beta, 256 +/- 38 min; mean residence time (MRT), 346 +/- 47 min; AUC, 4,972 +/- 629 micrograms min ml-1 (normalized to a dose of 100 mg/m2); volume of distribution at steady state (Vdss), 6.6 +/- 1.2 l/m2; and clearance (CL), 20.4 +/- 2.4 ml min-1 m-2.",Pharmacokinetics of high-dose etoposide after short-term infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537079/),[ml] / [(m)^2·min],20.4,199428,DB00773,Etoposide
,19701749,Cl,"Body weight (BW) was strongly associated with carboplatin clearance (Cl), with a slightly weaker relationship observed with etoposide Cl. Carboplatin Cl values ranged from 12.8 to 33.6 ml/min, with total AUC values of 4.2-9.3 mg/ml.min achieved over the 3 days of treatment.",Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701749/),[ml] / [min],12.8 to 33.6,199987,DB00773,Etoposide
,19701749,total AUC,"Body weight (BW) was strongly associated with carboplatin clearance (Cl), with a slightly weaker relationship observed with etoposide Cl. Carboplatin Cl values ranged from 12.8 to 33.6 ml/min, with total AUC values of 4.2-9.3 mg/ml.min achieved over the 3 days of treatment.",Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701749/),[mg] / [min·ml],4.2-9.3,199988,DB00773,Etoposide
,19701749,Cl,"Cl values normalized to BW were significantly higher in patients <12 kg than in children >12 kg, with mean +/- SD values of 2.9 +/- 0.4 and 2.5 +/- 0.4 ml/min/kg, respectively (P < 0.05).",Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701749/),[ml] / [kg·min],2.9,199989,DB00773,Etoposide
,19701749,Cl,"Cl values normalized to BW were significantly higher in patients <12 kg than in children >12 kg, with mean +/- SD values of 2.9 +/- 0.4 and 2.5 +/- 0.4 ml/min/kg, respectively (P < 0.05).",Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701749/),[ml] / [kg·min],2.5,199990,DB00773,Etoposide
,19701749,half-life,"Etoposide exhibited a median half-life of 4.6 h (range 4.1-6.6), a median AUC of 7.1 mg/ml.min (range 3.4-11.0) and a median Cl of 6.6 ml/min (range 3.2-13.0).",Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701749/),h,4.6,199991,DB00773,Etoposide
,19701749,AUC,"Etoposide exhibited a median half-life of 4.6 h (range 4.1-6.6), a median AUC of 7.1 mg/ml.min (range 3.4-11.0) and a median Cl of 6.6 ml/min (range 3.2-13.0).",Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701749/),[mg] / [min·ml],7.1,199992,DB00773,Etoposide
,19701749,Cl,"Etoposide exhibited a median half-life of 4.6 h (range 4.1-6.6), a median AUC of 7.1 mg/ml.min (range 3.4-11.0) and a median Cl of 6.6 ml/min (range 3.2-13.0).",Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19701749/),[ml] / [min],6.6,199993,DB00773,Etoposide
,7595746,bioavailability,"The mean bioavailability of etoposide from Etopophos, relative to VePesid, was 103% (90% confidence interval, 99% to 106%) based on Cmax, and 107% (90 confidence interval, 105% to 110%) based on area under the concentration versus time curve from zero to infinity (AUCinf) values.",Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595746/),%,103,200590,DB00773,Etoposide
,7595746,bioavailability,"The mean bioavailability of etoposide from Etopophos, relative to VePesid, was 103% (90% confidence interval, 99% to 106%) based on Cmax, and 107% (90 confidence interval, 105% to 110%) based on area under the concentration versus time curve from zero to infinity (AUCinf) values.",Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595746/),%,107,200591,DB00773,Etoposide
,7595746,terminal elimination half-life (t1/2),"Mean terminal elimination half-life (t1/2), steady-state volume of distribution (Vss), and total systemic clearance (CL) values of etoposide were approximately 7 hours, 7 L/m2, and 17 mL/min/m2 after Etopophos and VePesid treatments, respectively.",Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595746/),h,7,200592,DB00773,Etoposide
,7595746,steady-state volume of distribution (Vss),"Mean terminal elimination half-life (t1/2), steady-state volume of distribution (Vss), and total systemic clearance (CL) values of etoposide were approximately 7 hours, 7 L/m2, and 17 mL/min/m2 after Etopophos and VePesid treatments, respectively.",Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595746/),[l] / [m2],7,200593,DB00773,Etoposide
,7595746,total systemic clearance (CL),"Mean terminal elimination half-life (t1/2), steady-state volume of distribution (Vss), and total systemic clearance (CL) values of etoposide were approximately 7 hours, 7 L/m2, and 17 mL/min/m2 after Etopophos and VePesid treatments, respectively.",Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7595746/),[ml] / [m2·min],17,200594,DB00773,Etoposide
,9443625,unbound fraction,"For 67 pts, etoposide plasma protein binding was determined by equilibrium dialysis; the unbound fraction ranged from 4% to 24%.",Population pharmacokinetics of total and unbound etoposide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443625/),%,4,200957,DB00773,Etoposide
,9443625,unbound fraction,"For 67 pts, etoposide plasma protein binding was determined by equilibrium dialysis; the unbound fraction ranged from 4% to 24%.",Population pharmacokinetics of total and unbound etoposide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443625/),%,24,200958,DB00773,Etoposide
,9443625,Vc (L),"The central and peripheral volumes of distribution were significantly correlated with the body surface area [Vc (L) = 5.5 x BSA (m2) and Vp = 4.1 x BSA], but even after BSA had been taken into account, the interindividual variability of the two volumes remained high (34% and 57%, respectively).",Population pharmacokinetics of total and unbound etoposide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443625/),,5,200959,DB00773,Etoposide
,9443625,CL,The interindividual variability in CL (mean value 30 ml/min) decreased only from 32% to 26% when these covariates were taken into account.,Population pharmacokinetics of total and unbound etoposide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443625/),[ml] / [min],30,200960,DB00773,Etoposide
,9443625,oral bioavailability,"The mean oral bioavailability was 66%, showing an interindividual variability of 37%.",Population pharmacokinetics of total and unbound etoposide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443625/),%,66,200961,DB00773,Etoposide
,7724471,t 1/2,"For the 3 doses, mean t 1/2 of BMY-40481 ranged from 0.11-0.17 hr (6.6-11 min).",Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7724471/),h,0.11-0.17,201710,DB00773,Etoposide
,7724471,Cmax,"The mean Cmax and AUC values of BMY-40481 ranged from 1.72-40.5 micrograms/ml and 0.16-4.14 hr.micrograms/ml, respectively.",Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7724471/),[μg] / [ml],1.72-40.5,201711,DB00773,Etoposide
,7724471,AUC,"The mean Cmax and AUC values of BMY-40481 ranged from 1.72-40.5 micrograms/ml and 0.16-4.14 hr.micrograms/ml, respectively.",Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7724471/),[h·μg] / [ml],0.16-4.14,201712,DB00773,Etoposide
,7724471,Cmax,"In contrast, the mean Cmax and AUC values of etoposide ranged from 5.46-39.4 micrograms/ml and 2.28-22.6 hr.micrograms/ml, respectively.",Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7724471/),[μg] / [ml],5.46-39.4,201713,DB00773,Etoposide
,7724471,AUC,"In contrast, the mean Cmax and AUC values of etoposide ranged from 5.46-39.4 micrograms/ml and 2.28-22.6 hr.micrograms/ml, respectively.",Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7724471/),[h·μg] / [ml],2.28-22.6,201714,DB00773,Etoposide
,7724471,apparent systemic clearance,The apparent systemic clearance (range: 342-435 ml/min/m2) and apparent steady state volume of distribution (range: 21.5-26.6 l/m2) of etoposide were dose-independent.,Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7724471/),[ml] / [m2·min],342-435,201715,DB00773,Etoposide
,7724471,apparent steady state volume of distribution,The apparent systemic clearance (range: 342-435 ml/min/m2) and apparent steady state volume of distribution (range: 21.5-26.6 l/m2) of etoposide were dose-independent.,Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7724471/),[l] / [m2],21.5-26.6,201716,DB00773,Etoposide
,9747681,peak vitreous concentration,"Mean measured peak vitreous concentration of carboplatin after intravenous administration was 0.31 microg/mL, which was 1% of the peak plasma value.",Intraocular concentrations of chemotherapeutic agents after systemic or local administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9747681/),[μg] / [ml],0.31,203792,DB00773,Etoposide
,9747681,peak vitreous concentrations,"Mean measured peak vitreous concentrations of carboplatin after peribulbar or episcleral balloon administration were 2.38 microg/mL and 2.95 microg/mL, respectively, which represent 7.68- and 9.52-fold increases over the concentration achieved after intravenous administration.",Intraocular concentrations of chemotherapeutic agents after systemic or local administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9747681/),[μg] / [ml],2.38,203793,DB00773,Etoposide
,9747681,peak vitreous concentrations,"Mean measured peak vitreous concentrations of carboplatin after peribulbar or episcleral balloon administration were 2.38 microg/mL and 2.95 microg/mL, respectively, which represent 7.68- and 9.52-fold increases over the concentration achieved after intravenous administration.",Intraocular concentrations of chemotherapeutic agents after systemic or local administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9747681/),[μg] / [ml],2.95,203794,DB00773,Etoposide
above,9917083,ECpss,Values generated from this equation indicated that ECpss above 1.5 microg/ml was strongly associated with grade III-IV leukocyte toxicity.,Pharmacodynamic profile of prolonged etoposide administration in patients with small cell lung cancer and non-Hodgkin's lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9917083/),[μg] / [ml],1.5,203912,DB00773,Etoposide
,2842552,half-life,"HDC has a similar pharmacokinetic profile to low dose cyclophosphamide, with a half-life of 4.83 +/- 1.3 h.",The pharmacokinetics of high dose cyclophosphamide and high dose etoposide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842552/),h,4.83,205030,DB00773,Etoposide
,2842552,terminal half-life,"The terminal half-life of high dose etoposide was 7.7 +/- 2 h which is similar to our previous results with low dose etoposide (50-300 mg m-2), but the volume of distribution which was 35.5 +/- 11.6 1. was significantly increased (P less than 0.001).",The pharmacokinetics of high dose cyclophosphamide and high dose etoposide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842552/),h,7.7,205031,DB00773,Etoposide
,2842552,volume of distribution,"The terminal half-life of high dose etoposide was 7.7 +/- 2 h which is similar to our previous results with low dose etoposide (50-300 mg m-2), but the volume of distribution which was 35.5 +/- 11.6 1. was significantly increased (P less than 0.001).",The pharmacokinetics of high dose cyclophosphamide and high dose etoposide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842552/),1,35.5,205032,DB00773,Etoposide
,2842552,Plasma steady state concentrations,Plasma steady state concentrations of 26.2 +/- 11.7 micrograms ml-1 were achieved.,The pharmacokinetics of high dose cyclophosphamide and high dose etoposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842552/),[μg] / [ml],26.2,205033,DB00773,Etoposide
,1739628,area under the plasma concentration curve (AUC0-00),"Mean area under the plasma concentration curve (AUC0-00) and plasma half-life (beta) of nifedipine and its major metabolite MI at the highest dose level were 7.87 microM.h, 7.97 h and 4.97 microM.h, 14.0 h respectively.",A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1739628/),h·μM,7.87,206086,DB00773,Etoposide
,1739628,area under the plasma concentration curve (AUC0-00),"Mean area under the plasma concentration curve (AUC0-00) and plasma half-life (beta) of nifedipine and its major metabolite MI at the highest dose level were 7.87 microM.h, 7.97 h and 4.97 microM.h, 14.0 h respectively.",A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1739628/),h,7.97,206087,DB00773,Etoposide
,1739628,area under the plasma concentration curve (AUC0-00),"Mean area under the plasma concentration curve (AUC0-00) and plasma half-life (beta) of nifedipine and its major metabolite MI at the highest dose level were 7.87 microM.h, 7.97 h and 4.97 microM.h, 14.0 h respectively.",A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1739628/),h·μM,4.97,206088,DB00773,Etoposide
,1739628,plasma half-life (beta),"Mean area under the plasma concentration curve (AUC0-00) and plasma half-life (beta) of nifedipine and its major metabolite MI at the highest dose level were 7.87 microM.h, 7.97 h and 4.97 microM.h, 14.0 h respectively.",A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1739628/),h,7.97,206089,DB00773,Etoposide
,1739628,plasma half-life (beta),"Mean area under the plasma concentration curve (AUC0-00) and plasma half-life (beta) of nifedipine and its major metabolite MI at the highest dose level were 7.87 microM.h, 7.97 h and 4.97 microM.h, 14.0 h respectively.",A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1739628/),h·μM,4.97,206090,DB00773,Etoposide
,1739628,plasma half-life (beta),"Mean area under the plasma concentration curve (AUC0-00) and plasma half-life (beta) of nifedipine and its major metabolite MI at the highest dose level were 7.87 microM.h, 7.97 h and 4.97 microM.h, 14.0 h respectively.",A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1739628/),h,14.0,206091,DB00773,Etoposide
,2155586,t1/2 alpha,The post-infusion plasma decay of etoposide was biphasic with t1/2 alpha ranging from 0.59 approximately 0.63 h and t1/2 beta ranging from 5.40 approximately 6.57 h.,[Hepatic arterial infusion of etoposide in the treatment of primary liver neoplasms]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155586/),h,0.59 approximately 0.63,206291,DB00773,Etoposide
,2155586,t1/2 beta,The post-infusion plasma decay of etoposide was biphasic with t1/2 alpha ranging from 0.59 approximately 0.63 h and t1/2 beta ranging from 5.40 approximately 6.57 h.,[Hepatic arterial infusion of etoposide in the treatment of primary liver neoplasms]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155586/),h,5.40 approximately 6.57,206292,DB00773,Etoposide
,2348225,clearance,"Mean (+/- SE) measurements of clearance (24.5 +/- 2.06 v 26.5 +/- 2.05 mL/min/m2), half-life (5.7 +/- 0.5 v 6.4 +/- 0.5 hours), and volume of distribution (12.4 +/- 1.1 v 13.7 +/- 1.6 L/m2) were not significantly different in patients with jaundice when compared with controls.",Etoposide kinetics in patients with obstructive jaundice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348225/),[ml] / [m2·min],24.5,207146,DB00773,Etoposide
,2348225,clearance,"Mean (+/- SE) measurements of clearance (24.5 +/- 2.06 v 26.5 +/- 2.05 mL/min/m2), half-life (5.7 +/- 0.5 v 6.4 +/- 0.5 hours), and volume of distribution (12.4 +/- 1.1 v 13.7 +/- 1.6 L/m2) were not significantly different in patients with jaundice when compared with controls.",Etoposide kinetics in patients with obstructive jaundice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348225/),[ml] / [m2·min],26.5,207147,DB00773,Etoposide
,2348225,half-life,"Mean (+/- SE) measurements of clearance (24.5 +/- 2.06 v 26.5 +/- 2.05 mL/min/m2), half-life (5.7 +/- 0.5 v 6.4 +/- 0.5 hours), and volume of distribution (12.4 +/- 1.1 v 13.7 +/- 1.6 L/m2) were not significantly different in patients with jaundice when compared with controls.",Etoposide kinetics in patients with obstructive jaundice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348225/),h,5.7,207148,DB00773,Etoposide
,2348225,half-life,"Mean (+/- SE) measurements of clearance (24.5 +/- 2.06 v 26.5 +/- 2.05 mL/min/m2), half-life (5.7 +/- 0.5 v 6.4 +/- 0.5 hours), and volume of distribution (12.4 +/- 1.1 v 13.7 +/- 1.6 L/m2) were not significantly different in patients with jaundice when compared with controls.",Etoposide kinetics in patients with obstructive jaundice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348225/),h,6.4,207149,DB00773,Etoposide
,2348225,volume of distribution,"Mean (+/- SE) measurements of clearance (24.5 +/- 2.06 v 26.5 +/- 2.05 mL/min/m2), half-life (5.7 +/- 0.5 v 6.4 +/- 0.5 hours), and volume of distribution (12.4 +/- 1.1 v 13.7 +/- 1.6 L/m2) were not significantly different in patients with jaundice when compared with controls.",Etoposide kinetics in patients with obstructive jaundice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348225/),[l] / [m2],12.4,207150,DB00773,Etoposide
,2348225,volume of distribution,"Mean (+/- SE) measurements of clearance (24.5 +/- 2.06 v 26.5 +/- 2.05 mL/min/m2), half-life (5.7 +/- 0.5 v 6.4 +/- 0.5 hours), and volume of distribution (12.4 +/- 1.1 v 13.7 +/- 1.6 L/m2) were not significantly different in patients with jaundice when compared with controls.",Etoposide kinetics in patients with obstructive jaundice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348225/),[l] / [m2],13.7,207151,DB00773,Etoposide
,2348225,renal clearance,The calculated renal clearance of etoposide was 11.5 mL/min/m2 in patients with jaundice and 10.4 mL/min/m2 in controls (P = .53).,Etoposide kinetics in patients with obstructive jaundice. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348225/),[ml] / [m2·min],11.5,207152,DB00773,Etoposide
,2348225,renal clearance,The calculated renal clearance of etoposide was 11.5 mL/min/m2 in patients with jaundice and 10.4 mL/min/m2 in controls (P = .53).,Etoposide kinetics in patients with obstructive jaundice. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348225/),[ml] / [m2·min],10.4,207153,DB00773,Etoposide
,2348225,metabolic clearance,Respective metabolic clearance was 4.9 and 6.9 mL/min/m2 in these two study groups (P = .13).,Etoposide kinetics in patients with obstructive jaundice. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348225/),[ml] / [m2·min],4.9,207154,DB00773,Etoposide
,2348225,metabolic clearance,Respective metabolic clearance was 4.9 and 6.9 mL/min/m2 in these two study groups (P = .13).,Etoposide kinetics in patients with obstructive jaundice. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348225/),[ml] / [m2·min],6.9,207155,DB00773,Etoposide
,15661261,MTD,The MTD of idarubicin in this combination was 8 mg/(m(2) day) with a DLT of oral mucositis.,"A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),[mg] / [d·m(2)],8,208630,DB00773,Etoposide
,15661261,complete remission rate,"The complete remission rate (on an intent-to-treat basis) for this regimen was 33%, with a median duration of 6 months.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),%,33,208631,DB00773,Etoposide
,15661261,clearance,"The clearance of idarubicin was 140 +/- 200 and 181 +/- 94.3 l/h for idarubicin alone and with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),[l] / [h],140,208632,DB00773,Etoposide
,15661261,clearance,"The clearance of idarubicin was 140 +/- 200 and 181 +/- 94.3 l/h for idarubicin alone and with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),[l] / [h],181,208633,DB00773,Etoposide
,15661261,volume of distribution of the central compartment,"The volume of distribution of the central compartment was 423 +/- 443 and 337 +/- 394 l for idarubicin alone and in combination with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),l,423,208634,DB00773,Etoposide
,15661261,volume of distribution of the central compartment,"The volume of distribution of the central compartment was 423 +/- 443 and 337 +/- 394 l for idarubicin alone and in combination with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),l,337,208635,DB00773,Etoposide
,7083455,Systemic clearances,"These studies demonstrated substantial differences in the central volumes of distribution (VDc), steady-state volumes of distribution (VDss) and systemic clearances (Cls) of VM26 and VP16-213; with the VDc, VDss, and Cls all being smaller for VM26, Systemic clearances determined by model-independent methods were 5.2 +/- 1.0 ml/min/m2 (mean +/- SD) for VM26 and 17.8 +/- 11.2 ml/min/m2 for VP16-213.",Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083455/),[ml] / [m2·min],5.2,209388,DB00773,Etoposide
,7083455,Systemic clearances,"These studies demonstrated substantial differences in the central volumes of distribution (VDc), steady-state volumes of distribution (VDss) and systemic clearances (Cls) of VM26 and VP16-213; with the VDc, VDss, and Cls all being smaller for VM26, Systemic clearances determined by model-independent methods were 5.2 +/- 1.0 ml/min/m2 (mean +/- SD) for VM26 and 17.8 +/- 11.2 ml/min/m2 for VP16-213.",Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083455/),[ml] / [m2·min],17.8,209389,DB00773,Etoposide
,15614812,zeta potential,"The particle size distribution with polydispersity indices, zeta potential, entrapment efficacy, and assay of EPE were found to be 218.7 +/- 4.7 (0.14 +/- 0.0) nm, -53.5 +/- 0.2 mV, 75 +/- 2.1%, and 0.85 +/- 0.1 mg/mL, respectively.",Pharmacokinetics and tissue distribution of etoposide delivered in parenteral emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15614812/),nm,0.14,209418,DB00773,Etoposide
,15614812,entrapment efficacy,"The particle size distribution with polydispersity indices, zeta potential, entrapment efficacy, and assay of EPE were found to be 218.7 +/- 4.7 (0.14 +/- 0.0) nm, -53.5 +/- 0.2 mV, 75 +/- 2.1%, and 0.85 +/- 0.1 mg/mL, respectively.",Pharmacokinetics and tissue distribution of etoposide delivered in parenteral emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15614812/),[mg] / [ml],0.85,209419,DB00773,Etoposide
,15614812,drug,The EPE was stable for >6 months and drug leaching was 5.8 +/- 1.5%.,Pharmacokinetics and tissue distribution of etoposide delivered in parenteral emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15614812/),%,5.8,209420,DB00773,Etoposide
,15614812,leaching,The EPE was stable for >6 months and drug leaching was 5.8 +/- 1.5%.,Pharmacokinetics and tissue distribution of etoposide delivered in parenteral emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15614812/),%,5.8,209421,DB00773,Etoposide
,1411636,absolute bioavailability,"The mean absolute bioavailability was 41.6% +/- 14.2% with a large interindividual variability (range, 19.7% to 71.4%) and a low intraindividual variability (range, 2.8% to 13.9%).",Absolute bioavailability and pharmacokinetics of oral teniposide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1411636/),%,41.6,210521,DB00773,Etoposide
,7083454,elimination half-life (T1/2 beta),"In adult the elimination half-life (T1/2 beta), plasma clearance (Clp) and volume of distribution (Vd) were respectively 7.05 +/- 0.67 h, 26.8 +1- 2.4 ml/min/m2, and 15.7 +1- 1.8 l/m2; in children 3.37 +/- 0.5 h, 39.34 +1- 6.6 ml/min m2, and 9.97 +/- 3.7 l/m2.",Pharmacokinetics of VP16-213 given by different administration methods. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083454/),h,7.05,211250,DB00773,Etoposide
,7083454,plasma clearance (Clp),"In adult the elimination half-life (T1/2 beta), plasma clearance (Clp) and volume of distribution (Vd) were respectively 7.05 +/- 0.67 h, 26.8 +1- 2.4 ml/min/m2, and 15.7 +1- 1.8 l/m2; in children 3.37 +/- 0.5 h, 39.34 +1- 6.6 ml/min m2, and 9.97 +/- 3.7 l/m2.",Pharmacokinetics of VP16-213 given by different administration methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083454/),[ml] / [m2·min],26.8,211251,DB00773,Etoposide
,7083454,plasma clearance (Clp),"In adult the elimination half-life (T1/2 beta), plasma clearance (Clp) and volume of distribution (Vd) were respectively 7.05 +/- 0.67 h, 26.8 +1- 2.4 ml/min/m2, and 15.7 +1- 1.8 l/m2; in children 3.37 +/- 0.5 h, 39.34 +1- 6.6 ml/min m2, and 9.97 +/- 3.7 l/m2.",Pharmacokinetics of VP16-213 given by different administration methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083454/),h,3.37,211252,DB00773,Etoposide
,7083454,plasma clearance (Clp),"In adult the elimination half-life (T1/2 beta), plasma clearance (Clp) and volume of distribution (Vd) were respectively 7.05 +/- 0.67 h, 26.8 +1- 2.4 ml/min/m2, and 15.7 +1- 1.8 l/m2; in children 3.37 +/- 0.5 h, 39.34 +1- 6.6 ml/min m2, and 9.97 +/- 3.7 l/m2.",Pharmacokinetics of VP16-213 given by different administration methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083454/),[ml] / [m2·min],39.34,211253,DB00773,Etoposide
,7083454,volume of distribution (Vd),"In adult the elimination half-life (T1/2 beta), plasma clearance (Clp) and volume of distribution (Vd) were respectively 7.05 +/- 0.67 h, 26.8 +1- 2.4 ml/min/m2, and 15.7 +1- 1.8 l/m2; in children 3.37 +/- 0.5 h, 39.34 +1- 6.6 ml/min m2, and 9.97 +/- 3.7 l/m2.",Pharmacokinetics of VP16-213 given by different administration methods. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083454/),[l] / [m2],15.7,211254,DB00773,Etoposide
,7083454,volume of distribution (Vd),"In adult the elimination half-life (T1/2 beta), plasma clearance (Clp) and volume of distribution (Vd) were respectively 7.05 +/- 0.67 h, 26.8 +1- 2.4 ml/min/m2, and 15.7 +1- 1.8 l/m2; in children 3.37 +/- 0.5 h, 39.34 +1- 6.6 ml/min m2, and 9.97 +/- 3.7 l/m2.",Pharmacokinetics of VP16-213 given by different administration methods. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083454/),[l] / [m2],9.97,211255,DB00773,Etoposide
,7083454,bioavailability,"The bioavailability compared to the i.v. route was variable, mean values being 57% for capsules and 91% for ampoules.",Pharmacokinetics of VP16-213 given by different administration methods. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083454/),%,57,211256,DB00773,Etoposide
,7083454,bioavailability,"The bioavailability compared to the i.v. route was variable, mean values being 57% for capsules and 91% for ampoules.",Pharmacokinetics of VP16-213 given by different administration methods. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083454/),%,91,211257,DB00773,Etoposide
,7083454,Steady state levels,Steady state levels investigated in three patients after 72 h continuous VP16-213 infusion (100 mg/m2/24h) were around 2-5 micrograms/ml.,Pharmacokinetics of VP16-213 given by different administration methods. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083454/),[μg] / [ml],2-5,211258,DB00773,Etoposide
,16736888,overall duration,One partial response and 6 stabilizations were documented with a median overall duration of 13 weeks (range 8-32).,Oral etoposide in elderly patients with advanced non small cell lung cancer: a clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736888/),,13,211954,DB00773,Etoposide
,23069618,TGI,"Hybrid-dimer 1 also displayed potent in vitro activity against tumor cells and was found to be more active than etoposide against TK10, UACC62 and MCF7 cell lines (TGI values 3.45 vs. 43.33 μM, 2.21 vs. 45.52 μM and 2.99 vs. >100 μM, respectively).",Antimalarial and anticancer activities of artemisinin-quinoline hybrid-dimers and pharmacokinetic properties in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23069618/),μM,3.45,213162,DB00773,Etoposide
,23069618,TGI,"Hybrid-dimer 1 also displayed potent in vitro activity against tumor cells and was found to be more active than etoposide against TK10, UACC62 and MCF7 cell lines (TGI values 3.45 vs. 43.33 μM, 2.21 vs. 45.52 μM and 2.99 vs. >100 μM, respectively).",Antimalarial and anticancer activities of artemisinin-quinoline hybrid-dimers and pharmacokinetic properties in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23069618/),μM,43.33,213163,DB00773,Etoposide
,23069618,TGI,"Hybrid-dimer 1 also displayed potent in vitro activity against tumor cells and was found to be more active than etoposide against TK10, UACC62 and MCF7 cell lines (TGI values 3.45 vs. 43.33 μM, 2.21 vs. 45.52 μM and 2.99 vs. >100 μM, respectively).",Antimalarial and anticancer activities of artemisinin-quinoline hybrid-dimers and pharmacokinetic properties in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23069618/),μM,2.21,213164,DB00773,Etoposide
,23069618,TGI,"Hybrid-dimer 1 also displayed potent in vitro activity against tumor cells and was found to be more active than etoposide against TK10, UACC62 and MCF7 cell lines (TGI values 3.45 vs. 43.33 μM, 2.21 vs. 45.52 μM and 2.99 vs. >100 μM, respectively).",Antimalarial and anticancer activities of artemisinin-quinoline hybrid-dimers and pharmacokinetic properties in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23069618/),μM,45.52,213165,DB00773,Etoposide
,23069618,TGI,"Hybrid-dimer 1 also displayed potent in vitro activity against tumor cells and was found to be more active than etoposide against TK10, UACC62 and MCF7 cell lines (TGI values 3.45 vs. 43.33 μM, 2.21 vs. 45.52 μM and 2.99 vs. >100 μM, respectively).",Antimalarial and anticancer activities of artemisinin-quinoline hybrid-dimers and pharmacokinetic properties in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23069618/),μM,2.99,213166,DB00773,Etoposide
>,23069618,TGI,"Hybrid-dimer 1 also displayed potent in vitro activity against tumor cells and was found to be more active than etoposide against TK10, UACC62 and MCF7 cell lines (TGI values 3.45 vs. 43.33 μM, 2.21 vs. 45.52 μM and 2.99 vs. >100 μM, respectively).",Antimalarial and anticancer activities of artemisinin-quinoline hybrid-dimers and pharmacokinetic properties in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23069618/),μM,100,213167,DB00773,Etoposide
,11377013,flow rate,The mobile phase consists of Methanol: water (45:55 v/v) at a flow rate of 2.8 ml/min.,A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377013/),[ml] / [min],2.8,213979,DB00773,Etoposide
,11377013,recovery,The extraction method showed a recovery of 91.5+/-3% for etoposide.,A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377013/),%,91.5,213980,DB00773,Etoposide
,11377013,retention time,"In this system, the retention time of phenacetin and etoposide were 3.3 and 4.4 min, respectively.",A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377013/),min,3.3,213981,DB00773,Etoposide
,11377013,retention time,"In this system, the retention time of phenacetin and etoposide were 3.3 and 4.4 min, respectively.",A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377013/),min,4.4,213982,DB00773,Etoposide
,11377013,limit of detection,The limit of detection of etoposide in plasma is 20 ng/ml and the limit of quantitation is 40 ng/ml.,A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377013/),[ng] / [ml],20,213983,DB00773,Etoposide
,8656259,nadir neutrophil count,"Hematologic toxicity was more pronounced in those treated with 3 micrograms/mL versus 2 micrograms/mL (median nadir neutrophil count, 1.3 v 2.6 x 10(9)/L, P = .032).",Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8656259/),,1.3,214442,DB00773,Etoposide
,8656259,nadir neutrophil count,"Hematologic toxicity was more pronounced in those treated with 3 micrograms/mL versus 2 micrograms/mL (median nadir neutrophil count, 1.3 v 2.6 x 10(9)/L, P = .032).",Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8656259/),,2.6 x 10(9),214443,DB00773,Etoposide
,19382244,flow rate,A one-step liquid-liquid extraction method was used and the separation was carried out on an Acquity UPLC(TM) BEH C(18) column with gradient elution using a mobile phase composed of acetonitrile and water (containing 0.1% formic acid) at a flow rate of 0.20 mL/min.,Determination of teniposide in rat plasma by ultra performance liquid chromatography electrospray ionization tandem mass spectrometry after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19382244/),[ml] / [min],0.20,214902,DB00773,Etoposide
,10784627,remission rate,The remission rate was 35% (n = 23 of 66).,"Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784627/),%,35,214903,DB00773,Etoposide
,11551419,AUC,The carboplatin dosage was escalated from an AUC of 4 to 5 to 6 (Calvert formula).,"Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11551419/),,4 to 5,215057,DB00773,Etoposide
,11551419,steady-state plasma concentrations,"Mean steady-state plasma concentrations during topotecan infusion ranged from 0.73 to 1.69 ng/ml, and mean etoposide concentrations ranged from 60 to 230 ng/ml.","Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11551419/),[ng] / [ml],0.73 to 1.69,215058,DB00773,Etoposide
,33116490,polydispersity index,The optimized etoposide nanopowder showed as spherical particles with an average particle size and polydispersity index of 211.7 ± 10.4 nm and 0.125 ± 0.028.,"Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33116490/),,0.125,217488,DB00773,Etoposide
,33116490,Tmax,"Additionally, the Tmax value of nanopowder was 0.25 h, compared with 0.5 h of reference group.","Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33116490/),h,0.25,217489,DB00773,Etoposide
,33116490,Tmax,"Additionally, the Tmax value of nanopowder was 0.25 h, compared with 0.5 h of reference group.","Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33116490/),h,0.5,217490,DB00773,Etoposide
,8060139,maximum tolerated dose (MTD),The dose limiting factor was leukopenia and the maximum tolerated dose (MTD) was 75 mg/body/day.,[Phase I clinical study of 21-consecutive-day oral administration of etoposide]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060139/),mg,75,217808,DB00773,Etoposide
,7083456,retention times,"Both VM26 and VP16-213 could be eluted isocratically (28% v/v acetonitrile in water) from a c18 column with retention times of 6.6 and 13.3 min, respectively.","Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale? ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083456/),min,6.6,219463,DB00773,Etoposide
,7083456,retention times,"Both VM26 and VP16-213 could be eluted isocratically (28% v/v acetonitrile in water) from a c18 column with retention times of 6.6 and 13.3 min, respectively.","Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale? ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083456/),min,13.3,219464,DB00773,Etoposide
,7083456,volume of distribution,Subsequent pharmacokinetic analysis of one patient suggests that protein binding displacement of VP16-213 in plasma and perhaps ascites fluid increased the pharmacokinetic volume of distribution (28 l) and reduced the elimination half-life (12 h).,"Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale? ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083456/),l,28,219465,DB00773,Etoposide
,7083456,elimination half-life,Subsequent pharmacokinetic analysis of one patient suggests that protein binding displacement of VP16-213 in plasma and perhaps ascites fluid increased the pharmacokinetic volume of distribution (28 l) and reduced the elimination half-life (12 h).,"Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale? ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083456/),h,12,219466,DB00773,Etoposide
,2023280,maximum tolerated,The maximum tolerated dose of etoposide was 175 mg/m2 per day when administered with dipyridamole at a fixed dose of 24 mg/m2 per day.,Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2023280/),,175,220996,DB00773,Etoposide
more,7780594,extraction recovery,"The extraction recovery was more than 88% for I, II and IV and more than 83% for III.",High-performance liquid chromatographic assay for the determination of the novel etoposide derivative dimethylaminoetoposide (NK611) and its metabolites in urine of cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7780594/),%,88,221002,DB00773,Etoposide
more,7780594,extraction recovery,"The extraction recovery was more than 88% for I, II and IV and more than 83% for III.",High-performance liquid chromatographic assay for the determination of the novel etoposide derivative dimethylaminoetoposide (NK611) and its metabolites in urine of cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7780594/),%,83,221003,DB00773,Etoposide
,7670132,elimination half-life,There was a good tumor retention with a 22 h elimination half-life.,Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7670132/),h,22,225080,DB00773,Etoposide
,7670132,Plasma protein binding,Plasma protein binding ranged from 76 to 89%.,Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7670132/),%,76 to 89,225081,DB00773,Etoposide
,9470839,median concentrations,Plasma etoposide median concentrations at 2 h after administration on day 7 of course 1 were 1.5 (range 0.6-2.4) micrograms/ml.,Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9470839/),[μg] / [ml],1.5,227120,DB00773,Etoposide
>,9470839,AUC,Grade > or = 2 leucopenia was only observed in patients with a day 72 h etoposide concentration of > 2 micrograms/ml or a course 1 AUC of > 35 mg/ml.min.,Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9470839/),[mg] / [min·ml],35,227121,DB00773,Etoposide
,10430070,maximum tolerated dose,The maximum tolerated dose for elderly patients was 75 mg/body/day.,Pharmacological analysis of etoposide in elderly patients with lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430070/),[mg] / [body·d],75,227962,DB00773,Etoposide
,10430070,apparent oral clearance,"The apparent oral clearance in elderly patients was 37+/-10 (mean +/- SD) ml/min, which was not different from that in younger patients (44+/-12 ml/min).",Pharmacological analysis of etoposide in elderly patients with lung cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430070/),[ml] / [min],37,227963,DB00773,Etoposide
,10430070,apparent oral clearance,"The apparent oral clearance in elderly patients was 37+/-10 (mean +/- SD) ml/min, which was not different from that in younger patients (44+/-12 ml/min).",Pharmacological analysis of etoposide in elderly patients with lung cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430070/),[ml] / [min],44,227964,DB00773,Etoposide
,10430070,area under the concentration-versus-time curve of etoposide over the treatment period (total AUC),"The area under the concentration-versus-time curve of etoposide over the treatment period (total AUC) that produced a 50% decrease in absolute neutrophil counts was significantly different between elderly and younger patients, 14.3+/-2.5 and 21.6+/-2.7 mg x min/ml, respectively (P = 0.048).",Pharmacological analysis of etoposide in elderly patients with lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430070/),[mg·min] / [ml],14.3,227965,DB00773,Etoposide
,10430070,area under the concentration-versus-time curve of etoposide over the treatment period (total AUC),"The area under the concentration-versus-time curve of etoposide over the treatment period (total AUC) that produced a 50% decrease in absolute neutrophil counts was significantly different between elderly and younger patients, 14.3+/-2.5 and 21.6+/-2.7 mg x min/ml, respectively (P = 0.048).",Pharmacological analysis of etoposide in elderly patients with lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430070/),[mg·min] / [ml],21.6,227966,DB00773,Etoposide
,10430070,total AUC,The incidence of grade 3 or 4 neutropenia at total AUC of 30 mg x min/ml (corresponding to a plasma concentration of 1.5 microg/ml for 14 days) was 81% in elderly patients but only 48% in younger patients.,Pharmacological analysis of etoposide in elderly patients with lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430070/),[mg·min] / [ml],30,227967,DB00773,Etoposide
,20558939,area under the concentration-time curve,A pharmacokinetic study showed an area under the concentration-time curve of carboplatin of 3.41 to 4.88 mg.,Successful chemotherapy for small-cell lung cancer in an elderly patient undergoing continuous ambulatory peritoneal dialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20558939/),mg,3.41 to 4.88,228819,DB00773,Etoposide
,8765440,maximum tolerated dose,The maximum tolerated dose due to neutropenia was 75 mg/m2 per day for schedule A and 40 mg/m2 per day for schedule B.,Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765440/),,75,229417,DB00773,Etoposide
,8765440,maximum tolerated dose,The maximum tolerated dose due to neutropenia was 75 mg/m2 per day for schedule A and 40 mg/m2 per day for schedule B.,Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765440/),,40,229418,DB00773,Etoposide
> or =,8765440,Css,"Even though etoposide dose levels did not significantly correlate with plasma levels, the Css was > or = 1 microgram/ml in the majority of the patients.",Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765440/),[μg] / [ml],1,229419,DB00773,Etoposide
,15131033,maximum concentration (C(max)),The mean maximum concentration (C(max)) for total (0.262 +/- 0.107 micro g/ml) and free catechol (0.0186 +/- 0.0082 micro g/ml) on day 5 were higher than the mean C(max) for total (0.114 +/- 0.028 micro g/ml) and free catechol (0.0120 +/- 0.0091 micro g/ml) on day 1.,Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131033/),[μg] / [ml],0.262,230156,DB00773,Etoposide
,15131033,maximum concentration (C(max)),The mean maximum concentration (C(max)) for total (0.262 +/- 0.107 micro g/ml) and free catechol (0.0186 +/- 0.0082 micro g/ml) on day 5 were higher than the mean C(max) for total (0.114 +/- 0.028 micro g/ml) and free catechol (0.0120 +/- 0.0091 micro g/ml) on day 1.,Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131033/),[μg] / [ml],0.0186,230157,DB00773,Etoposide
,15131033,C(max),The mean maximum concentration (C(max)) for total (0.262 +/- 0.107 micro g/ml) and free catechol (0.0186 +/- 0.0082 micro g/ml) on day 5 were higher than the mean C(max) for total (0.114 +/- 0.028 micro g/ml) and free catechol (0.0120 +/- 0.0091 micro g/ml) on day 1.,Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131033/),[μg] / [ml],0.114,230158,DB00773,Etoposide
,15131033,C(max),The mean maximum concentration (C(max)) for total (0.262 +/- 0.107 micro g/ml) and free catechol (0.0186 +/- 0.0082 micro g/ml) on day 5 were higher than the mean C(max) for total (0.114 +/- 0.028 micro g/ml) and free catechol (0.0120 +/- 0.0091 micro g/ml) on day 1.,Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131033/),[μg] / [ml],0.0120,230159,DB00773,Etoposide
,15131033,area under the plasma concentration-time curve (AUC)(24h),The mean area under the plasma concentration-time curve (AUC)(24h) for total (105.4 +/- 49.1 micro g.min/ml) and free catechol (4.89 +/- 2.23 micro g x min/ml) on day 5 were much greater (P < 0.05) than those for total (55.9 +/- 16.1 micro g x min/ml) and free catechol (3.04 +/- 1.04 micro g x min/ml) on day 1.,Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131033/),[min·μg] / [ml],105.4,230160,DB00773,Etoposide
,15131033,area under the plasma concentration-time curve (AUC)(24h),The mean area under the plasma concentration-time curve (AUC)(24h) for total (105.4 +/- 49.1 micro g.min/ml) and free catechol (4.89 +/- 2.23 micro g x min/ml) on day 5 were much greater (P < 0.05) than those for total (55.9 +/- 16.1 micro g x min/ml) and free catechol (3.04 +/- 1.04 micro g x min/ml) on day 1.,Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131033/),[min·μg] / [ml],4.89,230161,DB00773,Etoposide
,15131033,area under the plasma concentration-time curve (AUC)(24h),The mean area under the plasma concentration-time curve (AUC)(24h) for total (105.4 +/- 49.1 micro g.min/ml) and free catechol (4.89 +/- 2.23 micro g x min/ml) on day 5 were much greater (P < 0.05) than those for total (55.9 +/- 16.1 micro g x min/ml) and free catechol (3.04 +/- 1.04 micro g x min/ml) on day 1.,Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131033/),[min·μg] / [ml],55.9,230162,DB00773,Etoposide
,15131033,area under the plasma concentration-time curve (AUC)(24h),The mean area under the plasma concentration-time curve (AUC)(24h) for total (105.4 +/- 49.1 micro g.min/ml) and free catechol (4.89 +/- 2.23 micro g x min/ml) on day 5 were much greater (P < 0.05) than those for total (55.9 +/- 16.1 micro g x min/ml) and free catechol (3.04 +/- 1.04 micro g x min/ml) on day 1.,Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15131033/),[min·μg] / [ml],3.04,230163,DB00773,Etoposide
,9743946,peak serum concentration,"The peak serum concentration, the time to peak concentration, the area under the concentration-time curve, the terminal half-life and the apparent clearance after oral application were calculated to be 6.7 micrograms/ml, 2.1 h, 51.8 (microgram.h/ml)/(100 mg/m2), 5.6 h, and 40.3 ml/min for total etoposide, and 0.23 microgram/ml, 1.9 h, 1.76 (microgram.h/ml)/ (100 mg/m2), 5.9 h, and 1172 ml/min for free serum etoposide, respectively.",[Pharmacokinetic aspects of oral administration of etoposide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743946/),[μg] / [ml],6.7,230346,DB00773,Etoposide
,9743946,area under the concentration-time curve,"The peak serum concentration, the time to peak concentration, the area under the concentration-time curve, the terminal half-life and the apparent clearance after oral application were calculated to be 6.7 micrograms/ml, 2.1 h, 51.8 (microgram.h/ml)/(100 mg/m2), 5.6 h, and 40.3 ml/min for total etoposide, and 0.23 microgram/ml, 1.9 h, 1.76 (microgram.h/ml)/ (100 mg/m2), 5.9 h, and 1172 ml/min for free serum etoposide, respectively.",[Pharmacokinetic aspects of oral administration of etoposide]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743946/),h,2.1,230347,DB00773,Etoposide
,9743946,area under the concentration-time curve,"The peak serum concentration, the time to peak concentration, the area under the concentration-time curve, the terminal half-life and the apparent clearance after oral application were calculated to be 6.7 micrograms/ml, 2.1 h, 51.8 (microgram.h/ml)/(100 mg/m2), 5.6 h, and 40.3 ml/min for total etoposide, and 0.23 microgram/ml, 1.9 h, 1.76 (microgram.h/ml)/ (100 mg/m2), 5.9 h, and 1172 ml/min for free serum etoposide, respectively.",[Pharmacokinetic aspects of oral administration of etoposide]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743946/),,51.8,230348,DB00773,Etoposide
,9743946,terminal half-life,"The peak serum concentration, the time to peak concentration, the area under the concentration-time curve, the terminal half-life and the apparent clearance after oral application were calculated to be 6.7 micrograms/ml, 2.1 h, 51.8 (microgram.h/ml)/(100 mg/m2), 5.6 h, and 40.3 ml/min for total etoposide, and 0.23 microgram/ml, 1.9 h, 1.76 (microgram.h/ml)/ (100 mg/m2), 5.9 h, and 1172 ml/min for free serum etoposide, respectively.",[Pharmacokinetic aspects of oral administration of etoposide]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743946/),h,2.1,230349,DB00773,Etoposide
,9743946,terminal half-life,"The peak serum concentration, the time to peak concentration, the area under the concentration-time curve, the terminal half-life and the apparent clearance after oral application were calculated to be 6.7 micrograms/ml, 2.1 h, 51.8 (microgram.h/ml)/(100 mg/m2), 5.6 h, and 40.3 ml/min for total etoposide, and 0.23 microgram/ml, 1.9 h, 1.76 (microgram.h/ml)/ (100 mg/m2), 5.9 h, and 1172 ml/min for free serum etoposide, respectively.",[Pharmacokinetic aspects of oral administration of etoposide]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743946/),,51.8,230350,DB00773,Etoposide
,9743946,apparent clearance,"The peak serum concentration, the time to peak concentration, the area under the concentration-time curve, the terminal half-life and the apparent clearance after oral application were calculated to be 6.7 micrograms/ml, 2.1 h, 51.8 (microgram.h/ml)/(100 mg/m2), 5.6 h, and 40.3 ml/min for total etoposide, and 0.23 microgram/ml, 1.9 h, 1.76 (microgram.h/ml)/ (100 mg/m2), 5.9 h, and 1172 ml/min for free serum etoposide, respectively.",[Pharmacokinetic aspects of oral administration of etoposide]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743946/),h,5.6,230351,DB00773,Etoposide
,9743946,apparent clearance,"The peak serum concentration, the time to peak concentration, the area under the concentration-time curve, the terminal half-life and the apparent clearance after oral application were calculated to be 6.7 micrograms/ml, 2.1 h, 51.8 (microgram.h/ml)/(100 mg/m2), 5.6 h, and 40.3 ml/min for total etoposide, and 0.23 microgram/ml, 1.9 h, 1.76 (microgram.h/ml)/ (100 mg/m2), 5.9 h, and 1172 ml/min for free serum etoposide, respectively.",[Pharmacokinetic aspects of oral administration of etoposide]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743946/),[ml] / [min],40.3,230352,DB00773,Etoposide
,9743946,apparent clearance,"The peak serum concentration, the time to peak concentration, the area under the concentration-time curve, the terminal half-life and the apparent clearance after oral application were calculated to be 6.7 micrograms/ml, 2.1 h, 51.8 (microgram.h/ml)/(100 mg/m2), 5.6 h, and 40.3 ml/min for total etoposide, and 0.23 microgram/ml, 1.9 h, 1.76 (microgram.h/ml)/ (100 mg/m2), 5.9 h, and 1172 ml/min for free serum etoposide, respectively.",[Pharmacokinetic aspects of oral administration of etoposide]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743946/),h,5.9,230353,DB00773,Etoposide
,9743946,apparent clearance,"The peak serum concentration, the time to peak concentration, the area under the concentration-time curve, the terminal half-life and the apparent clearance after oral application were calculated to be 6.7 micrograms/ml, 2.1 h, 51.8 (microgram.h/ml)/(100 mg/m2), 5.6 h, and 40.3 ml/min for total etoposide, and 0.23 microgram/ml, 1.9 h, 1.76 (microgram.h/ml)/ (100 mg/m2), 5.9 h, and 1172 ml/min for free serum etoposide, respectively.",[Pharmacokinetic aspects of oral administration of etoposide]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743946/),[ml] / [min],1172,230354,DB00773,Etoposide
,9743946,urinary recovery,"On an average, urinary recovery of etoposide was 21% of the oral dose.",[Pharmacokinetic aspects of oral administration of etoposide]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743946/),,21,230355,DB00773,Etoposide
,29034009,negativity,MRD negativity at end-induction was 85% in Arm A versus 67% in Arm B patients.,"A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29034009/),,85,230890,DB00773,Etoposide
,29034009,negativity,MRD negativity at end-induction was 85% in Arm A versus 67% in Arm B patients.,"A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29034009/),,67,230891,DB00773,Etoposide
,9184183,AUC(inf) (area under the concentration vs time curve from zero to infinity),The median AUC(inf) (area under the concentration vs time curve from zero to infinity) of etoposide was 77.7 mg l(-1) h after etoposide phosphate (95% CI 61.3-100.5) and 62.0 mg l(-1) h after oral etoposide (95% CI 52.2-76.9).,Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9184183/),[h·mg] / [l],77.7,232487,DB00773,Etoposide
,9184183,AUC(inf) (area under the concentration vs time curve from zero to infinity),The median AUC(inf) (area under the concentration vs time curve from zero to infinity) of etoposide was 77.7 mg l(-1) h after etoposide phosphate (95% CI 61.3-100.5) and 62.0 mg l(-1) h after oral etoposide (95% CI 52.2-76.9).,Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9184183/),[h·mg] / [l],62.0,232488,DB00773,Etoposide
,21789689,total clearance,"Mean simulated total clearance of high- and low-dose etoposide was 0.70 ml/min/kg (Cl(observed): 0.70 ml/min/kg) versus 0.50 ml/min/kg (Cl(observed): 0.60 ml/min/kg), respectively.",Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21789689/),[ml] / [kg·min],0.70,234089,DB00773,Etoposide
,21789689,total clearance,"Mean simulated total clearance of high- and low-dose etoposide was 0.70 ml/min/kg (Cl(observed): 0.70 ml/min/kg) versus 0.50 ml/min/kg (Cl(observed): 0.60 ml/min/kg), respectively.",Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21789689/),[ml] / [kg·min],0.50,234090,DB00773,Etoposide
,21789689,Cl(observed),"Mean simulated total clearance of high- and low-dose etoposide was 0.70 ml/min/kg (Cl(observed): 0.70 ml/min/kg) versus 0.50 ml/min/kg (Cl(observed): 0.60 ml/min/kg), respectively.",Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21789689/),[ml] / [kg·min],0.70,234091,DB00773,Etoposide
,21789689,Cl(observed),"Mean simulated total clearance of high- and low-dose etoposide was 0.70 ml/min/kg (Cl(observed): 0.70 ml/min/kg) versus 0.50 ml/min/kg (Cl(observed): 0.60 ml/min/kg), respectively.",Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21789689/),[ml] / [kg·min],0.50,234092,DB00773,Etoposide
,21789689,Cl(observed),"Mean simulated total clearance of high- and low-dose etoposide was 0.70 ml/min/kg (Cl(observed): 0.70 ml/min/kg) versus 0.50 ml/min/kg (Cl(observed): 0.60 ml/min/kg), respectively.",Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21789689/),[ml] / [kg·min],0.60,234093,DB00773,Etoposide
,27504190,Cmax,"The peak concentration (Cmax) of ETP and the area under the plasma concentration-time curve (AUC) of ETP differed greatly among patients (range of Cmax, 51.8 - 116.5 μg/mL; range of AUC, 870 - 2015 μg · h/mL).","Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504190/),[μg] / [ml],51.8 - 116.5,235331,DB00773,Etoposide
,27504190,AUC,"The peak concentration (Cmax) of ETP and the area under the plasma concentration-time curve (AUC) of ETP differed greatly among patients (range of Cmax, 51.8 - 116.5 μg/mL; range of AUC, 870 - 2015 μg · h/mL).","Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504190/),[h·μg] / [ml],870 - 2015,235332,DB00773,Etoposide
,27504190,Vd,"Distribution volume (Vd) was suggested to be one of the factors of inter-individual variation in plasma concentration of ETP in patients (range of Vd, 0.13 - 0.27 L/kg), and correlated with Alb and body weight (R = 0.56, P < 0.05; R = 0.40, P < 0.05 respectively).","Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504190/),[l] / [kg],0.13 - 0.27,235333,DB00773,Etoposide
,11550166,elimination half-life,The median elimination half-life of amifostine (9.3 minutes) and WR-1065 (15 minutes) was much shorter than the disulfide metabolites (74.4 minutes).,"Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550166/),min,9.3,235654,DB00773,Etoposide
,11550166,elimination half-life,The median elimination half-life of amifostine (9.3 minutes) and WR-1065 (15 minutes) was much shorter than the disulfide metabolites (74.4 minutes).,"Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550166/),min,15,235655,DB00773,Etoposide
,11550166,elimination half-life,The median elimination half-life of amifostine (9.3 minutes) and WR-1065 (15 minutes) was much shorter than the disulfide metabolites (74.4 minutes).,"Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11550166/),min,74.4,235656,DB00773,Etoposide
greater,8270989,at steady-state (Css),"Plasma concentrations of etoposide at steady-state (Css) showed approximately twofold interpatient variability at each dose level, and were greater than 1 microgram/mL in most patients at higher dose levels.",Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270989/),[μg] / [ml],1,236334,DB00773,Etoposide
,8270989,overall response rate,The overall response rate for the 29 assessable cases was 28%.,Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270989/),%,28,236335,DB00773,Etoposide
greater,8270989,Css,"Five of 11 patients with a Css greater than 1.2 micrograms/mL responded to the therapy, whereas only one of 10 patients with a Css less than 1 microgram/mL responded.",Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270989/),[μg] / [ml],1.2,236336,DB00773,Etoposide
less,8270989,Css,"Five of 11 patients with a Css greater than 1.2 micrograms/mL responded to the therapy, whereas only one of 10 patients with a Css less than 1 microgram/mL responded.",Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270989/),[μg] / [ml],1,236337,DB00773,Etoposide
greater,8270989,Css,"With long-term CI of etoposide, a Css greater than 1 or 1.2 micrograms/mL appeared necessary, but not sufficient, to achieve a major response against NSCLC.",Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270989/),[μg] / [ml],1,236338,DB00773,Etoposide
,8270989,Css,"With long-term CI of etoposide, a Css greater than 1 or 1.2 micrograms/mL appeared necessary, but not sufficient, to achieve a major response against NSCLC.",Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270989/),[μg] / [ml],1.2,236339,DB00773,Etoposide
,3697995,plasma clearance (Clp),"In the control group plasma clearance (Clp), volume of distribution (Vd), and elimination half-life (t1/2 beta) of VP16 were, respectively, 22.8 +/- 1.0 (SE) ml/min/m2, 11.4 +/- 0.8 liters/m2, and 5.6 +/- 0.4 h.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),[ml] / [m2·min],22.8,236417,DB00773,Etoposide
,3697995,volume of distribution (Vd),"In the control group plasma clearance (Clp), volume of distribution (Vd), and elimination half-life (t1/2 beta) of VP16 were, respectively, 22.8 +/- 1.0 (SE) ml/min/m2, 11.4 +/- 0.8 liters/m2, and 5.6 +/- 0.4 h.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),[l] / [m2],11.4,236418,DB00773,Etoposide
,3697995,elimination half-life (t1/2 beta),"In the control group plasma clearance (Clp), volume of distribution (Vd), and elimination half-life (t1/2 beta) of VP16 were, respectively, 22.8 +/- 1.0 (SE) ml/min/m2, 11.4 +/- 0.8 liters/m2, and 5.6 +/- 0.4 h.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),h,5.6,236419,DB00773,Etoposide
,3697995,Clp,"In patients with renal insufficiency Clp was 12.8 +/- 1.1 ml/min/m2, Vd was 20.8 +/- 4.9 liters/m2, and t1/2 beta was 19.2 +/- 4.7 h.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),[ml] / [m2·min],12.8,236420,DB00773,Etoposide
,3697995,Vd,"In patients with renal insufficiency Clp was 12.8 +/- 1.1 ml/min/m2, Vd was 20.8 +/- 4.9 liters/m2, and t1/2 beta was 19.2 +/- 4.7 h.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),[l] / [m2],20.8,236421,DB00773,Etoposide
,3697995,t1/2 beta,"In patients with renal insufficiency Clp was 12.8 +/- 1.1 ml/min/m2, Vd was 20.8 +/- 4.9 liters/m2, and t1/2 beta was 19.2 +/- 4.7 h.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),h,19.2,236422,DB00773,Etoposide
,3697995,Clp,"In 12 of 15 patients with abnormal liver tests Clp, Vd, and t1/2 beta were, respectively, 27.9 +/- 2.7 ml/min/m2, 12.4 +/- 1.5 liters/m2, and 5.4 +/- 0.6 h and are thus similar to those of the control group.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),[ml] / [m2·min],27.9,236423,DB00773,Etoposide
,3697995,Vd,"In 12 of 15 patients with abnormal liver tests Clp, Vd, and t1/2 beta were, respectively, 27.9 +/- 2.7 ml/min/m2, 12.4 +/- 1.5 liters/m2, and 5.4 +/- 0.6 h and are thus similar to those of the control group.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),[l] / [m2],12.4,236424,DB00773,Etoposide
,3697995,t1/2 beta,"In 12 of 15 patients with abnormal liver tests Clp, Vd, and t1/2 beta were, respectively, 27.9 +/- 2.7 ml/min/m2, 12.4 +/- 1.5 liters/m2, and 5.4 +/- 0.6 h and are thus similar to those of the control group.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),h,5.4,236425,DB00773,Etoposide
,3697995,t1/2 beta,"In these cases VP16 t1/2 beta values were similar (5.1, 4.4, and 5.1 h) whereas Clp values (320, 87, and 96 ml/min/m2) and Vd values (142, 33, and 42 liters/m2) were much larger than in controls.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),h,5.1,236426,DB00773,Etoposide
,3697995,t1/2 beta,"In these cases VP16 t1/2 beta values were similar (5.1, 4.4, and 5.1 h) whereas Clp values (320, 87, and 96 ml/min/m2) and Vd values (142, 33, and 42 liters/m2) were much larger than in controls.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),h,4.4,236427,DB00773,Etoposide
,3697995,Clp,"In these cases VP16 t1/2 beta values were similar (5.1, 4.4, and 5.1 h) whereas Clp values (320, 87, and 96 ml/min/m2) and Vd values (142, 33, and 42 liters/m2) were much larger than in controls.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),[ml] / [m2·min],320,236428,DB00773,Etoposide
,3697995,Clp,"In these cases VP16 t1/2 beta values were similar (5.1, 4.4, and 5.1 h) whereas Clp values (320, 87, and 96 ml/min/m2) and Vd values (142, 33, and 42 liters/m2) were much larger than in controls.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),[ml] / [m2·min],87,236429,DB00773,Etoposide
,3697995,Clp,"In these cases VP16 t1/2 beta values were similar (5.1, 4.4, and 5.1 h) whereas Clp values (320, 87, and 96 ml/min/m2) and Vd values (142, 33, and 42 liters/m2) were much larger than in controls.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),[ml] / [m2·min],96,236430,DB00773,Etoposide
,3697995,Vd,"In these cases VP16 t1/2 beta values were similar (5.1, 4.4, and 5.1 h) whereas Clp values (320, 87, and 96 ml/min/m2) and Vd values (142, 33, and 42 liters/m2) were much larger than in controls.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),[l] / [m2],142,236431,DB00773,Etoposide
,3697995,Vd,"In these cases VP16 t1/2 beta values were similar (5.1, 4.4, and 5.1 h) whereas Clp values (320, 87, and 96 ml/min/m2) and Vd values (142, 33, and 42 liters/m2) were much larger than in controls.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),[l] / [m2],33,236432,DB00773,Etoposide
,3697995,Vd,"In these cases VP16 t1/2 beta values were similar (5.1, 4.4, and 5.1 h) whereas Clp values (320, 87, and 96 ml/min/m2) and Vd values (142, 33, and 42 liters/m2) were much larger than in controls.",Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697995/),[l] / [m2],42,236433,DB00773,Etoposide
,1490803,half-life,During short-term infusion half-life (3.3 +/- 0.7 h) and total body clearance (26 +/- 6 ml/min/m2) showed a relatively narrow range.,Investigation of the variability of etoposide pharmacokinetics in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490803/),h,3.3,240806,DB00773,Etoposide
,1490803,total body clearance,During short-term infusion half-life (3.3 +/- 0.7 h) and total body clearance (26 +/- 6 ml/min/m2) showed a relatively narrow range.,Investigation of the variability of etoposide pharmacokinetics in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490803/),[ml] / [m2·min],26,240807,DB00773,Etoposide
,1490803,AUC,The AUC then was 68 +/- 17 (micrograms.h/ml)/(100 mg/m2) with a coefficient of variation of 25%.,Investigation of the variability of etoposide pharmacokinetics in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490803/),[h·μg] / [ml)],68,240808,DB00773,Etoposide
,1490803,AUC,In the subgroup of 10 patients who received 150 mg/m2 the AUC was 106 +/- 15 micrograms.h/ml with only 14% coefficient of variation.,Investigation of the variability of etoposide pharmacokinetics in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490803/),[h·μg] / [ml],106,240809,DB00773,Etoposide
,1490803,Css,With continuous infusion of 125 mg/m2 etoposide the interpatient variability was greater with a 33% coefficient of variation of the Css (4.4 +/- 1.4 micrograms/ml; n = 24).,Investigation of the variability of etoposide pharmacokinetics in children. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490803/),[μg] / [ml],4.4,240810,DB00773,Etoposide
,1490803,Css,Standardization of these levels showed Css (125 mg/m2) of 4.6 +/- 1.4 micrograms/ml and a coefficient of variation of 31%.,Investigation of the variability of etoposide pharmacokinetics in children. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490803/),[μg] / [ml],4.6,240811,DB00773,Etoposide
,11319295,overall objective response rate,"The overall objective response rate was 83%, with 2 complete remissions documented (11%).",Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319295/),%,83,241103,DB00773,Etoposide
,11319295,duration of responses,The median duration of responses was 12 weeks (range: 3-45 weeks).,Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319295/),weeks,12,241104,DB00773,Etoposide
,11319295,t1/2,"The median t1/2 of etoposide in plasma was 4.11 hours (range: 1.95-9.64), area under the curve was 13.51 microg/h/ml (range: 7.12-24.42), Cmax was 2.17 microg/ml (1.40-4.41), tmax (1.00-2.00), mean residence time 4.62 hours (range: 3.75-5.20 hours), CIt (total clearance) 3.13 l/m2/h (range: 1.49-5.20 l/m2/h), Vd 13.08 l/m2 (range: 6.23-19.65 l/m2), and the median etoposide plasma concentration time greater than 1 microg/ml was 3.69 hours (range: 1.00-6.80 hours).",Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319295/),h,4.11,241105,DB00773,Etoposide
,11319295,area under the curve,"The median t1/2 of etoposide in plasma was 4.11 hours (range: 1.95-9.64), area under the curve was 13.51 microg/h/ml (range: 7.12-24.42), Cmax was 2.17 microg/ml (1.40-4.41), tmax (1.00-2.00), mean residence time 4.62 hours (range: 3.75-5.20 hours), CIt (total clearance) 3.13 l/m2/h (range: 1.49-5.20 l/m2/h), Vd 13.08 l/m2 (range: 6.23-19.65 l/m2), and the median etoposide plasma concentration time greater than 1 microg/ml was 3.69 hours (range: 1.00-6.80 hours).",Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319295/),[μg] / [h·ml],13.51,241106,DB00773,Etoposide
,11319295,Cmax,"The median t1/2 of etoposide in plasma was 4.11 hours (range: 1.95-9.64), area under the curve was 13.51 microg/h/ml (range: 7.12-24.42), Cmax was 2.17 microg/ml (1.40-4.41), tmax (1.00-2.00), mean residence time 4.62 hours (range: 3.75-5.20 hours), CIt (total clearance) 3.13 l/m2/h (range: 1.49-5.20 l/m2/h), Vd 13.08 l/m2 (range: 6.23-19.65 l/m2), and the median etoposide plasma concentration time greater than 1 microg/ml was 3.69 hours (range: 1.00-6.80 hours).",Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319295/),[μg] / [ml],2.17,241107,DB00773,Etoposide
,11319295,mean residence time,"The median t1/2 of etoposide in plasma was 4.11 hours (range: 1.95-9.64), area under the curve was 13.51 microg/h/ml (range: 7.12-24.42), Cmax was 2.17 microg/ml (1.40-4.41), tmax (1.00-2.00), mean residence time 4.62 hours (range: 3.75-5.20 hours), CIt (total clearance) 3.13 l/m2/h (range: 1.49-5.20 l/m2/h), Vd 13.08 l/m2 (range: 6.23-19.65 l/m2), and the median etoposide plasma concentration time greater than 1 microg/ml was 3.69 hours (range: 1.00-6.80 hours).",Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319295/),h,4.62,241108,DB00773,Etoposide
,11319295,CIt (total clearance),"The median t1/2 of etoposide in plasma was 4.11 hours (range: 1.95-9.64), area under the curve was 13.51 microg/h/ml (range: 7.12-24.42), Cmax was 2.17 microg/ml (1.40-4.41), tmax (1.00-2.00), mean residence time 4.62 hours (range: 3.75-5.20 hours), CIt (total clearance) 3.13 l/m2/h (range: 1.49-5.20 l/m2/h), Vd 13.08 l/m2 (range: 6.23-19.65 l/m2), and the median etoposide plasma concentration time greater than 1 microg/ml was 3.69 hours (range: 1.00-6.80 hours).",Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319295/),[l] / [h·m2],3.13,241109,DB00773,Etoposide
,11319295,Vd,"The median t1/2 of etoposide in plasma was 4.11 hours (range: 1.95-9.64), area under the curve was 13.51 microg/h/ml (range: 7.12-24.42), Cmax was 2.17 microg/ml (1.40-4.41), tmax (1.00-2.00), mean residence time 4.62 hours (range: 3.75-5.20 hours), CIt (total clearance) 3.13 l/m2/h (range: 1.49-5.20 l/m2/h), Vd 13.08 l/m2 (range: 6.23-19.65 l/m2), and the median etoposide plasma concentration time greater than 1 microg/ml was 3.69 hours (range: 1.00-6.80 hours).",Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319295/),[l] / [m2],13.08,241110,DB00773,Etoposide
greater,11319295,plasma concentration time,"The median t1/2 of etoposide in plasma was 4.11 hours (range: 1.95-9.64), area under the curve was 13.51 microg/h/ml (range: 7.12-24.42), Cmax was 2.17 microg/ml (1.40-4.41), tmax (1.00-2.00), mean residence time 4.62 hours (range: 3.75-5.20 hours), CIt (total clearance) 3.13 l/m2/h (range: 1.49-5.20 l/m2/h), Vd 13.08 l/m2 (range: 6.23-19.65 l/m2), and the median etoposide plasma concentration time greater than 1 microg/ml was 3.69 hours (range: 1.00-6.80 hours).",Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319295/),[μg] / [ml],1,241111,DB00773,Etoposide
,11319295,plasma concentration time,"The median t1/2 of etoposide in plasma was 4.11 hours (range: 1.95-9.64), area under the curve was 13.51 microg/h/ml (range: 7.12-24.42), Cmax was 2.17 microg/ml (1.40-4.41), tmax (1.00-2.00), mean residence time 4.62 hours (range: 3.75-5.20 hours), CIt (total clearance) 3.13 l/m2/h (range: 1.49-5.20 l/m2/h), Vd 13.08 l/m2 (range: 6.23-19.65 l/m2), and the median etoposide plasma concentration time greater than 1 microg/ml was 3.69 hours (range: 1.00-6.80 hours).",Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11319295/),h,3.69,241112,DB00773,Etoposide
,12969965,clearance,"On day 29, etoposide clearance was higher (47.4 versus 29.2 mL/min/m2, P <.0001) than at week 54.",Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12969965/),[ml] / [m2·min],47.4,241630,DB00773,Etoposide
,12969965,clearance,"On day 29, etoposide clearance was higher (47.4 versus 29.2 mL/min/m2, P <.0001) than at week 54.",Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12969965/),[ml] / [m2·min],29.2,241631,DB00773,Etoposide
,8823496,bioavailability,"At all dose levels, bioavailability values were around 100%.","Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823496/),%,100,242890,DB00773,Etoposide
,11127945,clearance,"The median clearance of VP-16 was 0.96 l/h per m2 (range 0.8-1.5 l/h per m2), which is lower than for VP-16 alone and similar to previously reported effects of CSA on VP-16 elimination.","A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127945/),[l] / [h·m2],0.96,245132,DB00773,Etoposide
,11127945,AUC,The median measured CBDCA AUC was 3.0 mg/ml x min (range 2.4-4.8 mg/ml x min).,"A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127945/),[mg] / [min·ml],3.0,245133,DB00773,Etoposide
,11127945,plasma concentrations,"The median end of infusion PCZ and total DP plasma concentrations were 1.2 microM (range 0.5-2.2 microM) and 4.4 microM (range 1.3-5.9 microM), respectively, consistent with in vitro resistance modulatory levels.","A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127945/),μM,4.4,245134,DB00773,Etoposide
,11127945,free,"However, free DP was only 0.02 microM (range 0.004-0.04 microM).","A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127945/),μM,0.02,245135,DB00773,Etoposide
,14581337,time to tumor progression,"The median time to tumor progression was 4 months, with a median survival of 11 months.",Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581337/),month,4,246292,DB00773,Etoposide
,8652278,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 110 mg/m2/day for 5 days every 3 weeks and the dose-limiting toxicity was neutropenia.,"Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8652278/),mg,110,247468,DB00773,Etoposide
<,8652278,area under the plasma concentration versus time curve (AUC) ratio,The etoposide phosphate:etoposide area under the plasma concentration versus time curve (AUC) ratio was < 1% and the pharmacokinetic parameters for etoposide were within previously reported ranges.,"Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481). ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8652278/),%,1,247469,DB00773,Etoposide
,15752378,clearance (CL),Children who did not have carboplatin (n = 27) had median melphalan clearance (CL) of 15.5 l h(-1) m(-2) (interquartile range: 12.4-19.9 l h(-1) m(-2)) and steady state volume of distribution (Vss) of 14.9 l m(-2) (interquartile range: 12.7-18.3 l m(-2)).,"Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752378/),[l] / [(m)^2·h],15.5,247614,DB00773,Etoposide
,15752378,steady state volume of distribution (Vss),Children who did not have carboplatin (n = 27) had median melphalan clearance (CL) of 15.5 l h(-1) m(-2) (interquartile range: 12.4-19.9 l h(-1) m(-2)) and steady state volume of distribution (Vss) of 14.9 l m(-2) (interquartile range: 12.7-18.3 l m(-2)).,"Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752378/),[l] / [(m)^2],14.9,247615,DB00773,Etoposide
,15752378,CL,Children who had carboplatin (n = 25) had 34% lower median CL (10.2 l h(-1) m(-2)) and 18% lower median Vss (12.2 l m(-2)) (P < 0.001).,"Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752378/),[l] / [(m)^2·h],10.2,247616,DB00773,Etoposide
,15752378,Vss,Children who had carboplatin (n = 25) had 34% lower median CL (10.2 l h(-1) m(-2)) and 18% lower median Vss (12.2 l m(-2)) (P < 0.001).,"Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752378/),[l] / [(m)^2],12.2,247617,DB00773,Etoposide
,8899852,ECF,"The liver ECF-to-plasma AUC ratios of VP-16 were 32-39 and 0.17 with local CS application and iv administration, respectively, indicating a remarkable advantage of the local drug delivery system.","Microdialysis assessment of microfibrous collagen containing a P-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8899852/),,32,248930,DB00773,Etoposide
,8899852,ECF,"The liver ECF-to-plasma AUC ratios of VP-16 were 32-39 and 0.17 with local CS application and iv administration, respectively, indicating a remarkable advantage of the local drug delivery system.","Microdialysis assessment of microfibrous collagen containing a P-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8899852/),,0.17,248931,DB00773,Etoposide
,8899852,-to-plasma AUC ratios,"The liver ECF-to-plasma AUC ratios of VP-16 were 32-39 and 0.17 with local CS application and iv administration, respectively, indicating a remarkable advantage of the local drug delivery system.","Microdialysis assessment of microfibrous collagen containing a P-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8899852/),,32,248932,DB00773,Etoposide
,8899852,-to-plasma AUC ratios,"The liver ECF-to-plasma AUC ratios of VP-16 were 32-39 and 0.17 with local CS application and iv administration, respectively, indicating a remarkable advantage of the local drug delivery system.","Microdialysis assessment of microfibrous collagen containing a P-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8899852/),,0.17,248933,DB00773,Etoposide
,8523060,Css,"Dose calculation on the basis of BSA led to Css of 4.9 +/- 1.2 micrograms/mL, which on the basis of BW was 3.5 +/- 1.1 micrograms/mL and 1.95 +/- 0.6 micrograms/mL (2/3.kg-dose), respectively.",Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523060/),[μg] / [ml],4.9,248954,DB00773,Etoposide
,8523060,Css,"Dose calculation on the basis of BSA led to Css of 4.9 +/- 1.2 micrograms/mL, which on the basis of BW was 3.5 +/- 1.1 micrograms/mL and 1.95 +/- 0.6 micrograms/mL (2/3.kg-dose), respectively.",Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523060/),,3,248955,DB00773,Etoposide
,8523060,Css,"Dose calculation on the basis of BSA led to Css of 4.9 +/- 1.2 micrograms/mL, which on the basis of BW was 3.5 +/- 1.1 micrograms/mL and 1.95 +/- 0.6 micrograms/mL (2/3.kg-dose), respectively.",Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523060/),μ,1.95,248956,DB00773,Etoposide
,8523060,clearance rates,"Etoposide clearance rates related to BW (0.8 +/- 0.3 mL/min/kg) or BW (19 +/- 6 mL/min/m2) did not show any differences between children and infants, even in the age range of 3 to 12 months.",Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523060/),[ml] / [kg·min],0.8,248957,DB00773,Etoposide
,8523060,clearance rates,"Etoposide clearance rates related to BW (0.8 +/- 0.3 mL/min/kg) or BW (19 +/- 6 mL/min/m2) did not show any differences between children and infants, even in the age range of 3 to 12 months.",Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8523060/),m,19,248958,DB00773,Etoposide
,15447993,peak plasma concentrations,"Etoposide peak plasma concentrations ranged from 1.9 to 6.9 microg/mL (mean, 3.6 microg/mL).",Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15447993/),[μg] / [ml],3.6,250916,DB00773,Etoposide
,15447993,peak plasma concentration,The peak plasma concentration of topotecan was 12.82 +/- 8.55 microg/mL with a plasma half-life of 6.17 +/- 2.75 hours.,Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15447993/),[μg] / [ml],12.82,250917,DB00773,Etoposide
,15447993,plasma half-life,The peak plasma concentration of topotecan was 12.82 +/- 8.55 microg/mL with a plasma half-life of 6.17 +/- 2.75 hours.,Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15447993/),h,6.17,250918,DB00773,Etoposide
,15447993,overall response rate,"The overall response rate was 38% [complete response, three (14%); partial response, five (24%)].",Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15447993/),%,38,250919,DB00773,Etoposide
,3018396,t1/2 alpha,After i.v. administration the mean +/- SD half-lives were t1/2 alpha 0.62 +/- 1.01 h and t1/2 beta 6.04 +/- 2.5 h.,Etoposide: a pharmacokinetic profile including an assessment of bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3018396/),h,0.62,251787,DB00773,Etoposide
,3018396,t1/2 beta,After i.v. administration the mean +/- SD half-lives were t1/2 alpha 0.62 +/- 1.01 h and t1/2 beta 6.04 +/- 2.5 h.,Etoposide: a pharmacokinetic profile including an assessment of bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3018396/),h,6.04,251788,DB00773,Etoposide
,3018396,bioavailability,The bioavailability of etoposide was extremely variable: for the capsule it was 38 +/- 14% (range 10-55) and for the i.v. formulation it was 53 +/- 25% (range 31-88).,Etoposide: a pharmacokinetic profile including an assessment of bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3018396/),%,38,251789,DB00773,Etoposide
,3018396,bioavailability,The bioavailability of etoposide was extremely variable: for the capsule it was 38 +/- 14% (range 10-55) and for the i.v. formulation it was 53 +/- 25% (range 31-88).,Etoposide: a pharmacokinetic profile including an assessment of bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3018396/),%,53,251790,DB00773,Etoposide
,11736859,clearance,Mean clearance was 1.14 l h(-1) (CV 25%).,Population pharmacokinetics and pharmacodynamics of oral etoposide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736859/),[l] / [h],1.14,253928,DB00773,Etoposide
,11736859,bioavailability,Mean bioavailability was 45% (CV 22%) and mean protein binding 91.5% (CV 5%).,Population pharmacokinetics and pharmacodynamics of oral etoposide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736859/),%,45,253929,DB00773,Etoposide
,11736859,protein binding,Mean bioavailability was 45% (CV 22%) and mean protein binding 91.5% (CV 5%).,Population pharmacokinetics and pharmacodynamics of oral etoposide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736859/),%,91.5,253930,DB00773,Etoposide
,11736859,AUC,"Exposure to free, pharmacologically active etoposide (free AUC p.o.) was highly variable (mean value 2.8 mg l(-1) h; CV 64%; range 0.4-9.5).",Population pharmacokinetics and pharmacodynamics of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736859/),[h·mg] / [l],2.8,253931,DB00773,Etoposide
,11736859,Free,Free AUC50 (exposure producing a 50% reduction in absolute neutrophil count) was 1.80 mg l(-1) h.,Population pharmacokinetics and pharmacodynamics of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736859/),[h·mg] / [l],1.80,253932,DB00773,Etoposide
,11736859,AUC50,Free AUC50 (exposure producing a 50% reduction in absolute neutrophil count) was 1.80 mg l(-1) h.,Population pharmacokinetics and pharmacodynamics of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736859/),[h·mg] / [l],1.80,253933,DB00773,Etoposide
,11736859,free AUC p.o.,"In patients with lung cancer, the free AUC p.o. was higher in the two patients with responsive tumour (5.9 mg l(-1) h) than in patients with stable (2.1 mg l-1 h) or progressive disease (2.3 mg l-1 h) (P = 0.01).",Population pharmacokinetics and pharmacodynamics of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736859/),[h·mg] / [l],5.9,253934,DB00773,Etoposide
,11736859,free AUC p.o.,"In patients with lung cancer, the free AUC p.o. was higher in the two patients with responsive tumour (5.9 mg l(-1) h) than in patients with stable (2.1 mg l-1 h) or progressive disease (2.3 mg l-1 h) (P = 0.01).",Population pharmacokinetics and pharmacodynamics of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736859/),[h·mg] / [l],2.1,253935,DB00773,Etoposide
,11736859,free AUC p.o.,"In patients with lung cancer, the free AUC p.o. was higher in the two patients with responsive tumour (5.9 mg l(-1) h) than in patients with stable (2.1 mg l-1 h) or progressive disease (2.3 mg l-1 h) (P = 0.01).",Population pharmacokinetics and pharmacodynamics of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736859/),[h·mg] / [l],2.3,253936,DB00773,Etoposide
,11914637,IC50,XR11576 demonstrated potent cytotoxic activity against a variety of human and murine tumor cell lines (IC50=6-47 nM).,"In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914637/),nM,6-47,253958,DB00773,Etoposide
,20176514,flow rate,"The analytes were separated on a reverse phase C18 column using methanol-water (72:28, v/v) mobile phase with a flow rate of 250 microL/min.",Simultaneous determination of etoposide and a piperine analogue (PA-1) by UPLC-qTOF-MS: evidence that PA-1 enhances the oral bioavailability of etoposide in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20176514/),[μl] / [min],250,254127,DB00773,Etoposide
,20176514,m/z,"The major product ions for etoposide and PA-1 were at m/z 185.1350 and 164.1581, respectively.",Simultaneous determination of etoposide and a piperine analogue (PA-1) by UPLC-qTOF-MS: evidence that PA-1 enhances the oral bioavailability of etoposide in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20176514/),,185.1350,254128,DB00773,Etoposide
,20176514,m/z,"The major product ions for etoposide and PA-1 were at m/z 185.1350 and 164.1581, respectively.",Simultaneous determination of etoposide and a piperine analogue (PA-1) by UPLC-qTOF-MS: evidence that PA-1 enhances the oral bioavailability of etoposide in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20176514/),,164.1581,254129,DB00773,Etoposide
,20176514,total run time,"The total run time was 6 min and the elution of etoposide and PA-1 occurred at 1.24 and 2.84 min, respectively.",Simultaneous determination of etoposide and a piperine analogue (PA-1) by UPLC-qTOF-MS: evidence that PA-1 enhances the oral bioavailability of etoposide in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20176514/),min,6,254130,DB00773,Etoposide
,11012554,clearance (CL),Dox clearance (CL) and volume of distribution (Vd) were 32.0 l h-1 and 9.3 l (Inter-individual variability: 17.2% and 19.2%).,"Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11012554/),[l] / [h],32.0,255043,DB00773,Etoposide
,11012554,volume of distribution (Vd),Dox clearance (CL) and volume of distribution (Vd) were 32.0 l h-1 and 9.3 l (Inter-individual variability: 17.2% and 19.2%).,"Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11012554/),l,9.3,255044,DB00773,Etoposide
,11012554,Vd,"Eto CL (l h-1) and Vd were, respectively, 3.34-0.0083* serum creatinine (micromol l-1) and 6.38 l (interindividual variability: 15.6% and 18.7%).","Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11012554/),l,6.38,255045,DB00773,Etoposide
,11012554,CL,"Ifo CL and Vd at day 1 were 5.6 l h-1 and 26.0 l (interindividual variability: 10.1% and 17.2%, respectively).","Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11012554/),[l] / [h],5.6,255046,DB00773,Etoposide
,11012554,Vd,"Ifo CL and Vd at day 1 were 5.6 l h-1 and 26.0 l (interindividual variability: 10.1% and 17.2%, respectively).","Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11012554/),l,26.0,255047,DB00773,Etoposide
,10965746,area under the blood concentration-time curve (AUC),"The area under the blood concentration-time curve (AUC) of free-cisplatin was 6.82 micrograms.hr/ml in first course, 4.07 micrograms.hr/ml in second course.",[Chemotherapy in hemodialysis patient with metastatic testicular cancer; pharmacokinetics of etoposide and cisplatin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965746/),[h·μg] / [ml],6.82,256292,DB00773,Etoposide
,10965746,area under the blood concentration-time curve (AUC),"The area under the blood concentration-time curve (AUC) of free-cisplatin was 6.82 micrograms.hr/ml in first course, 4.07 micrograms.hr/ml in second course.",[Chemotherapy in hemodialysis patient with metastatic testicular cancer; pharmacokinetics of etoposide and cisplatin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965746/),[h·μg] / [ml],4.07,256293,DB00773,Etoposide
,10965746,peak concentration,"The peak concentration of peripheral blood free-cisplatin was 0.58 microgram/ml in first course, 0.43 microgram/ml in second course.",[Chemotherapy in hemodialysis patient with metastatic testicular cancer; pharmacokinetics of etoposide and cisplatin]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965746/),[μg] / [ml],0.58,256294,DB00773,Etoposide
,10965746,peak concentration,"The peak concentration of peripheral blood free-cisplatin was 0.58 microgram/ml in first course, 0.43 microgram/ml in second course.",[Chemotherapy in hemodialysis patient with metastatic testicular cancer; pharmacokinetics of etoposide and cisplatin]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965746/),[μg] / [ml],0.43,256295,DB00773,Etoposide
,10965746,AUC,"The AUC of etoposide was 241.9 micrograms.hr/ml in first course, 216.9 micrograms.hr/ml in second course.",[Chemotherapy in hemodialysis patient with metastatic testicular cancer; pharmacokinetics of etoposide and cisplatin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965746/),[h·μg] / [ml],241.9,256296,DB00773,Etoposide
,10965746,AUC,"The AUC of etoposide was 241.9 micrograms.hr/ml in first course, 216.9 micrograms.hr/ml in second course.",[Chemotherapy in hemodialysis patient with metastatic testicular cancer; pharmacokinetics of etoposide and cisplatin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10965746/),[h·μg] / [ml],216.9,256297,DB00773,Etoposide
,32376439,solubility,"A formulation consisting of 10% (w/v) of pluronic® F-127 and polyvinylpyrrolidone/vinyl acetate (PVP/VA), and 57% (v/v) ethanol enhanced etoposide's solubility approximately 100 times (16 mg mL-1) compared to its aqueous solubility.","High-dose etoposide formulations do not saturate intestinal P-glycoprotein: Development, stability, and pharmacokinetics in Sprague-Dawley rats. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32376439/),[mg] / [ml],16,258479,DB00773,Etoposide
,17001183,total body clearance,"Median total body clearance in children 0.5-1.8 (n=4) and 2.3-17.7 years old (n=36) without Down's syndrome was 17.1 and 17.6 ml/min/m, respectively (P=0.96).",Etoposide pharmacokinetics in children treated for acute myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17001183/),[ml] / [m·min],17.1,258624,DB00773,Etoposide
,17001183,total body clearance,"Median total body clearance in children 0.5-1.8 (n=4) and 2.3-17.7 years old (n=36) without Down's syndrome was 17.1 and 17.6 ml/min/m, respectively (P=0.96).",Etoposide pharmacokinetics in children treated for acute myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17001183/),[ml] / [m·min],17.6,258625,DB00773,Etoposide
,17001183,clearance,Five children with Down's syndrome had a median clearance of 13.6 ml/min/m (P=0.067 compared with non-Down's syndrome children).,Etoposide pharmacokinetics in children treated for acute myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17001183/),[ml] / [m·min],13.6,258626,DB00773,Etoposide
,2230875,total systemic clearance,"The mean etoposide total systemic clearance was not different in 15 patients with total bilirubin less than 1.0 mg/dL versus six patients with total bilirubin 1.1 to 21.5 mg/dL (18.7 +/- 5.9 mL/min/m2 v 26.4 +/- 10.7 mL/min/m2; t-test P = .06), with a trend toward higher total clearance in the patients with abnormal bilirubin values.",Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2230875/),[ml] / [m2·min],18.7,258772,DB00773,Etoposide
,2230875,total systemic clearance,"The mean etoposide total systemic clearance was not different in 15 patients with total bilirubin less than 1.0 mg/dL versus six patients with total bilirubin 1.1 to 21.5 mg/dL (18.7 +/- 5.9 mL/min/m2 v 26.4 +/- 10.7 mL/min/m2; t-test P = .06), with a trend toward higher total clearance in the patients with abnormal bilirubin values.",Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2230875/),[ml] / [m2·min],26.4,258773,DB00773,Etoposide
,2230875,clearance,"However, the mean clearance of unbound etoposide was significantly lower in patients with increased total bilirubin (220 +/- 90 mL/min/m2 v 135 +/- 61 mL/min/m2; t-test P = .027).",Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2230875/),[ml] / [m2·min],220,258774,DB00773,Etoposide
,2230875,clearance,"However, the mean clearance of unbound etoposide was significantly lower in patients with increased total bilirubin (220 +/- 90 mL/min/m2 v 135 +/- 61 mL/min/m2; t-test P = .027).",Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2230875/),[ml] / [m2·min],135,258775,DB00773,Etoposide
,7799021,MTDs,"The MTDs were defined as 175 mg/m2 and 220 mg/m2 in previously treated and untreated patients, respectively.",Phase I clinical and pharmacokinetic study of oral etoposide phosphate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799021/),[mg] / [m2],175,260186,DB00773,Etoposide
,7799021,MTDs,"The MTDs were defined as 175 mg/m2 and 220 mg/m2 in previously treated and untreated patients, respectively.",Phase I clinical and pharmacokinetic study of oral etoposide phosphate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799021/),[mg] / [m2],220,260187,DB00773,Etoposide
,7799021,relative F,"The relative F (mean +/- SD) of etoposide after oral etoposide phosphate was 76 +/- 27%, with a range of 37% to 144%.",Phase I clinical and pharmacokinetic study of oral etoposide phosphate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7799021/),%,76,260188,DB00773,Etoposide
,11533095,plasma clearance of unbound cisplatin (CL(free)),"The mean plasma clearance of unbound cisplatin (CL(free)) was 57.1 +/- 14.7 L/h (range, 31.0 to 116 L/h), with an interpatient variability of 25.6%.",Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11533095/),[l] / [h],57.1,262601,DB00773,Etoposide
,11533095,BSA,"BSA varied between 1.43 and 2.40 m(2) (mean, 1.86 +/- 0.19 m(2)), with an interpatient variability of 10.4%.",Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11533095/),m(2),1.86,262602,DB00773,Etoposide
,18626752,bioavailability,"The bioavailability of etoposide was 12.9 and 13.9% in monkeys and rats, respectively.",Species difference in intestinal absorption mechanism of etoposide and digoxin between cynomolgus monkey and rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18626752/),%,12.9,264608,DB00773,Etoposide
,18626752,bioavailability,"The bioavailability of etoposide was 12.9 and 13.9% in monkeys and rats, respectively.",Species difference in intestinal absorption mechanism of etoposide and digoxin between cynomolgus monkey and rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18626752/),%,13.9,264609,DB00773,Etoposide
,7497587,area under the plasma concentration time curve (AUC) (0-24 h),"There was considerable interpatient variability in the day 1 pharmacokinetic parameters: area under the plasma concentration time curve (AUC) (0-24 h) 1.95 +/- 0.87 mg/ml per min (mean +/- SD), apparent oral clearance 60.9 +/- 21.7 ml/min per 1.73 m2, peak plasma concentration 5.6 +/- 2.5 micrograms/ml, time to peak concentration 73 +/- 35 min and half-life 220 +/- 83 min.",Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497587/),[mg] / [min·ml],1.95,265132,DB00773,Etoposide
,7497587,apparent oral clearance,"There was considerable interpatient variability in the day 1 pharmacokinetic parameters: area under the plasma concentration time curve (AUC) (0-24 h) 1.95 +/- 0.87 mg/ml per min (mean +/- SD), apparent oral clearance 60.9 +/- 21.7 ml/min per 1.73 m2, peak plasma concentration 5.6 +/- 2.5 micrograms/ml, time to peak concentration 73 +/- 35 min and half-life 220 +/- 83 min.",Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497587/),[ml] / [1.73·m2·min],60.9,265133,DB00773,Etoposide
,7497587,peak plasma concentration,"There was considerable interpatient variability in the day 1 pharmacokinetic parameters: area under the plasma concentration time curve (AUC) (0-24 h) 1.95 +/- 0.87 mg/ml per min (mean +/- SD), apparent oral clearance 60.9 +/- 21.7 ml/min per 1.73 m2, peak plasma concentration 5.6 +/- 2.5 micrograms/ml, time to peak concentration 73 +/- 35 min and half-life 220 +/- 83 min.",Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497587/),[μg] / [ml],5.6,265134,DB00773,Etoposide
,7497587,time to peak concentration,"There was considerable interpatient variability in the day 1 pharmacokinetic parameters: area under the plasma concentration time curve (AUC) (0-24 h) 1.95 +/- 0.87 mg/ml per min (mean +/- SD), apparent oral clearance 60.9 +/- 21.7 ml/min per 1.73 m2, peak plasma concentration 5.6 +/- 2.5 micrograms/ml, time to peak concentration 73 +/- 35 min and half-life 220 +/- 83 min.",Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497587/),min,73,265135,DB00773,Etoposide
,7497587,half-life,"There was considerable interpatient variability in the day 1 pharmacokinetic parameters: area under the plasma concentration time curve (AUC) (0-24 h) 1.95 +/- 0.87 mg/ml per min (mean +/- SD), apparent oral clearance 60.9 +/- 21.7 ml/min per 1.73 m2, peak plasma concentration 5.6 +/- 2.5 micrograms/ml, time to peak concentration 73 +/- 35 min and half-life 220 +/- 83 min.",Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497587/),min,220,265136,DB00773,Etoposide
>,7497587,AUC,All patients who had a day 1 AUC > 2.0 mg/ml per min had WHO grade III or IV neutropenia.,Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497587/),[mg] / [min·ml],2.0,265137,DB00773,Etoposide
,15020613,area under the curve (AUC),"Cohort 1 (n=5) received G3139 5 mg/kg/d on days 1 to 8 of a 21 day cycle, with carboplatin area under the curve (AUC)=6 on day 6, and etoposide 80 mg/m2/d on days 6 to 8.","Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020613/),,6,266744,DB00773,Etoposide
,15020613,AUC,"In cohort 2 (n=4), carboplatin dose was reduced to AUC=5.","Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020613/),,5,266745,DB00773,Etoposide
,15020613,time to progression,Median time to progression was 5.9 months.,"Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020613/),month,5.9,266746,DB00773,Etoposide
,30533000,clearance,"Etoposide clearance was two-fold higher with concomitant mitotane (4.95 L/h) than after mitotane discontinuation (2.53 L/h, P = 0.014), and 2.5-fold higher than that in reference population not treated with mitotane (1.81 L/h).",Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30533000/),[l] / [h],4.95,267858,DB00773,Etoposide
,30533000,clearance,"Etoposide clearance was two-fold higher with concomitant mitotane (4.95 L/h) than after mitotane discontinuation (2.53 L/h, P = 0.014), and 2.5-fold higher than that in reference population not treated with mitotane (1.81 L/h).",Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30533000/),[l] / [h],2.53,267859,DB00773,Etoposide
,30533000,clearance,"Etoposide clearance was two-fold higher with concomitant mitotane (4.95 L/h) than after mitotane discontinuation (2.53 L/h, P = 0.014), and 2.5-fold higher than that in reference population not treated with mitotane (1.81 L/h).",Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30533000/),[l] / [h],1.81,267860,DB00773,Etoposide
,30533000,AUC,"Tumor response was associated with higher etoposide AUC (267.3 vs 188.8 mg.h/L, P = 0.04).",Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30533000/),[h·mg] / [l],267.3,267861,DB00773,Etoposide
,30533000,AUC,"Tumor response was associated with higher etoposide AUC (267.3 vs 188.8 mg.h/L, P = 0.04).",Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30533000/),[h·mg] / [l],188.8,267862,DB00773,Etoposide
,1411635,bioavailability,The bioavailability of oral etoposide is about 50% at doses of 200 mg or less and decreases as drug doses increase.,Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1411635/),%,50,268097,DB00773,Etoposide
,12654074,peak serum concentration (Cmax),"Pharmacokinetic parameters (mean~SD) of the 14 patients (24 courses) who received etoposide 100 mg/m2 were as follows: peak serum concentration (Cmax), 18.5~6.4 microg/mL; trough serum concentration, 0.2~0.1 microg/mL; biological half-life (T1/2), 3.6~0.7 h; volume of distribution (Vd), 6.3~3.4 L/m2; area under the etoposide serum concentration-time curve (AUC), 129~38 hr x microg/mL; systemic clearance, 21.1~10.8 mL/min per m2.",Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654074/),[μg] / [ml],18.5~6.4,269762,DB00773,Etoposide
,12654074,trough serum concentration,"Pharmacokinetic parameters (mean~SD) of the 14 patients (24 courses) who received etoposide 100 mg/m2 were as follows: peak serum concentration (Cmax), 18.5~6.4 microg/mL; trough serum concentration, 0.2~0.1 microg/mL; biological half-life (T1/2), 3.6~0.7 h; volume of distribution (Vd), 6.3~3.4 L/m2; area under the etoposide serum concentration-time curve (AUC), 129~38 hr x microg/mL; systemic clearance, 21.1~10.8 mL/min per m2.",Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654074/),[μg] / [ml],0.2~0.1,269763,DB00773,Etoposide
,12654074,biological half-life (T1/2),"Pharmacokinetic parameters (mean~SD) of the 14 patients (24 courses) who received etoposide 100 mg/m2 were as follows: peak serum concentration (Cmax), 18.5~6.4 microg/mL; trough serum concentration, 0.2~0.1 microg/mL; biological half-life (T1/2), 3.6~0.7 h; volume of distribution (Vd), 6.3~3.4 L/m2; area under the etoposide serum concentration-time curve (AUC), 129~38 hr x microg/mL; systemic clearance, 21.1~10.8 mL/min per m2.",Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654074/),h,3.6~0.7,269764,DB00773,Etoposide
,12654074,volume of distribution (Vd),"Pharmacokinetic parameters (mean~SD) of the 14 patients (24 courses) who received etoposide 100 mg/m2 were as follows: peak serum concentration (Cmax), 18.5~6.4 microg/mL; trough serum concentration, 0.2~0.1 microg/mL; biological half-life (T1/2), 3.6~0.7 h; volume of distribution (Vd), 6.3~3.4 L/m2; area under the etoposide serum concentration-time curve (AUC), 129~38 hr x microg/mL; systemic clearance, 21.1~10.8 mL/min per m2.",Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654074/),[l] / [m2],6.3~3.4,269765,DB00773,Etoposide
,12654074,area under the etoposide serum concentration-time curve (AUC),"Pharmacokinetic parameters (mean~SD) of the 14 patients (24 courses) who received etoposide 100 mg/m2 were as follows: peak serum concentration (Cmax), 18.5~6.4 microg/mL; trough serum concentration, 0.2~0.1 microg/mL; biological half-life (T1/2), 3.6~0.7 h; volume of distribution (Vd), 6.3~3.4 L/m2; area under the etoposide serum concentration-time curve (AUC), 129~38 hr x microg/mL; systemic clearance, 21.1~10.8 mL/min per m2.",Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654074/),[h·μg] / [ml],129~38,269766,DB00773,Etoposide
,12654074,systemic clearance,"Pharmacokinetic parameters (mean~SD) of the 14 patients (24 courses) who received etoposide 100 mg/m2 were as follows: peak serum concentration (Cmax), 18.5~6.4 microg/mL; trough serum concentration, 0.2~0.1 microg/mL; biological half-life (T1/2), 3.6~0.7 h; volume of distribution (Vd), 6.3~3.4 L/m2; area under the etoposide serum concentration-time curve (AUC), 129~38 hr x microg/mL; systemic clearance, 21.1~10.8 mL/min per m2.",Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654074/),[ml] / [m2·min],21.1~10.8,269767,DB00773,Etoposide
,15020609,disease-free survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,10,270463,DB00773,Etoposide
,15020609,disease-free survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,9.3,270464,DB00773,Etoposide
,15020609,overall survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,4.6,270465,DB00773,Etoposide
,15020609,overall survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,5.4,270466,DB00773,Etoposide
,15020609,CR rates,The CR rates in MDR+ (69% of patients) versus MDR- patients were similar for those receiving either chemotherapy regimen (16% versus 24%).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),%,16,270467,DB00773,Etoposide
,15020609,CR rates,The CR rates in MDR+ (69% of patients) versus MDR- patients were similar for those receiving either chemotherapy regimen (16% versus 24%).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),,24,270468,DB00773,Etoposide
,15020609,CR rate,"The CR rate for unfavorable cytogenetic patients (45% of patients) was 13% compared to the remainder, 28% (P=.09).","Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),%,13,270469,DB00773,Etoposide
,10406209,limit of detection,The limit of detection for etoposide was 1.2 nM and for etoposide catechol was 0.2 nM.,Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10406209/),nM,1.2,270932,DB00773,Etoposide
,10406209,limit of detection,The limit of detection for etoposide was 1.2 nM and for etoposide catechol was 0.2 nM.,Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10406209/),nM,0.2,270933,DB00773,Etoposide
,10406209,Recovery,"Recovery of etoposide and etoposide catechol ranged from 93 to 95% and 90 to 98%, respectively.",Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10406209/),%,93 to 95,270934,DB00773,Etoposide
,10406209,Recovery,"Recovery of etoposide and etoposide catechol ranged from 93 to 95% and 90 to 98%, respectively.",Simultaneous quantitation of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10406209/),%,90 to 98,270935,DB00773,Etoposide
up to,7902206,steady-state levels,Conclusions from the initial phase I trial with the use of CsA as a modulator of etoposide are: (1) Serum CsA steady-state levels of up to 4800 ng/ml (4 microM) could be achieved with acceptable toxicity.,Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902206/),[ng] / [ml],4800,270936,DB00773,Etoposide
above,7902206,steady-state plasma CsA levels,"Renal toxicity was uncommon, but severe in two patients with steady-state plasma CsA levels above 6000 ng/ml.",Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902206/),[ng] / [ml],6000,270937,DB00773,Etoposide
,7902206,steady-state serum levels,(4) The recommended dose of CsA is a 6-7 mg/kg loading dose administered as a 2-hour intravenous infusion followed by a continuous infusion of 18-21 mg/kg/day for 60 hours with adjustments in the infusion rate to maintain steady-state serum levels of 3000-4800 ng/ml (2.5-4.0 M).,Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902206/),[ng] / [ml],3000-4800,270938,DB00773,Etoposide
,10198733,duration of response,The median duration of response was 3.5 months.,Oral etoposide for patients with metastatic gastric adenocarcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10198733/),month,3.5,273058,DB00773,Etoposide
,1662234,peak plasma concentration,The pharmacokinetic parameters of both groups in serum were as follows: 1) mean peak plasma concentration of 0.91 +/- 0.18 micrograms/mL (25 mg) and 1.24 +/- 0.12 micrograms/mL (25 mg twice); 2) elimination half-lives of 6.48 +/- 1.09 hours (25 mg) and 3.64 +/- 0.27 hours (25 mg twice); and 3) the area under the plasma concentration curve of 7.09 +/- 1.26 micrograms.hr/mL (25 mg) and 8.67 +/- 0.77 micrograms.hr/mL (25 mg twice).,Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662234/),[μg] / [ml],0.91,273110,DB00773,Etoposide
,1662234,peak plasma concentration,The pharmacokinetic parameters of both groups in serum were as follows: 1) mean peak plasma concentration of 0.91 +/- 0.18 micrograms/mL (25 mg) and 1.24 +/- 0.12 micrograms/mL (25 mg twice); 2) elimination half-lives of 6.48 +/- 1.09 hours (25 mg) and 3.64 +/- 0.27 hours (25 mg twice); and 3) the area under the plasma concentration curve of 7.09 +/- 1.26 micrograms.hr/mL (25 mg) and 8.67 +/- 0.77 micrograms.hr/mL (25 mg twice).,Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662234/),[μg] / [ml],1.24,273111,DB00773,Etoposide
,1662234,elimination half-lives,The pharmacokinetic parameters of both groups in serum were as follows: 1) mean peak plasma concentration of 0.91 +/- 0.18 micrograms/mL (25 mg) and 1.24 +/- 0.12 micrograms/mL (25 mg twice); 2) elimination half-lives of 6.48 +/- 1.09 hours (25 mg) and 3.64 +/- 0.27 hours (25 mg twice); and 3) the area under the plasma concentration curve of 7.09 +/- 1.26 micrograms.hr/mL (25 mg) and 8.67 +/- 0.77 micrograms.hr/mL (25 mg twice).,Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662234/),h,6.48,273112,DB00773,Etoposide
,1662234,elimination half-lives,The pharmacokinetic parameters of both groups in serum were as follows: 1) mean peak plasma concentration of 0.91 +/- 0.18 micrograms/mL (25 mg) and 1.24 +/- 0.12 micrograms/mL (25 mg twice); 2) elimination half-lives of 6.48 +/- 1.09 hours (25 mg) and 3.64 +/- 0.27 hours (25 mg twice); and 3) the area under the plasma concentration curve of 7.09 +/- 1.26 micrograms.hr/mL (25 mg) and 8.67 +/- 0.77 micrograms.hr/mL (25 mg twice).,Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662234/),h,3.64,273113,DB00773,Etoposide
,1662234,area under the plasma concentration curve,The pharmacokinetic parameters of both groups in serum were as follows: 1) mean peak plasma concentration of 0.91 +/- 0.18 micrograms/mL (25 mg) and 1.24 +/- 0.12 micrograms/mL (25 mg twice); 2) elimination half-lives of 6.48 +/- 1.09 hours (25 mg) and 3.64 +/- 0.27 hours (25 mg twice); and 3) the area under the plasma concentration curve of 7.09 +/- 1.26 micrograms.hr/mL (25 mg) and 8.67 +/- 0.77 micrograms.hr/mL (25 mg twice).,Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662234/),[h·μg] / [ml],7.09,273114,DB00773,Etoposide
,1662234,area under the plasma concentration curve,The pharmacokinetic parameters of both groups in serum were as follows: 1) mean peak plasma concentration of 0.91 +/- 0.18 micrograms/mL (25 mg) and 1.24 +/- 0.12 micrograms/mL (25 mg twice); 2) elimination half-lives of 6.48 +/- 1.09 hours (25 mg) and 3.64 +/- 0.27 hours (25 mg twice); and 3) the area under the plasma concentration curve of 7.09 +/- 1.26 micrograms.hr/mL (25 mg) and 8.67 +/- 0.77 micrograms.hr/mL (25 mg twice).,Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1662234/),[h·μg] / [ml],8.67,273115,DB00773,Etoposide
,22931186,CL,"The final model parameter estimates for the typical (normalised to 70 kg) values of CL and V(d) were 2.31 L/hr and 17.5 L, respectively.",Clinical pharmacology of etoposide in children undergoing autologous stem cell transplantation for various solid tumours. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22931186/),[l] / [h],2.31,274168,DB00773,Etoposide
,22931186,V(d),"The final model parameter estimates for the typical (normalised to 70 kg) values of CL and V(d) were 2.31 L/hr and 17.5 L, respectively.",Clinical pharmacology of etoposide in children undergoing autologous stem cell transplantation for various solid tumours. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22931186/),l,17.5,274169,DB00773,Etoposide
